Condition	USMLE Classic Presentation	Pathophysiology	Epidemiology	Salient Signs & Symptoms	Time Course	Differential	Diagnostics	Treatment	Never Miss	More Info																
Acanthosis Nigricans	Velvety, hyperpigmented plaques in axillae and neck folds in obese adolescent; “bunch of grapes” appearance	Hyperkeratosis and papillomatosis triggered by insulin resistance, hyperinsulinemia, or rarely malignancy-associated growth factors	Prevalence 5.5% to 34.2%; commonly seen in adolescents, especially those with obesity or metabolic syndrome	Irregularly defined, hyperpigmented, velvety patches typically on posterior neck, axilla, and groin; may affect oral mucosa	Develops during adolescence; chronic and progressive if underlying condition persists	Confluent and reticulated papillomatosis, tinea versicolor, seborrheic dermatitis	Clinical diagnosis; dermoscopy shows crista cutis, sulcus cutis, papillary projections; evaluate for diabetes, insulin resistance, PCOS, or malignancy if atypical presentation	Address underlying condition: weight loss for obesity-related cases, manage diabetes or insulin resistance; topical retinoids for cosmetic improvement	Y	https://www.uptodate.com/contents/acanthosis-nigricans																
Acne keloidalis nuchae	Keloid-like papules and plaques on posterior neck in young Black male after close haircut	Chronic inflammatory folliculitis with abnormal immune response to follicular injury leading to scarring and cicatricial alopecia	Prevalence 0.5% to 13.6%; predominantly affects Black males (20:1 male to female ratio); onset postadolescence	Firm papules, pustules, or keloid-like plaques on nuchal and occipital scalp; may be pruritic, painful, or bleed; cicatricial alopecia develops	Begins hours to days after haircut; chronic and progressive without treatment	Folliculitis, keloids, bacterial folliculitis, dissecting cellulitis of scalp	Clinical diagnosis; biopsy shows deep scarring folliculitis with naked hair shafts and inflammation in upper two-thirds of dermis	Mild: topical triamcinolone with retinoids or clindamycin; moderate: intralesional triamcinolone 5-40 mg/mL; severe: laser therapy, phototherapy, or surgical excision; avoid close shaves and tight collars	N	https://www.uptodate.com/contents/acne-keloidalis-nuchae																
Acne vulgaris	Teenager with comedones, papules, and pustules on face and upper back	Follicular hyperkeratinization, sebum production, Cutibacterium acnes colonization, and inflammation	Most prevalent chronic skin disease; affects nearly 50 million people per year in US; primarily adolescents and young adults	Comedones (open or closed), inflammatory papules, pustules, nodules on face, upper back, chest, shoulders; may have postinflammatory hyperpigmentation or scarring	Onset typically during adolescence; may persist into adulthood	Rosacea, folliculitis, perioral dermatitis, drug-induced acne	Clinical diagnosis based on lesion morphology and distribution; evaluate for hyperandrogenism if severe, sudden onset, or signs of PCOS	Mild: topical retinoids with benzoyl peroxide; moderate: add topical or oral antibiotics (maximum 12 weeks) with retinoids and benzoyl peroxide; severe: oral isotretinoin; maintenance with topical retinoids	N	https://www.uptodate.com/contents/acne-vulgaris-management																
Acral lentiginous melanoma	Irregularly pigmented macule on sole or under nail in older Asian or Black patient	Lentiginous proliferation of atypical melanocytes along basal layer of glabrous skin; not UV-induced; associated with mechanical stress; mutations in KIT, NF1, TERT, TP53	Represents 2% to 3% of all melanomas; disproportionately affects Black, Hispanic, and Asian populations; higher proportion of melanoma cases in richly pigmented skin	Irregularly pigmented macule or patch on palms, soles, or subungual regions; asymmetry, border irregularity, color variegation	Insidious onset; often delayed diagnosis due to subtle presentation	Benign nevus, subungual hematoma, tinea nigra, plantar wart, traumatic pigmentation	Dermoscopy shows parallel ridge pattern; biopsy demonstrates lentiginous basal proliferation with dermal invasion; histopathology required for diagnosis	Wide local excision; sentinel lymph node biopsy if indicated; advanced disease may require lymph node surgery, radiotherapy, or systemic therapy	Y	https://www.uptodate.com/contents/acral-lentiginous-melanoma																
Acrochordon	Soft, pedunculated skin-colored papules in axillae and neck of middle-aged obese patient	Benign fibroepithelial polyps; pathogenesis unclear but associated with insulin resistance, metabolic syndrome	Common; increases with age and obesity; associated with diabetes, hyperlipidemia, hypertension	Soft, pedunculated or sessile skin-colored to brown papules typically in intertriginous areas (neck, axillae, groin); usually asymptomatic	Develops in adulthood; may increase in number over time	Seborrheic keratosis, neurofibromas, dermatosis papulosa nigra, warts	Clinical diagnosis; biopsy rarely needed	Observation if asymptomatic; removal by snip excision, cryotherapy, or electrodesiccation for cosmetic or symptomatic lesions; evaluate for metabolic abnormalities	N	https://www.uptodate.com/contents/skin-tags-acrochordons																
Actinic keratosis	Rough, scaly, erythematous papules on sun-exposed areas in elderly fair-skinned individual	UV-induced keratinocyte dysplasia with epidermal hyperplasia and cellular atypia; precursor to cutaneous squamous cell carcinoma	Very common in elderly with fair skin and chronic sun exposure; prevalence increases with age and cumulative UV exposure	Rough or scaly erythematous, pink, or brown papules or patches on sun-exposed areas (face, scalp, forearms, hands); may be tender	Develops after years of cumulative sun exposure; chronic; may progress to squamous cell carcinoma in situ or invasive squamous cell carcinoma	Seborrheic keratosis, squamous cell carcinoma, basal cell carcinoma, Bowen disease, superficial spreading melanoma	Clinical diagnosis; biopsy if uncertain or concern for malignancy shows epidermal hyperplasia with cellular atypia	Lesion-directed: cryotherapy, curettage; field-directed: topical 5-fluorouracil, imiquimod, ingenol mebutate, diclofenac; photodynamic therapy; combination therapy; sun protection	N	https://www.uptodate.com/contents/actinic-keratosis																
Acute Cutaneous Lupus Erythematosus	Photosensitive malar rash sparing nasolabial folds in young woman with fever and joint pain	Immune complex deposition and complement activation causing inflammation in sun-exposed skin; associated with systemic lupus erythematosus	Predominantly affects women (9:1 female to male ratio); peak onset in childbearing years; more common in Black, Hispanic, and Asian populations	Erythematous malar butterfly rash sparing nasolabial folds; photosensitivity; may have fever, arthralgia, oral ulcers, alopecia; associated with systemic manifestations	Acute onset; may be first manifestation of systemic lupus erythematosus or occur during disease flare	Rosacea, seborrheic dermatitis, dermatomyositis, drug-induced lupus, subacute cutaneous lupus erythematosus	Antinuclear antibody positive (titer greater than or equal to 1:80); anti-double-stranded DNA and anti-Smith antibodies; low complement (C3, C4); skin biopsy shows interface dermatitis with immunofluorescence showing immunoglobulin and complement deposition at dermal-epidermal junction	Topical corticosteroids and calcineurin inhibitors; hydroxychloroquine for systemic disease; systemic corticosteroids for severe cases; strict sun protection; treat underlying systemic lupus erythematosus	Y	https://www.uptodate.com/contents/cutaneous-lupus-erythematosus-diagnosis-and-treatment																
Acute Generalized Exanthematous Pustulosis	Widespread sterile pustules on erythematous base with fever 1 to 2 days after starting antibiotic (especially beta-lactam)	Type 4 hypersensitivity reaction with T-cell mediated neutrophil recruitment; drug-induced activation of innate immune system causing pustule formation	Rare; incidence 1 to 5 cases per million per year; no sex predilection; can occur at any age	Sudden onset of numerous small sterile pustules on erythematous edematous skin; starts in intertriginous areas and spreads; high fever (greater than 38.3 degrees Celsius); facial edema; purpura may develop	Onset within 1 to 2 days of drug exposure (median 1 day); resolves within 15 days after drug withdrawal with characteristic desquamation	Pustular psoriasis, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms	Clinical diagnosis; skin biopsy shows subcorneal or intraepidermal pustules with papillary dermal edema and neutrophilic infiltrate; leukocytosis with neutrophilia; eosinophilia in 30%; elevated liver enzymes possible	Immediate withdrawal of offending drug; supportive care; topical corticosteroids; systemic corticosteroids for severe cases; resolves spontaneously after drug cessation	N	https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis																
Allergic Contact Dermatitis	Pruritic vesicular rash in distribution of exposure (poison ivy linear streaks, nickel under jewelry or belt buckle)	Type 4 delayed hypersensitivity reaction; sensitization phase followed by elicitation phase upon re-exposure; T-cell mediated inflammation	Very common; affects all ages; occupational exposure common in adults	Pruritic erythematous papules and vesicles in distribution of allergen contact; may have weeping, crusting, or lichenification with chronic exposure; linear arrangement suggests exogenous contactant	Sensitization requires 10 to 14 days on first exposure; elicitation occurs 24 to 72 hours after re-exposure	Irritant contact dermatitis, atopic dermatitis, dyshidrotic eczema, cellulitis	Clinical diagnosis based on distribution and history; patch testing identifies specific allergen; biopsy shows spongiotic dermatitis with lymphocytic infiltrate	Remove offending allergen; topical corticosteroids (high potency for acute, moderate for maintenance); oral corticosteroids for severe or widespread disease; antihistamines for pruritus	N	https://www.uptodate.com/contents/allergic-contact-dermatitis																
Alopecia Areata	Well-demarcated round patches of hair loss with exclamation point hairs at margins in child or young adult	Autoimmune attack on hair follicles by T-cells; follicles remain intact but enter premature catagen phase; associated with other autoimmune conditions	Lifetime risk 2%; affects all ages but peak onset in childhood and young adulthood; equal sex distribution	Smooth, well-circumscribed patches of complete hair loss; exclamation point hairs (broken hairs wider at distal end); may progress to alopecia totalis (entire scalp) or alopecia universalis (entire body); nail pitting in 10% to 66%	Sudden onset; unpredictable course with spontaneous remission and relapse; 34% to 50% regrow hair within 1 year	Tinea capitis, trichotillomania, telogen effluvium, scarring alopecia, secondary syphilis	Clinical diagnosis; pull test positive at margins; dermoscopy shows yellow dots, black dots, broken hairs; potassium hydroxide preparation and fungal culture to exclude tinea; biopsy shows peribulbar lymphocytic infiltrate (swarm of bees pattern)	Observation for limited disease; intralesional corticosteroids (triamcinolone 5 to 10 milligrams per milliliter); topical immunotherapy (diphenylcyclopropenone, squaric acid); minoxidil; JAK inhibitors for extensive disease	N	https://www.uptodate.com/contents/alopecia-areata-management																
Anaphylaxis	Acute onset of urticaria, angioedema, wheezing, and hypotension after bee sting or peanut exposure	Immunoglobulin E mediated mast cell and basophil degranulation releasing histamine, tryptase, and other mediators causing vasodilation, increased vascular permeability, and bronchospasm	Lifetime prevalence 0.05% to 2%; can occur at any age; history of atopy increases risk	Rapid onset of skin findings (urticaria, angioedema, flushing) with respiratory (dyspnea, wheezing, stridor) or cardiovascular (hypotension, syncope) compromise; gastrointestinal symptoms (nausea, vomiting, cramping); sense of impending doom	Onset within minutes to 2 hours of exposure; biphasic reactions occur in 1% to 20% within 4 to 12 hours	Asthma exacerbation, vasovagal syncope, panic attack, hereditary angioedema, scombroid poisoning	Clinical diagnosis; elevated serum tryptase (peak 1 to 2 hours after onset, remains elevated up to 6 hours); skin testing or specific immunoglobulin E to identify trigger	Immediate intramuscular epinephrine 0.3 to 0.5 milligrams (1:1000 dilution) in anterolateral thigh; repeat every 5 to 15 minutes as needed; supplemental oxygen; intravenous fluids; supine positioning with legs elevated; antihistamines and corticosteroids as adjuncts; observation 4 to 8 hours; prescribe epinephrine autoinjector	Y	https://www.uptodate.com/contents/anaphylaxis-acute-diagnosis-and-treatment																
Albinism	Congenital absence of pigmentation with white hair, pale skin, nystagmus, and photophobia in infant	Genetic defects in melanin synthesis pathway; oculocutaneous albinism affects eyes and skin (tyrosinase gene mutations most common); ocular albinism affects eyes only	Oculocutaneous albinism affects 1 in 17,000 to 20,000 worldwide; higher prevalence in sub-Saharan Africa; autosomal recessive inheritance (X-linked for ocular albinism)	White to light brown hair and skin; blue to light brown irides with iris transillumination; nystagmus; reduced visual acuity; photophobia; foveal hypoplasia; increased skin cancer risk	Present from birth; lifelong condition; pigmentation may increase slightly with age in some subtypes	Piebaldism, vitiligo, phenylketonuria, Chediak-Higashi syndrome, Hermansky-Pudlak syndrome	Clinical diagnosis; genetic testing confirms subtype; ophthalmologic examination shows foveal hypoplasia, reduced pigmentation, nystagmus; skin biopsy shows melanocytes with absent or reduced melanin	No cure; rigorous sun protection with sunscreen and protective clothing; ophthalmologic care with corrective lenses, low vision aids; skin cancer surveillance; genetic counseling	N	https://www.uptodate.com/contents/oculocutaneous-albinism																
Anaplasmosis	Fever, headache, myalgia after tick bite in endemic area; absence of rash distinguishes from Rocky Mountain spotted fever	Obligate intracellular bacteria (Anaplasma phagocytophilum) transmitted by Ixodes tick; infects granulocytes forming morulae; causes systemic inflammatory response	Endemic in northeastern, mid-Atlantic, and upper midwestern United States; incidence peaks May through July; median age 60 years	Fever, headache, myalgia, malaise 5 to 14 days after tick bite; rash uncommon (less than 10%); may have nausea, vomiting, cough; severe cases develop respiratory failure, renal failure, neurologic complications	Incubation 5 to 14 days after tick bite; acute illness lasts 1 to 2 weeks without treatment	Ehrlichiosis, Rocky Mountain spotted fever, influenza, Lyme disease, viral syndrome	Thrombocytopenia, leukopenia, elevated transaminases; morulae in granulocytes on peripheral smear (20% to 80% sensitivity); polymerase chain reaction most sensitive; serology shows fourfold rise in antibody titer	Doxycycline 100 milligrams twice daily for 10 to 14 days; start empirically if suspected; do not wait for confirmatory testing; rifampin alternative for pregnant patients	Y	https://www.uptodate.com/contents/anaplasmosis																
Androgenetic alopecia	Gradual hair thinning in a male patient with bitemporal recession and vertex balding; female patient with diffuse vertex thinning sparing frontal hairline	Testosterone converted to dihydrotestosterone by 5-alpha-reductase binds androgen receptors on hair follicles causing terminal follicles to miniaturize into vellus follicles	Most common form of hair loss; affects at least 50% of males and 30% of females; prevalence increases with age and varies with genetics	Males: bitemporal and vertex hair loss with occipital and temporal fringe preservation; Females: diffuse vertex thinning with frontal hairline sparing; miniaturization of follicles on examination	Gradually progressive over years to decades; onset typically postpubertal in males, postmenopausal in females	Telogen effluvium, alopecia areata, tinea capitis, traction alopecia, thyroid disease	Clinical diagnosis based on sex-specific pattern; scalp examination shows follicular miniaturization	Topical minoxidil 2% to 5% solution applied to scalp; oral finasteride 1 mg daily for males; treatment must be continuous or hair loss recurs	N	https://www.aafp.org/afp/2024/0900/hair-loss.html																
Angioedema	Sudden onset of nonpitting swelling of face, lips, tongue, or airway; may occur with or without urticaria; patient taking ACE inhibitor	Histaminergic: IgE-mediated mast cell degranulation releasing histamine; Non-histaminergic: bradykinin accumulation from C1-inhibitor deficiency or ACE inhibitor use prolonging bradykinin half-life	Common in allergic and ACE inhibitor-induced forms; rare in hereditary angioedema and acquired C1-inhibitor deficiency	Nonpitting edema of face, lips, tongue, larynx, or extremities; may have abdominal pain if gastrointestinal involvement; urticaria present in histaminergic forms but absent in bradykinin-mediated forms	Rapid onset over minutes to hours in allergic forms; can occur anytime during ACE inhibitor therapy even after years of use	Anaphylaxis, hereditary angioedema, acquired C1-inhibitor deficiency, idiopathic angioedema, drug-induced angioedema	Clinical diagnosis; complement levels C4 and C1-inhibitor for hereditary angioedema; medication history for ACE inhibitor use	Airway management is priority; histaminergic: epinephrine, antihistamines, corticosteroids; bradykinin-mediated: C1-inhibitor concentrate, icatibant, ecallantide; discontinue ACE inhibitor if implicated	Y	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4100605/																
Aplasia Cutis Congenita	Newborn with congenital absence of skin on scalp vertex; may appear as ulcer or healed scar at birth	Congenital localized absence of skin with variable involvement of underlying bone and soft tissue; etiology unclear but may involve vascular disruption or developmental defect	Rare; scalp vertex involved in 96% of cases	Localized area of absent skin most commonly on scalp vertex; lesions may be round, oval, rectangular, or star-shaped; underlying bone defect in some cases; alopecia in affected area after healing	Present at birth; lesions may be ulcerated or already healed; healing occurs over weeks to months leaving scar	Birth trauma, infection, amniotic band syndrome, epidermolysis bullosa	Clinical diagnosis; imaging if bone involvement suspected; evaluate for associated syndromes such as Adams-Oliver syndrome or trisomy 13	Small defects: conservative wound care with dressings; large or deep defects with vascular exposure: immediate surgical intervention; bone reconstruction if needed	Y	https://medlineplus.gov/genetics/condition/nonsyndromic-aplasia-cutis-congenita/																
Arterial Ulcers	Painful ulcer on toes or foot in patient with peripheral arterial disease; severe pain, irregular pink base, diminished pulses	Atherosclerotic peripheral arterial disease causing tissue ischemia and impaired wound healing; may also result from acute arterial occlusion or thromboangiitis obliterans	Common in patients with atherosclerotic risk factors including smoking, diabetes, hypertension, hyperlipidemia	Severe pain; irregular ulcer with pink or pale base on toes or foot; diminished or absent pulses; cool extremity; dependent rubor; pallor on elevation	Chronic progressive course in atherosclerotic disease; acute onset if embolic or thrombotic occlusion	Venous ulcers, neurotrophic ulcers, vasculitis, pyoderma gangrenosum	Ankle-brachial index; arterial duplex ultrasound; angiography if revascularization considered; assess cardiovascular risk factors	Revascularization when feasible; wound care; pain management; cardiovascular risk factor modification including antiplatelet therapy, statin, smoking cessation; amputation if nonviable tissue	Y	https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.106.174526																
Atopic Dermatitis	Child with chronic relapsing pruritic eczema on flexural surfaces; personal or family history of atopy; dry skin	Type 2 helper T cell-mediated inflammation with skin barrier dysfunction; elevated IgE in up to 80% of patients; genetic and environmental factors contribute	Common; onset typically between 2 months and 6 months of age; affects up to 20% of children and 3% of adults	Pruritus; chronic or relapsing eczema with age-specific distribution; infants: face and extensor surfaces; children and adults: flexural areas; xerosis; lichenification in chronic cases; increased risk of skin infections	Chronic relapsing course; onset typically in infancy; may persist into adulthood or resolve with age	Contact dermatitis, seborrheic dermatitis, psoriasis, scabies, cutaneous T-cell lymphoma	Clinical diagnosis based on morphology, distribution, and history; severity assessed by EASI or SCORAD scores	Emollients and skin hydration; topical corticosteroids; topical calcineurin inhibitors; severe cases: phototherapy, systemic immunosuppressants, dupilumab, JAK inhibitors; treat secondary infections	N	https://www.nejm.org/doi/full/10.1056/NEJMra2023911																
Babesiosis	Fever and hemolytic anemia after tick bite in Northeast/upper Midwest; "Maltese cross" on blood smear	Intraerythrocytic protozoan parasite (Babesia microti) transmitted by Ixodes scapularis tick; causes red blood cell lysis	Endemic to Northeast and upper Midwest United States; also transmitted via blood transfusion; higher risk in immunocompromised and elderly	Fever, fatigue, chills, sweats, headache, myalgia, arthralgia, anorexia; thrombocytopenia, hemolytic anemia, elevated liver enzymes	Acute onset days to weeks after tick exposure; can persist weeks to months if untreated	Malaria, ehrlichiosis, anaplasmosis, viral syndromes, other causes of hemolytic anemia	Giemsa or Wright-stained thin blood smear showing intraerythrocytic parasites with ring forms or Maltese cross tetrads; polymerase chain reaction for low-grade parasitemia; serology	Atovaquone plus azithromycin for 7-10 days (mild to moderate); clindamycin plus quinine for severe disease	N	https://www.uptodate.com/contents/babesiosis																
Basal Cell Carcinoma	Pearly papule with rolled borders and telangiectasias on sun-exposed skin; "rodent ulcer"	Malignant proliferation of basal keratinocytes; associated with ultraviolet radiation exposure, mutations in hedgehog signaling pathway	Most common skin cancer; primarily affects older adults with fair skin and chronic sun exposure	Pearly or translucent papule or nodule with rolled borders, central ulceration, telangiectasias; typically on face, head, neck	Slow-growing over months to years; rarely metastasizes but can be locally destructive	Squamous cell carcinoma, melanoma, seborrheic keratosis, actinic keratosis, dermatofibroma, molluscum contagiosum	Skin biopsy with histopathologic examination; shave or punch biopsy acceptable for low-risk lesions	Low-risk: curettage and electrodesiccation, standard excision with 4 millimeter margins, topical imiquimod for superficial types; High-risk: Mohs micrographic surgery or excision with peripheral and deep en face margin assessment; radiation therapy for nonsurgical candidates	N	https://www.uptodate.com/contents/basal-cell-carcinoma																
Bedbugs	Pruritic papules in linear distribution ("breakfast, lunch, and dinner" sign) after awakening; recent travel to hotels or shelters	Allergic reaction to salivary proteins from Cimex lectularius or Cimex hemipterus bites during nocturnal blood feeding	Worldwide distribution; increased incidence with travel and shared accommodations; no socioeconomic boundaries	Multiple pruritic erythematous papules with possible hemorrhagic punctum on exposed areas (head, neck, extremities); linear or grouped distribution; may cause bullous reactions or papular urticaria	Lesions appear hours to days after bites; infestation persists until environmental treatment	Scabies, flea bites, other arthropod bites, contact dermatitis, urticaria, papular urticaria	Clinical diagnosis based on history and examination; environmental inspection for bedbugs in mattresses, furniture, walls; skin scraping to exclude scabies if uncertain	Symptomatic relief with topical corticosteroids and oral antihistamines; environmental pest control measures essential (professional extermination, heat treatment, insecticides)	N	https://www.uptodate.com/contents/bedbugs-cimicidae																
Behcet's Disease	Recurrent painful oral and genital ulcers with uveitis in young adult from Silk Road region; positive pathergy test	Systemic vasculitis affecting arteries and veins of all sizes; immune dysregulation with neutrophil hyperactivity; strong association with HLA-B51	Most common along historical Silk Road (Turkey, Middle East, East Asia); onset typically in third decade; more severe if onset before age 25	Recurrent oral ulcers (nearly universal), genital ulcers with scarring, uveitis (anterior or posterior), skin lesions (erythema nodosum, papulopustular), arthritis, vascular thrombosis, neurologic involvement (brainstem lesions)	Chronic relapsing-remitting course over years; severe manifestations can occur early	Herpes simplex virus, inflammatory bowel disease, syphilis, sarcoidosis, multiple sclerosis, systemic lupus erythematosus, reactive arthritis, aphthous stomatitis	Clinical diagnosis using International Criteria for Behcet Disease (4 or more points from oral ulcers, genital ulcers, ocular lesions, skin lesions, vascular manifestations, neurologic manifestations, positive pathergy test); biopsy shows nonspecific vasculitis	Colchicine for mucocutaneous manifestations; corticosteroids and immunosuppressives (azathioprine, cyclosporine) for severe disease; anti-tumor necrosis factor agents (infliximab, adalimumab) for refractory cases; anticoagulation controversial for thrombosis	Y	https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-behcet-syndrome																
Biotin (Vitamin B7) Deficiency	Alopecia, dermatitis, and neurologic symptoms in patient on prolonged raw egg whites or total parenteral nutrition	Biotin is cofactor for carboxylases in fatty acid synthesis, gluconeogenesis, and amino acid metabolism; deficiency impairs these pathways; raw egg whites contain avidin which binds biotin	Rare; occurs with prolonged total parenteral nutrition without biotin supplementation, genetic biotinidase deficiency, chronic anticonvulsant use, excessive raw egg white consumption	Alopecia, scaly erythematous dermatitis (especially periorificial), conjunctivitis, ataxia, seizures, developmental delay in infants, paresthesias, depression	Develops over weeks to months of inadequate intake; symptoms resolve with supplementation	Zinc deficiency, essential fatty acid deficiency, acrodermatitis enteropathica, seborrheic dermatitis, other causes of alopecia	Clinical diagnosis; decreased urinary biotin excretion, decreased serum biotin levels, increased urinary 3-hydroxyisovaleric acid; genetic testing for biotinidase deficiency	Oral biotin supplementation 5-10 milligrams daily for acquired deficiency; higher doses (5-20 milligrams daily) for biotinidase deficiency; symptoms improve within weeks	N	https://www.uptodate.com/contents/biotin																
Bullous Pemphigoid	Elderly patient with tense bullae on erythematous base and severe pruritus; spares mucous membranes	Autoantibodies (immunoglobulin G) against hemidesmosomal proteins BP180 (collagen XVII) and BP230 cause subepidermal blister formation	Most common autoimmune blistering disease; primarily affects elderly (over 60 years); incidence increasing with aging population	Tense bullae on erythematous or normal skin, severe pruritus (may precede blisters by weeks to months), urticarial plaques; typically trunk and flexural areas; oral involvement uncommon	Chronic course with relapses and remissions over months to years; high morbidity and mortality in elderly	Pemphigus vulgaris, epidermolysis bullosa acquisita, linear immunoglobulin A disease, dermatitis herpetiformis, drug eruptions, insect bites	Skin biopsy showing subepidermal blister with eosinophils; direct immunofluorescence showing linear immunoglobulin G and complement C3 at basement membrane zone; serology for anti-BP180 and anti-BP230 antibodies	Topical corticosteroids (clobetasol) for localized disease; systemic corticosteroids (prednisone 0.5-1 milligram per kilogram daily) for widespread disease; steroid-sparing agents (azathioprine, mycophenolate mofetil); biologics (rituximab, omalizumab, dupilumab) for refractory cases	N	https://www.uptodate.com/contents/bullous-pemphigoid																
Café-au-Lait Macules	Light brown macules; multiple lesions suggest neurofibromatosis type 1 (6 or more greater than 5 millimeters prepubertal or greater than 15 millimeters postpubertal)	Increased melanin production in melanocytes and keratinocytes; isolated lesions are benign; multiple lesions associated with genetic syndromes affecting melanocyte regulation	Present in 10-20% of general population as isolated finding; multiple lesions seen in neurofibromatosis type 1, McCune-Albright syndrome, Legius syndrome	Well-demarcated, uniformly pigmented light to dark brown macules; smooth borders; present at birth or develop in early childhood; distribution varies	Present from birth or appear in first few years of life; persist throughout life; do not change significantly	Neurofibromatosis type 1, McCune-Albright syndrome, Legius syndrome, normal variant (isolated lesions), post-inflammatory hyperpigmentation	Clinical diagnosis based on appearance and number; Wood lamp examination shows enhanced pigmentation; skin biopsy rarely needed; evaluate for associated syndromes if 6 or more lesions present	No treatment needed for isolated lesions; laser therapy for cosmetic concerns; monitor for associated conditions if multiple lesions present	N	https://www.uptodate.com/contents/cafe-au-lait-macules																
Calciphylaxis	Extremely painful skin lesions with retiform purpura or necrotic ulcers in end-stage renal disease patient; pain out of proportion to exam	Vascular calcification of small and medium-sized vessels in dermis and subcutaneous tissue causing ischemic necrosis; associated with abnormal calcium-phosphate metabolism and uremia	Occurs in 1-4% of dialysis patients; risk factors include end-stage renal disease, diabetes, obesity, female sex, warfarin use, hyperparathyroidism, elevated calcium-phosphate product	Extremely painful violaceous plaques with retiform purpura progressing to necrotic ulcers with black eschar; typically affects areas with high adipose tissue (abdomen, thighs, buttocks); systemic symptoms may be absent early	Acute to subacute onset over days to weeks; rapidly progressive; high mortality (60-80% at 1 year) if untreated	Warfarin-induced skin necrosis, cellulitis, pyoderma gangrenosum, cholesterol embolization, necrotizing vasculitis, atherosclerotic vascular disease, venous stasis ulcer	Skin biopsy showing medial calcification of small to medium vessels with intimal proliferation and thrombosis; von Kossa or alizarin red staining highlights calcium; radiographs may show vascular calcification	Discontinue calcium-containing phosphate binders and vitamin D; optimize dialysis; sodium thiosulfate intravenous 25 grams three times weekly during dialysis; wound care; pain management; parathyroidectomy if hyperparathyroidism; avoid trauma	Y	https://www.uptodate.com/contents/calciphylaxis-calcific-uremic-arteriolopathy																
Candida albicans	Budding yeast with pseudohyphae on potassium hydroxide preparation; white plaques in immunocompromised patient	Opportunistic dimorphic fungus; normal commensal of skin, mucous membranes, and gastrointestinal tract; causes infection when host defenses compromised or normal flora disrupted	Most common fungal pathogen in humans; colonizes 30-50% of healthy individuals; infection risk increased with immunosuppression, diabetes, antibiotic use, corticosteroids	Varies by site: oral thrush (white plaques on tongue and buccal mucosa), vulvovaginal candidiasis (pruritus, white discharge), cutaneous candidiasis (erythematous patches with satellite pustules in intertriginous areas), invasive candidiasis in immunocompromised	Acute onset over days; chronic or recurrent in immunocompromised; invasive disease develops rapidly in critically ill	Other Candida species, dermatophytosis, bacterial infections, contact dermatitis, psoriasis (intertriginous), oral leukoplakia, lichen planus	Potassium hydroxide preparation showing budding yeast with pseudohyphae; culture on Sabouraud agar; germ tube test positive; blood cultures for invasive disease; beta-D-glucan and mannan antigen for systemic infection	Topical azoles (clotrimazole, miconazole) for localized mucocutaneous; oral fluconazole for vulvovaginal or refractory cases; echinocandins (caspofungin, micafungin) or fluconazole for invasive disease; address underlying risk factors	N	https://www.uptodate.com/contents/candida-infections-of-the-mouth-throat-and-esophagus																
Candidiasis	White plaques or erythematous patches with satellite pustules; diaper rash with satellite lesions; vaginal discharge with pruritus	Infection caused by Candida species (most commonly Candida albicans); overgrowth occurs with disruption of normal flora, moisture, maceration, or immunosuppression	Very common; affects all ages; risk factors include diabetes, obesity, antibiotic use, immunosuppression, pregnancy, oral contraceptives, dentures	Oral: white plaques on tongue and buccal mucosa that scrape off; Cutaneous: erythematous patches with satellite pustules in skin folds; Vulvovaginal: pruritus, white cottage cheese-like discharge, erythema; Invasive: fever, sepsis in immunocompromised	Acute onset over days for mucocutaneous; chronic or recurrent in predisposed individuals; invasive disease progresses rapidly	Bacterial intertrigo, dermatophytosis, seborrheic dermatitis, psoriasis, contact dermatitis, bacterial vaginosis, trichomoniasis	Potassium hydroxide preparation showing budding yeast with pseudohyphae; culture; clinical diagnosis often sufficient for mucocutaneous disease	Topical antifungals (nystatin, clotrimazole, miconazole) for mucocutaneous; oral fluconazole for vulvovaginal or extensive cutaneous; keep affected areas dry; systemic antifungals for invasive disease	N	https://www.uptodate.com/contents/candidiasis-mucocutaneous																
Carbuncles	Cluster of furuncles forming deep, interconnected abscesses</strong> with multiple drainage points; "bunch of grapes" appearance; commonly on back of neck	Deep infection of multiple adjacent hair follicles caused by Staphylococcus aureus; extends into subcutaneous tissue forming multiloculated abscess with multiple drainage sites	Less common than furuncles; more frequent in men; risk factors include diabetes, obesity, immunosuppression, poor hygiene, friction	Painful, deep, erythematous, indurated nodule or plaque with multiple pustular drainage points; systemic symptoms (fever, malaise) more common than with furuncles; commonly on posterior neck, back, thighs	Develops over days to weeks; slower evolution than furuncles; may persist for weeks without treatment	Furuncle, hidradenitis suppurativa, ruptured epidermal cyst, mycobacterial infection, deep fungal infection, cutaneous anthrax	Clinical diagnosis; culture of purulent drainage; blood cultures if systemic symptoms present; consider imaging (ultrasound or computed tomography) for deep or extensive lesions	Incision and drainage; warm compresses; oral antibiotics covering methicillin-resistant Staphylococcus aureus (trimethoprim-sulfamethoxazole, doxycycline, clindamycin) for extensive lesions or systemic symptoms; intravenous antibiotics for severe cases	N	https://www.uptodate.com/contents/furuncles-and-carbuncles																
Cellulitis	Acute spreading erythema, warmth, and tenderness</strong> with poorly demarcated borders; unilateral lower extremity involvement most common	Acute bacterial infection of dermis and subcutaneous tissue; most commonly caused by beta-hemolytic streptococci (especially Streptococcus pyogenes) and Staphylococcus aureus; entry through breaks in skin barrier	Common; affects all ages; risk factors include lymphedema, venous insufficiency, obesity, diabetes, tinea pedis, prior cellulitis, immunosuppression	Erythema, warmth, swelling, tenderness with poorly demarcated borders; may have associated lymphangitis (red streaking) or regional lymphadenopathy; systemic symptoms (fever, chills) variable; lower extremities most common	Acute onset over hours to days; spreads rapidly without treatment; improves within 24-48 hours with appropriate antibiotics	Erysipelas, deep vein thrombosis, stasis dermatitis, contact dermatitis, necrotizing fasciitis, abscess, erythema migrans (Lyme disease), calciphylaxis	Clinical diagnosis; blood cultures have low yield; imaging (ultrasound, computed tomography, magnetic resonance imaging) if abscess or necrotizing infection suspected; mark borders to monitor progression	Oral antibiotics for uncomplicated cases: cephalexin, dicloxacillin, or clindamycin; add methicillin-resistant Staphylococcus aureus coverage (trimethoprim-sulfamethoxazole, doxycycline) if purulence present; intravenous antibiotics for severe cases; elevate affected limb; address predisposing factors	Y	https://www.uptodate.com/contents/cellulitis-and-skin-abscess-in-adults-treatment																
Cherry Angioma	Bright red, dome-shaped papules; increase in number with age; "Campbell de Morgan spots"	Benign vascular proliferation of capillaries in papillary dermis; exact etiology unknown; may be associated with aging, pregnancy, chemical exposure	Extremely common; present in most adults over 30 years; increase in number and size with age; no gender predilection	Bright red to violaceous, dome-shaped or slightly pedunculated papules; typically 1-5 millimeters; blanch partially with pressure; most common on trunk; asymptomatic; may bleed if traumatized	Appear in early adulthood; increase in number throughout life; individual lesions persist indefinitely	Petechiae, purpura, angiokeratoma, pyogenic granuloma, melanoma (amelanotic), Kaposi sarcoma, bacillary angiomatosis	Clinical diagnosis based on appearance; dermoscopy shows red lacunae; biopsy rarely needed but shows dilated capillaries in papillary dermis	No treatment necessary; electrocautery, laser therapy (pulsed dye laser), or cryotherapy for cosmetic concerns or if bleeding	N	https://www.uptodate.com/contents/cherry-angioma-campbell-de-morgan-spots																
Chilblains (Pernio)	Erythematous to violaceous papules on toes and fingers after cold, wet exposure; "COVID toes" during pandemic	Exaggerated inflammatory response to cold exposure causing vasospasm and hypoxemia; vessel wall inflammation with dermal edema; type I interferon immune response likely involved	Uncommon; affects individuals with prolonged cold, wet exposure (1-5 hours); increased incidence during COVID-19 pandemic in young patients without typical cold exposure	Erythematous to violaceous papules or plaques on acral sites (toes, fingers, thighs); pruritus, burning, pain; swelling; may blister or ulcerate; typically bilateral	Develops hours to days after cold exposure; lesions persist weeks; recurrent with repeated cold exposure	Frostbite, immersion foot, Raynaud phenomenon, vasculitis, erythromelalgia, COVID-19-associated pernio, acrocyanosis	Clinical diagnosis based on history of cold exposure and characteristic appearance; skin biopsy shows superficial and deep perivascular lymphocytic infiltrate with papillary dermal edema; consider COVID-19 testing if no cold exposure	Avoid cold exposure and keep extremities warm and dry; topical corticosteroids for inflammation; nifedipine or other calcium channel blockers for severe or recurrent cases; pentoxifylline may improve microcirculation	N	https://www.uptodate.com/contents/pernio-chilblains																
Cobalamin (Vitamin B12) Deficiency	Megaloblastic anemia with neurologic symptoms (paresthesias, ataxia, loss of vibration and proprioception); glossitis; older adult on metformin or proton pump inhibitors	Impaired DNA synthesis due to inadequate cobalamin cofactor for methionine synthase and methylmalonyl-CoA mutase; causes megaloblastic anemia and demyelination of posterior and lateral spinal cord columns	Affects 2-3% of adults in United States; risk factors include older age, malabsorption (pernicious anemia, gastrectomy, ileal disease), strict vegan diet, metformin use, proton pump inhibitor use	Fatigue, weakness, pallor, glossitis, paresthesias (hands and feet), ataxia, loss of vibration and proprioception, memory loss, depression, cognitive impairment; may have macrocytic anemia or pancytopenia	Insidious onset over months to years; neurologic symptoms may precede hematologic changes; neurologic damage may be irreversible if prolonged	Folate deficiency, copper deficiency, hypothyroidism, myelodysplastic syndrome, alcohol use disorder, medication effects, multiple sclerosis (for neurologic symptoms)	Serum vitamin B12 less than 180 picograms per milliliter diagnostic; borderline levels (180-350 picograms per milliliter) require methylmalonic acid measurement (elevated if deficient); complete blood count shows macrocytosis and megaloblastic anemia; evaluate for pernicious anemia with anti-intrinsic factor antibodies	Oral vitamin B12 1000-2000 micrograms daily for most patients; intramuscular vitamin B12 1000 micrograms daily for 1 week, then weekly for 1 month, then monthly for severe deficiency or neurologic symptoms; treat underlying cause	Y	https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-vitamin-b12-and-folate-deficiency																
Condyloma Acuminata	Cauliflower-like genital warts; sexually active young adult; associated with human papillomavirus types 6 and 11	Benign epithelial proliferation caused by low-risk human papillomavirus (primarily types 6 and 11); virus infects basal keratinocytes causing hyperplasia and koilocytosis	Very common sexually transmitted infection; affects sexually active individuals; increased prevalence in immunosuppressed patients; peak incidence in young adults (20-24 years)	Flesh-colored to pink, exophytic, papillomatous lesions with cauliflower-like appearance on anogenital skin; may be single or multiple; typically asymptomatic but may cause pruritus, bleeding, or pain	Develops weeks to months after human papillomavirus exposure; may spontaneously regress, persist, or enlarge; recurrence common after treatment	Condyloma lata (secondary syphilis), molluscum contagiosum, seborrheic keratosis, skin tags, squamous cell carcinoma, bowenoid papulosis, verrucous carcinoma	Clinical diagnosis based on appearance; biopsy if diagnosis uncertain showing papillomatosis, acanthosis, hyperkeratosis, koilocytosis; human papillomavirus testing not routinely needed	Patient-applied: imiquimod cream, podofilox gel, sinecatechins ointment; Provider-applied: cryotherapy, trichloroacetic acid, surgical excision, electrocautery, laser therapy; no single treatment superior; recurrence rates 20-30%	N	https://www.uptodate.com/contents/genital-warts-condyloma-acuminata-in-adults-and-adolescents-treatment																
Congenital Dermal Melanocytosis	Blue-gray macules on lumbosacral area in Asian or darker-skinned newborn; "Mongolian spots"	Dermal melanocytes that failed to migrate from neural crest to epidermis during embryonic development; melanin in dermis appears blue-gray due to Tyndall effect	Present in 80-90% of Asian, African, and Native American infants; less common in Caucasian infants (5-10%); no gender predilection	Blue-gray to slate-gray macules or patches; most commonly lumbosacral region but may occur on buttocks, back, shoulders, extremities; well-demarcated or ill-defined borders; asymptomatic	Present at birth; most fade by age 1-4 years; extensive or dark lesions may persist into adulthood; rarely associated with inborn errors of metabolism (Hurler syndrome, GM1 gangliosidosis) if extensive and persistent	Bruising (child abuse consideration), nevus of Ota, nevus of Ito, blue nevus, dermal melanocytic hamartoma	Clinical diagnosis; biopsy rarely needed but shows dendritic melanocytes in dermis; consider metabolic workup if extensive, dark, progressive, or associated with other abnormalities	No treatment needed; reassure parents; lesions typically fade spontaneously; laser therapy (Q-switched alexandrite or ruby laser) for cosmetic concerns if persistent	N	https://www.uptodate.com/contents/dermal-melanocytosis																
Congenital Melanocytic Nevus	Brown to black pigmented lesion present at birth; may have hypertrichosis; "bathing trunk" distribution for giant lesions	Postzygotic somatic mutations in mitogen-activated protein kinase pathway (most commonly NRAS); proliferation of melanocytes in dermis and epidermis during embryonic development	Occurs in 1-2% of newborns; no gender or racial predilection; giant congenital melanocytic nevi (greater than 20 centimeters projected adult size) rare (1 in 20,000-500,000 births)	Brown to black macule, papule, plaque, or nodule with irregular borders; may have hypertrichosis, surface irregularity, or nodularity; size ranges from small (less than 1.5 centimeters) to giant (greater than 20 centimeters projected adult size)	Present at birth or appears within first few weeks of life; grows proportionally with child; darkens and becomes more raised over time; hair growth increases with age	Café-au-lait macule, nevus spilus, Becker nevus, acquired melanocytic nevus, melanoma	Clinical diagnosis; dermoscopy shows pigment network, globules, structureless areas; biopsy if concern for malignant transformation showing melanocytes in dermis extending to deep reticular dermis or subcutis; magnetic resonance imaging of brain and spine if giant congenital melanocytic nevus to evaluate for neurocutaneous melanosis	Small to medium: observation with serial photography and dermoscopy; excision for cosmetic concerns or atypical features; Giant: staged excision, tissue expansion, or observation; laser therapy not recommended due to inability to monitor for melanoma	Y	https://www.uptodate.com/contents/congenital-melanocytic-nevi																
Coxsackieviruses and Echoviruses	Child with hand, foot, and mouth disease or aseptic meningitis in summer/fall	Small non-enveloped RNA viruses in Picornaviridae family causing vasculopathy and tissue-specific damage via receptor-mediated entry (SCARB2, CAR, CD55, sialic acid)	Most common in neonates, infants, and young children; seasonal peaks in summer and fall; coxsackievirus A6 and echovirus 30 most frequently reported	Mild: respiratory infections, herpangina, hand-foot-mouth disease. Severe: aseptic meningitis, encephalitis, myocarditis, acute flaccid paralysis, neonatal sepsis	Incubation 3-6 days; most infections self-limited within 1-2 weeks; severe complications can develop rapidly in neonates	Herpes simplex virus, bacterial meningitis, other viral exanthems, Kawasaki disease	Clinical diagnosis for mild cases; PCR from cerebrospinal fluid, stool, or respiratory specimens for severe cases; viral culture; serotype identification when available	Supportive care for most cases; intravenous immunoglobulin for severe myocarditis or neonatal sepsis; no specific antiviral therapy available	Y	https://www.cdc.gov/non-polio-enterovirus/																
Cutaneous Metastases	Firm painless dermal nodule in patient with known malignancy	Hematogenous or lymphatic spread of neoplastic cells from primary cancer to skin; histopathology often mimics primary tumor	Affects 0.7-10.4% of patients with internal malignancies; women: breast, melanoma, ovarian most common; men: melanoma, lung, colon, head and neck squamous cell carcinoma most common	Firm, painless, flesh-colored to erythematous dermal nodules or tumors; may present as inflammatory, cicatricial, or bullous lesions; can mimic lipomas, hemangiomas, cellulitis	Can be synchronous (at time of primary diagnosis) or metachronous (after treatment); 30% diagnosed before primary cancer identified	Benign skin tumors (lipoma, hemangioma), primary skin malignancy, cellulitis, other inflammatory dermatoses	Skin biopsy with histopathologic examination; immunohistochemistry to identify primary source; dermoscopy may aid initial assessment	Excision, chemotherapy, immunotherapy, radiation therapy, or palliative care depending on extent of disease and primary malignancy	Y	https://www.uptodate.com/contents/cutaneous-metastases																
Cutaneous Systemic Scleroderma	Woman with Raynaud phenomenon, puffy fingers, and skin thickening starting distally	Vasculopathy, immune dysregulation, and progressive fibrosis on permissive genetic background; excessive collagen deposition in skin and organs	Rare disease; female predominance; peak onset 30-50 years; autoantibody profiles predict organ involvement and disease course	Early: Raynaud phenomenon, puffy fingers, fatigue. Progressive: skin thickening starting distally, joint contractures, tight hidebound skin, cutaneous calcinosis (25%); systemic features include interstitial lung disease, pulmonary hypertension, renal crisis	Progressive over months to years; skin can become atrophic after years; early diagnosis critical for disease-modifying treatment	Localized scleroderma (morphea), eosinophilic fasciitis, nephrogenic systemic fibrosis, scleromyxedema, graft-versus-host disease	Clinical diagnosis with modified Rodnan Skin Score; antinuclear antibodies; systemic sclerosis-specific antibodies (anti-centromere, anti-Scl-70, anti-RNA polymerase III); nailfold capillaroscopy showing scleroderma pattern; skin biopsy if uncertain	Immunosuppression (methotrexate, mycophenolate); vasodilators for Raynaud; organ-specific therapies; early treatment improves outcomes	N	https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-systemic-sclerosis-scleroderma-in-adults																
Cutaneous T-cell lymphoma	Elderly patient with chronic pruritic patches and plaques unresponsive to topical steroids	Clonal proliferation of malignant T lymphocytes in skin; mycosis fungoides most common subtype; pathogenesis involves immune dysregulation and loss of tumor suppressor function	Rare; median age 55-60 years; male predominance; mycosis fungoides accounts for approximately 50% of primary cutaneous lymphomas	Mycosis fungoides: erythematous patches, plaques, tumors in sun-protected areas; intense pruritus. Sezary syndrome: erythroderma, lymphadenopathy, circulating atypical lymphocytes. CD30-positive disorders: papules, nodules with spontaneous regression	Indolent course over years to decades for mycosis fungoides; can progress from patches to plaques to tumors; Sezary syndrome more aggressive	Eczema, psoriasis, drug eruption, other inflammatory dermatoses, benign lymphoid infiltrates	Skin biopsy with histopathology; immunophenotyping (CD3, CD4, CD8, CD30); T-cell receptor gene rearrangement studies; flow cytometry of peripheral blood if Sezary suspected; imaging for staging	Skin-directed therapies (topical steroids, phototherapy, radiation) for early stage; systemic therapies (retinoids, interferon, chemotherapy, targeted agents) for advanced disease	N	https://www.cancer.gov/types/lymphoma/hp/mycosis-fungoides-treatment-pdq																
Cutis Marmorata	Newborn with reticular bluish rash that disappears with warming	Physiologic dilation of capillaries and venules in response to cold temperature; reflects immaturity of vascular system	Common in newborns, especially in first weeks of life; resolves by 4-6 months of age	Symmetrical reticular, lacy, bluish rash on trunk and extremities; completely resolves with warming; no skin atrophy or ulceration	Transient; appears with cold exposure; disappears with warming; resolves spontaneously by 4-6 months	Cutis marmorata telangiectatica congenita, livedo reticularis, neonatal lupus	Clinical diagnosis; no testing required; if persistent, unilateral, or associated with skin atrophy, consider alternative diagnosis	Reassurance; no treatment needed; keep infant warm	N	https://www.aafp.org/pubs/afp/issues/2024/0300/newborn-skin-part-1.html																
Cutis Marmorata Telangiectatica Congenita	Newborn with persistent reticular violaceous skin lesions that do not completely resolve with warming	Congenital vascular anomaly with persistent dilation of capillaries and venules; exact pathogenesis unknown; may involve hemihypoplasia in classic form	Rare; affects approximately 57.5% as isolated form; 300-500 cases reported in literature	Irregular, marbled, net-like, reddish-to-violaceous flat skin lesions that persist despite warming; may have skin atrophy or ulceration; classic form includes hemihypoplasia and possible glaucoma	Congenital; present at birth; lesions may improve over time but do not acutely resolve with warming	Physiologic cutis marmorata, Klippel-Trenaunay syndrome, neonatal lupus, diffuse capillary malformation with undergrowth	Clinical diagnosis based on persistent lesions that do not completely resolve with warming; skin biopsy rarely needed; ophthalmologic examination if classic form suspected	Observation for isolated form; treatment of associated complications (glaucoma screening, limb length discrepancy management); laser therapy for cosmetic concerns	N	https://www.ncbi.nlm.nih.gov/books/NBK581081/																
Cyanosis	Patient with bluish discoloration of lips and nail beds	Central: inadequate oxygenation of blood (cardiac or pulmonary pathology, methemoglobinemia). Peripheral: increased oxygen extraction in tissues (low cardiac output, vasoconstriction, venous obstruction)	Common clinical finding; central cyanosis suggests serious cardiopulmonary disease; peripheral cyanosis may be benign or pathologic	Central: bluish discoloration of tongue, lips, mucous membranes. Peripheral: bluish discoloration of extremities, nail beds. Visible when deoxygenated hemoglobin exceeds 5 grams per deciliter	Acute onset suggests pulmonary embolism, pneumothorax, acute heart failure; chronic suggests congenital heart disease, chronic lung disease	Acrocyanosis (benign), Raynaud phenomenon, polycythemia, abnormal hemoglobins	Pulse oximetry; arterial blood gas; chest radiograph; echocardiography; methemoglobin level if suspected; complete blood count	Supplemental oxygen for hypoxemia; treat underlying cause (cardiac disease, pulmonary disease, methemoglobinemia with methylene blue)	Y	https://www.uptodate.com/contents/cyanosis-in-children																
Dermatitis Herpetiformis	Patient with celiac disease presenting with intensely pruritic vesicles on elbows, knees, and buttocks	Autoimmune response to gluten in genetically susceptible individuals (HLA-DQ2 or DQ8); IgA autoantibodies against epidermal transglutaminase 3 deposit in papillary dermis forming immune complexes	Mean age at onset approximately 50 years; slightly more common in males; affects gluten-sensitive individuals; incidence decreasing while celiac disease incidence increasing	Intensely pruritic, symmetrical, grouped (herpetiform) vesicles and papules on extensor surfaces (elbows, knees), buttocks, sacral region, and scalp; most patients have villous atrophy on small bowel biopsy though gastrointestinal symptoms are rare	Chronic condition; rash improves slowly (mean 2 years) on gluten-free diet; dapsone provides rapid symptom control	Bullous pemphigoid, linear IgA disease, scabies, eczema, contact dermatitis	Direct immunofluorescence of perilesional skin showing granular IgA deposits in papillary dermis (pathognomonic); serum tissue transglutaminase antibodies supportive but not required; small bowel biopsy shows villous atrophy or celiac-type inflammation	Strict lifelong gluten-free diet (including uncontaminated oats); dapsone for rapid control of rash and itching at onset (can be stopped after mean 2 years once diet takes effect); topical clobetasol for adjunctive symptom relief	N	https://www.uptodate.com/contents/dermatitis-herpetiformis																
Dermatofibroma	Firm, fixed dermal nodule on lower extremity that dimples with lateral compression	Benign fibrous proliferation of dermal fibroblasts and histiocytes; exact etiology unknown; may develop after minor trauma or insect bites	Common; more frequent in women; typically occurs in young to middle-aged adults	Firm, fixed, dome-shaped papule or nodule (usually less than 1 cm); brown, red, or skin-colored; most commonly on lower extremities; positive dimple sign (lateral compression causes central depression); usually asymptomatic but may be tender or pruritic	Slow-growing; persists indefinitely; does not spontaneously resolve	Melanoma, basal cell carcinoma, nevus, keloid, lipoma, epidermoid cyst	Clinical diagnosis based on appearance and dimple sign; dermoscopy shows peripheral pigment network; skin biopsy if diagnosis uncertain or to exclude melanoma	Observation for asymptomatic lesions; surgical excision if symptomatic, cosmetically concerning, or diagnosis uncertain; cryotherapy alternative but higher recurrence rate	N	https://www.aafp.org/pubs/afp/issues/2003/0215/p729.html																
Dermatomyositis	Patient with proximal muscle weakness, heliotrope rash, and Gottron papules	Autoimmune-mediated inflammation of muscle and skin; complement-mediated microangiopathy; associated with myositis-specific autoantibodies; increased risk of underlying malignancy (especially in adults over 40 years)	Bimodal age distribution: children (5-15 years) and adults (40-60 years); female predominance (2:1); incidence approximately 1-10 per million	Proximal symmetric muscle weakness; characteristic skin findings include heliotrope rash (violaceous periorbital edema), Gottron papules (erythematous papules over knuckles), Gottron sign (erythema over extensor surfaces), shawl sign, V-sign; dysphagia; respiratory muscle weakness; interstitial lung disease	Subacute onset over weeks to months; progressive without treatment; skin manifestations may precede, follow, or occur simultaneously with muscle weakness	Polymyositis, systemic lupus erythematosus, mixed connective tissue disease, inclusion body myositis, drug-induced myopathy, hypothyroidism	Elevated creatine kinase and aldolase; myositis-specific autoantibodies (anti-Jo-1, anti-Mi-2); electromyography showing myopathic changes; muscle biopsy showing perifascicular atrophy; MRI showing muscle edema; malignancy screening in adults	Systemic corticosteroids (first-line); steroid-sparing agents (methotrexate, azathioprine, mycophenolate); intravenous immunoglobulin for refractory cases; physical therapy; sun protection for skin manifestations	Y	https://www.uptodate.com/contents/clinical-manifestations-of-dermatomyositis-and-polymyositis-in-adults																
Dermatophytosis	Pruritic annular scaly plaque with central clearing and raised border	Superficial fungal infection of keratinized tissues (skin, hair, nails) caused by dermatophyte fungi (Trichophyton, Microsporum, Epidermophyton species); transmission via direct contact or fomites	Common worldwide; affects all ages; tinea pedis most common form in adults; tinea capitis most common in children; increased risk with warm humid environments, occlusive footwear, immunosuppression	Varies by location: tinea corporis (annular plaques with peripheral scaling and central clearing on trunk/extremities); tinea pedis (interdigital maceration, scaling on soles); tinea cruris (groin involvement sparing scrotum); tinea capitis (patchy alopecia, scaling); tinea unguium (onychomycosis with nail thickening, discoloration)	Gradual onset; chronic and progressive without treatment; may spread to other body sites or contacts	Eczema, psoriasis, pityriasis rosea, erythrasma, candidiasis, contact dermatitis, seborrheic dermatitis	Clinical diagnosis for typical presentations; potassium hydroxide preparation of skin scrapings showing hyphae; fungal culture for confirmation and speciation; dermoscopy may aid diagnosis	Topical antifungals (terbinafine, azoles) for localized skin infections; oral antifungals (terbinafine, itraconazole, fluconazole) for extensive disease, scalp involvement, or nail infections; griseofulvin alternative for tinea capitis in children	N	https://www.aafp.org/pubs/afp/issues/2003/0101/p101.html																
Dermatosis Papulosa Nigra	Asymptomatic hyperpigmented facial papules in patient with skin of color	Benign variant of seborrheic keratosis; exact pathogenesis unknown; genetic predisposition; may be related to sun exposure and aging	Affects approximately 33% of individuals with skin of color; onset typically in adolescence; increases in number and size with age; strong familial tendency; more common in Black individuals	Multiple small (1-5 mm), smooth, hyperpigmented, filiform or sessile papules; most commonly on face (especially malar regions, forehead, periorbital areas) and neck; asymptomatic; cosmetic concern for some patients	Onset in adolescence; gradually increases in number and size throughout adulthood; does not spontaneously resolve	Seborrheic keratosis, skin tags (acrochordons), melanocytic nevi, syringomas, flat warts	Clinical diagnosis based on characteristic appearance and distribution; biopsy rarely needed but shows features of seborrheic keratosis if performed	Treatment optional (cosmetic indication only); options include scissor excision, light electrodesiccation, cryotherapy (risk of hypopigmentation), curettage, laser therapy; observation acceptable	N	https://www.aafp.org/pubs/afp/issues/2023/0100/p26.html																
Diabetic Bullae	Patient with long-standing diabetes presenting with painless tense bullae on lower extremities	Exact mechanism unknown; proposed theories include microangiopathy, altered collagen metabolism, and increased skin fragility from chronic hyperglycemia; non-inflammatory subepidermal or intraepidermal blister formation	Rare; affects less than 0.5% of diabetic patients; more common in males with long-standing diabetes (typically over 10 years); associated with diabetic neuropathy and nephropathy	Sudden onset of painless, tense, clear fluid-filled bullae on acral surfaces (feet, lower legs, hands); typically bilateral; no surrounding erythema; heal without scarring	Spontaneous onset; heal within 2-6 weeks without treatment; may recur	Bullous pemphigoid, epidermolysis bullosa acquisita, porphyria cutanea tarda, bullous drug eruption, friction blisters	Clinical diagnosis in diabetic patient; skin biopsy if diagnosis uncertain shows subepidermal or intraepidermal split without inflammation; direct immunofluorescence negative	Supportive care; protect bullae from rupture; sterile drainage if large; wound care if ruptured; optimize glycemic control; typically heal spontaneously	N	https://www.aafp.org/pubs/afp/issues/2015/0901/p427.html																
Diabetic Ulcers	Patient with diabetes presenting with painless foot ulcer over pressure point	Multifactorial: peripheral neuropathy (loss of protective sensation), peripheral arterial disease (impaired perfusion), repetitive trauma, impaired wound healing from hyperglycemia, and increased infection susceptibility	Affects 15-25% of diabetic patients during lifetime; leading cause of non-traumatic lower extremity amputation; risk increases with duration of diabetes, poor glycemic control, peripheral neuropathy, and peripheral arterial disease	Painless ulcer (due to neuropathy) typically on plantar surface over metatarsal heads or other pressure points; surrounding callus; may have purulent drainage if infected; diminished or absent pedal pulses if arterial disease present	Chronic; slow to heal; high recurrence rate (40% within 1 year, 65% within 5 years)	Venous ulcers, arterial ulcers, pressure ulcers, vasculitic ulcers, pyoderma gangrenosum, malignancy	Clinical examination; monofilament testing for neuropathy; ankle-brachial index for arterial disease; probe-to-bone test for osteomyelitis; wound culture if infection suspected; radiographs or MRI if osteomyelitis suspected	Offloading with total contact cast or specialized footwear; debridement of necrotic tissue and callus; infection control with antibiotics if indicated; revascularization if arterial insufficiency; glycemic control; advanced therapies (growth factors, bioengineered skin) for refractory ulcers	Y	https://www.uptodate.com/contents/evaluation-and-management-of-diabetic-foot-ulcers																
Discoid Lupus Erythematosus	Patient with well-demarcated erythematous scaly plaques on sun-exposed areas that heal with scarring and hypopigmentation	Autoimmune disease with T-cell and B-cell activation; photosensitivity triggers inflammation; immune complex deposition and complement activation in skin; genetic predisposition (HLA-DR2, HLA-DR3)	More common in women (female to male ratio 2-3:1); peak onset 20-40 years; more common and severe in Black individuals; 5-10% of patients with systemic lupus erythematosus have discoid lesions; only 5-10% of isolated discoid lupus progresses to systemic disease	Well-demarcated, coin-shaped (discoid), erythematous plaques with adherent scale (carpet tack sign when removed); follicular plugging; central atrophy, scarring, and dyspigmentation; permanent alopecia if scalp involved; typically on face (malar areas, ears), scalp, and sun-exposed areas	Chronic and progressive without treatment; individual lesions evolve over months; scarring is permanent	Psoriasis, seborrheic dermatitis, tinea faciei, polymorphous light eruption, cutaneous sarcoidosis, cutaneous T-cell lymphoma	Skin biopsy showing interface dermatitis with basement membrane thickening; direct immunofluorescence showing lupus band test (granular IgG and C3 at dermal-epidermal junction); antinuclear antibodies and extractable nuclear antigens to assess for systemic disease	Sun protection (broad-spectrum sunscreen, protective clothing); topical corticosteroids; topical calcineurin inhibitors; intralesional corticosteroids for thick plaques; antimalarials (hydroxychloroquine, chloroquine) for widespread or refractory disease; systemic immunosuppressants for severe cases	N	https://www.uptodate.com/contents/cutaneous-lupus-erythematosus-diagnosis-and-treatment																
Drug Reaction with Eosinophilia and Systemic Symptoms	Patient on anticonvulsant, allopurinol, or antibiotic presenting 2-6 weeks after drug initiation with fever, facial edema, rash, and eosinophilia	Delayed type IV hypersensitivity reaction; complex interplay between drug, viral reactivation (especially HHV-6, EBV, CMV), and immune system; T-cell mediated; genetic predisposition with certain HLA alleles	Incidence 2-5 cases per million per year; mortality 5-10%; most common culprits: aromatic anticonvulsants (carbamazepine, phenytoin, lamotrigine), allopurinol, sulfonamides, minocycline, dapsone	Triad: morbilliform or exfoliative rash, fever, and internal organ involvement (hepatitis most common, also nephritis, pneumonitis, myocarditis); facial edema; lymphadenopathy; eosinophilia (not always present); atypical lymphocytosis	Latency 2-6 weeks (longer than other drug reactions); prolonged course with relapsing-remitting pattern over weeks to months even after drug discontinuation; slow taper of treatment needed	Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, viral exanthem, hemophagocytic lymphohistiocytosis, angioimmunoblastic T-cell lymphoma	Clinical diagnosis using RegiSCAR criteria; complete blood count with differential (eosinophilia, atypical lymphocytes); comprehensive metabolic panel (elevated transaminases, creatinine); skin biopsy (interface dermatitis with eosinophils); viral studies if indicated	Immediate discontinuation of culprit drug; systemic corticosteroids (first-line: prednisone 0.5-1 milligrams per kilogram per day with slow taper over months); supportive care; monitor organ function; consider antivirals if robust viral replication; steroid-sparing agents or biologics for refractory cases	Y	https://www.uptodate.com/contents/drug-reaction-with-eosinophilia-and-systemic-symptoms-dress																
Drug Exanthems	Patient with new medication presenting 1-2 weeks later with symmetric pink maculopapular rash starting on trunk	Type IV delayed hypersensitivity reaction; T-cell mediated; drug or metabolite acts as hapten or directly activates T-cells via pharmacologic interaction; cytokine and chemokine release causes inflammation	Most common cutaneous drug reaction (greater than 80% of drug rashes); common culprits: penicillins, cephalosporins, sulfonamides, anticonvulsants, allopurinol; incidence up to 100 per 1000 new users for high-risk drugs	Symmetric, widespread, pink-to-red macules and papules that may coalesce; starts on trunk and spreads to extremities; pruritus common; mucous membranes usually spared; no systemic symptoms; no blistering	Onset 7-14 days after drug initiation (sooner with reexposure); resolves within 1-2 weeks after drug discontinuation	Viral exanthem, drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, scarlet fever, secondary syphilis	Clinical diagnosis; skin biopsy if diagnosis uncertain shows perivascular lymphocytic infiltrate; no eosinophilia or organ involvement distinguishes from drug reaction with eosinophilia and systemic symptoms	Discontinue suspected drug; antihistamines for pruritus; topical corticosteroids for symptomatic relief; observation; typically self-limited	N	https://www.aafp.org/pubs/afp/issues/2003/0715/p221.html																
Drug-Induced Hyperpigmentation	Patient on chemotherapy, antimalarial, or minocycline with new areas of skin darkening	Multiple mechanisms depending on drug: increased melanin synthesis, melanin deposition in dermis, drug or metabolite deposition in skin (blue-gray discoloration), post-inflammatory hyperpigmentation	Common; affects up to 10-20% of patients on certain medications; common culprits: antimalarials (hydroxychloroquine), chemotherapy (bleomycin, busulfan, cyclophosphamide), minocycline, amiodarone, heavy metals	Varies by drug: diffuse hyperpigmentation, localized pigmentation, blue-gray discoloration, flagellate hyperpigmentation (bleomycin), pigmentation in sun-exposed areas or mucous membranes	Gradual onset over weeks to months of drug exposure; may persist for months to years after drug discontinuation; some cases permanent	Addison disease, hemochromatosis, melasma, post-inflammatory hyperpigmentation, primary skin disorders	Clinical history of medication use; skin biopsy if diagnosis uncertain shows increased melanin or drug deposition; rule out systemic causes if no clear drug culprit	Discontinue offending drug if possible; sun protection; topical depigmenting agents (hydroquinone, tretinoin, kojic acid) with limited efficacy; laser therapy for refractory cases; often slow or incomplete resolution	N	https://www.aafp.org/pubs/afp/issues/2007/0915/p851.html																
Drug-Induced Hypopigmentation	Patient on topical corticosteroid or chemotherapy with new areas of skin lightening	Multiple mechanisms: inhibition of melanocyte function, melanocyte destruction, interference with melanin synthesis; topical corticosteroids cause vasoconstriction and melanocyte suppression	Less common than drug-induced hyperpigmentation; common culprits: topical corticosteroids (especially potent formulations), chemotherapy (imatinib, hydroxychloroquine), intralesional corticosteroids	Localized or diffuse areas of decreased pigmentation; may be patchy or confluent; topical corticosteroids cause localized hypopigmentation at application sites; chemotherapy may cause diffuse hypopigmentation	Gradual onset over weeks to months; may be reversible after drug discontinuation but can take months to years; some cases permanent	Vitiligo, pityriasis alba, tinea versicolor, post-inflammatory hypopigmentation, idiopathic guttate hypomelanosis	Clinical history of medication use; Wood lamp examination to accentuate hypopigmentation; skin biopsy if diagnosis uncertain shows decreased melanin	Discontinue offending drug if possible; observation for spontaneous repigmentation; camouflage cosmetics; phototherapy may help stimulate repigmentation; avoid potent topical corticosteroids on face and intertriginous areas	N	https://www.ncbi.nlm.nih.gov/books/NBK430862/																
Dyshidrotic Dermatitis	Patient with recurrent pruritic vesicles on palms, soles, and lateral fingers	Exact pathogenesis unknown; not related to sweat gland dysfunction despite name; proposed mechanisms include atopy, contact allergens, stress, seasonal variation, nickel sensitivity, fungal infection elsewhere	Common; affects 5-20% of hand dermatitis cases; peak incidence 20-40 years; slight female predominance; associated with atopic dermatitis in 50% of cases	Intensely pruritic, deep-seated, clear vesicles on palms, soles, and lateral aspects of fingers; symmetric distribution; vesicles may coalesce into bullae; desquamation and fissuring as lesions resolve; no erythema initially	Acute flares last 2-3 weeks; chronic relapsing course with seasonal variation (worse in spring and summer); may have periods of remission	Contact dermatitis, palmoplantar pustulosis, tinea manuum/pedis, bullous pemphigoid, pompholyx, id reaction	Clinical diagnosis; potassium hydroxide preparation to exclude fungal infection; patch testing if contact allergen suspected; skin biopsy if diagnosis uncertain shows spongiotic dermatitis	High-potency topical corticosteroids; topical calcineurin inhibitors; antihistamines for pruritus; phototherapy for severe cases; systemic corticosteroids for acute severe flares; botulinum toxin for refractory cases; identify and avoid triggers	N	https://www.aafp.org/pubs/afp/issues/2020/0601/p649.html																
Eosinophilic Granulomatosis with Polyangiitis	Patient with asthma, eosinophilia, and mononeuritis multiplex; "Churg-Strauss syndrome"	Small-vessel vasculitis with tissue eosinophilia and granulomatous inflammation; two phenotypes: ANCA-positive (vasculitic manifestations) and ANCA-negative (eosinophilic manifestations); interplay between T cells, B cells, and eosinophils	Rare; incidence 2-5 per million per year; peak onset 40-60 years; slight male predominance; mortality 5-10%	Asthma (nearly universal); blood eosinophilia (greater than 1000 cells per microliter if untreated, greater than 500 if treated); mononeuritis multiplex; palpable purpura; nasal polyposis; lung infiltrates; cardiomyopathy; pericarditis; glomerulonephritis; gastrointestinal involvement	Prodromal phase (asthma, rhinosinusitis) for years; eosinophilic phase (tissue infiltration); vasculitic phase (systemic manifestations); chronic relapsing course	Hypereosinophilic syndrome, other ANCA-associated vasculitides, parasitic infections, drug-induced eosinophilia, eosinophilic pneumonia	Blood eosinophil count; ANCA testing (anti-myeloperoxidase positive in 30-40%); tissue biopsy showing eosinophilic infiltration and vasculitis; chest imaging; cardiac evaluation; nerve conduction studies	Systemic corticosteroids (first-line); cyclophosphamide or rituximab for severe organ-threatening disease; mepolizumab (anti-IL-5) for relapsing or refractory disease; maintenance immunosuppression with azathioprine or methotrexate	Y	https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis																
Ehrlichiosis	Patient from southeastern United States with fever, headache, and thrombocytopenia after tick exposure; "spotless Rocky Mountain spotted fever"	Obligate intracellular bacteria (Ehrlichia chaffeensis, ewingii, muris eauclairensis) transmitted by Amblyomma americanum (lone star tick); infects monocytes forming morulae; causes systemic inflammatory response	Southeastern and south-central United States (Oklahoma, Missouri, Arkansas account for 35% of cases); incubation 5-14 days; all ages affected; increased risk in immunocompromised	Fever, chills, headache, malaise, myalgia; gastrointestinal symptoms (nausea, vomiting, diarrhea); altered mental status; rash (more common in children, less than 30% overall); thrombocytopenia, leukopenia, anemia, elevated transaminases	Incubation 5-14 days; acute illness lasting 1-2 weeks; can progress to severe disease with multiorgan failure if untreated	Anaplasmosis, Rocky Mountain spotted fever, viral syndrome, other tick-borne diseases, sepsis	PCR of whole blood (most sensitive in first week); indirect immunofluorescence assay showing fourfold rise in IgG antibodies between acute and convalescent sera; peripheral blood smear may show morulae in monocytes; immunohistochemistry of tissue biopsy	Doxycycline 100 milligrams twice daily for adults or 2.2 milligrams per kilogram twice daily for children; treat for at least 3 days after fever subsides and symptoms improve, minimum 5-7 days; start empirically on clinical suspicion	Y	https://www.cdc.gov/ehrlichiosis/																
Ephelides	Child with light skin and red hair presenting with small brown macules on sun-exposed areas; "freckles"	Increased melanin production in melanocytes without increase in melanocyte number; triggered by ultraviolet radiation exposure; genetic predisposition associated with MC1R gene variants	Common in fair-skinned individuals; onset in childhood; more prevalent in those with red or blonde hair, blue or green eyes; Fitzpatrick skin types I-II	Multiple small (1-2 millimeters), light-to-dark brown macules on sun-exposed areas (face, shoulders, arms); darken with sun exposure; fade in winter; no textural change	Appear in early childhood; darken and increase in number with sun exposure; fade with reduced sun exposure; persist throughout life	Solar lentigines, café-au-lait macules, melanocytic nevi, lentigo simplex	Clinical diagnosis based on appearance and distribution; dermoscopy shows homogeneous pigmentation; no biopsy needed	Sun protection (broad-spectrum sunscreen, protective clothing, sun avoidance); cosmetic treatments (laser therapy, chemical peels, topical lightening agents) if desired; no medical necessity for treatment	N	https://www.aafp.org/pubs/afp/issues/2015/0901/p427.html																
Epidermal Cyst	Patient with firm, mobile, skin-colored nodule with central punctum on face, neck, or trunk; "sebaceous cyst" (misnomer)	Benign cyst lined by stratified squamous epithelium; accumulation of keratin material within dermis; may result from follicular occlusion or traumatic implantation of epidermis	Most common cutaneous cyst; affects all ages; slight male predominance; can occur anywhere but most common on face, neck, trunk	Firm, mobile, discrete subcutaneous nodule with central punctum (dilated pore); skin-colored to yellow; usually asymptomatic; may become inflamed, infected, or spontaneously rupture with foul-smelling discharge	Slow-growing over months to years; may remain stable indefinitely; can become acutely inflamed or infected	Pilar cyst, lipoma, dermoid cyst, abscess, inflamed hair follicle	Clinical diagnosis based on appearance and palpation of central punctum; ultrasound if diagnosis uncertain; histopathology after excision shows cyst wall of stratified squamous epithelium with keratin contents	Observation if asymptomatic; intralesional corticosteroid injection for inflamed cysts; incision and drainage for infected cysts; complete surgical excision with cyst wall removal for definitive treatment and to prevent recurrence	N	https://www.aafp.org/pubs/afp/issues/2024/1000/p353.html																
Epidermolysis Bullosa	Newborn or infant with skin fragility and blister formation after minimal trauma; "butterfly child"	Inherited mechanobullous disorder; mutations in genes encoding structural proteins of skin (keratins, collagen, laminin, integrin); four major types based on level of skin cleavage: simplex (intraepidermal), junctional (lamina lucida), dystrophic (sublamina densa), Kindler (mixed)	Rare; incidence approximately 20 per million live births; all ethnic groups affected; inheritance patterns vary (autosomal dominant or recessive depending on subtype)	Skin fragility with blister formation after minor trauma; mucosal involvement; nail dystrophy; scarring and milia formation (dystrophic types); extracutaneous manifestations (esophageal strictures, corneal erosions, anemia); severity varies by subtype	Congenital or early infancy onset; chronic lifelong condition; dystrophic forms associated with progressive scarring, pseudosyndactyly, and increased squamous cell carcinoma risk	Bullous pemphigoid, porphyria cutanea tarda, bullous impetigo, child abuse	Skin biopsy with immunofluorescence mapping and electron microscopy to determine level of cleavage; genetic testing to identify specific mutation; prenatal diagnosis available for at-risk families	Wound care (non-adherent dressings, infection prevention); pain management; nutritional support; multidisciplinary care; gene therapy and protein replacement therapies under investigation; surveillance for squamous cell carcinoma in dystrophic types	Y	https://www.uptodate.com/contents/epidermolysis-bullosa-pathogenesis-clinical-features-and-diagnosis																
Erysipelas	Patient with well-demarcated, raised, bright red, warm plaque on lower leg or face with fever; "St. Anthony's fire"	Superficial bacterial infection of upper dermis and superficial lymphatics; usually caused by beta-hemolytic streptococci (primarily group A Streptococcus); involves lymphatic vessels	Common; affects all ages; slight female predominance; lower extremity most common site (76%), followed by face (17%); predisposing factors include lymphedema, venous insufficiency, obesity, diabetes	Well-demarcated, raised, bright red, warm, tender plaque with sharp borders; often on lower leg or face; fever in 25% of cases; regional lymphadenopathy; possible entry portal (tinea pedis, trauma, ulcer) in 62% of cases; elevated erythrocyte sedimentation rate	Acute onset; symptoms develop over hours to days; responds to antibiotics within 24-48 hours; recurrence common (up to 30% within 3 years), especially with persistent risk factors	Cellulitis, contact dermatitis, deep vein thrombosis, necrotizing fasciitis, stasis dermatitis	Clinical diagnosis based on characteristic appearance; blood cultures usually negative; skin biopsy rarely needed; elevated inflammatory markers (erythrocyte sedimentation rate, C-reactive protein, white blood cell count)	Intravenous penicillin G (first-line); oral penicillin V or amoxicillin for mild cases; alternative: cephalosporins, macrolides if penicillin-allergic; treat for 10-14 days; address predisposing factors; prophylactic antibiotics for recurrent cases	Y	https://www.uptodate.com/contents/erysipelas																
Erythema Annulare Centrifugum	Patient with slowly expanding annular erythematous patch with trailing scale	Hypersensitivity reaction to various triggers (infections, drugs, malignancy); perivascular lymphocytic infiltrate in dermis; exact mechanism unknown	Rare; affects all ages; slight male predominance; can occur at any age but peak incidence in middle-aged adults	Slowly expanding annular or polycyclic erythematous patches and plaques with central clearing; characteristic trailing scale on inner border; typically on trunk and proximal extremities; usually asymptomatic or mildly pruritic	Chronic course over weeks to months; individual lesions expand slowly (2-5 millimeters per day); may persist for months to years; can be recurrent	Tinea corporis, urticaria, erythema migrans, granuloma annulare, subacute cutaneous lupus erythematosus	Clinical diagnosis; potassium hydroxide preparation to exclude fungal infection; skin biopsy shows tight perivascular lymphocytic infiltrate (coat-sleeve pattern); workup for underlying trigger if indicated	Identify and treat underlying cause; topical corticosteroids for symptomatic relief; typically self-limited once trigger removed	N	https://www.aafp.org/pubs/afp/issues/2018/0901/p283.html																
Erythema Migrans	Patient from endemic area with expanding red rash after tick bite; "bull's-eye rash" of Lyme disease	Immune response to Borrelia burgdorferi spirochete transmitted by Ixodes tick; local skin infection with centrifugal spread	Occurs in 70-80% of Lyme disease cases; endemic areas include northeastern, mid-Atlantic, and upper midwestern United States; peak incidence May through August; all ages affected	Expanding erythematous patch or plaque at site of tick bite; may have central clearing (classic bull's-eye in only 19% of endemic United States cases, 79% in Europe); homogeneous erythema more common; incubation 7-14 days (range 1-36 days); associated symptoms include fever, headache, myalgia, arthralgia	Incubation 7-14 days after tick bite; expands slowly over days; untreated lesions persist for weeks; resolves with antibiotic treatment	Tinea corporis, erythema annulare centrifugum, southern tick-associated rash illness, cellulitis, fixed drug eruption	Clinical diagnosis based on characteristic appearance and epidemiologic context; serologic testing usually negative in early disease (only 20% positive in first week); skin biopsy rarely needed	Doxycycline 100 milligrams twice daily for 10 days (first-line for adults and children 8 years and older); amoxicillin or cefuroxime for children under 8 years or pregnant women; prevents later manifestations of Lyme disease	Y	https://www.cdc.gov/lyme/																
Erythema Gyratum Repens	Patient with rapidly moving wood-grain pattern rash and underlying malignancy; "wood-grain rash"	Paraneoplastic phenomenon; exact mechanism unknown; likely immune-mediated response to tumor antigens; strongly associated with internal malignancy (especially lung, esophageal, breast)	Extremely rare; fewer than 100 cases reported; strong association with malignancy (80-90% of cases); mean age 60-70 years	Distinctive rapidly migrating concentric erythematous bands in wood-grain or zebra-stripe pattern; trailing scale; intense pruritus; typically on trunk and extremities; moves up to 1 centimeter per day	Rapid progression over days to weeks; resolves with treatment of underlying malignancy; may precede cancer diagnosis by months	Erythema annulare centrifugum, ichthyosis, tinea corporis, other paraneoplastic dermatoses	Skin biopsy shows nonspecific findings (spongiosis, perivascular lymphocytic infiltrate); comprehensive malignancy workup mandatory (chest imaging, endoscopy, age-appropriate cancer screening)	Treat underlying malignancy; symptomatic treatment with topical corticosteroids and antihistamines; rash typically resolves with successful cancer treatment	Y	https://www.uptodate.com/contents/cutaneous-manifestations-of-internal-malignancy																
Erythema Marginatum	Child with acute rheumatic fever presenting with evanescent pink rings on trunk; "one of Jones criteria"	Immune-mediated vasculitis following group A Streptococcus pharyngitis; part of acute rheumatic fever; immune cross-reactivity between streptococcal antigens and host tissues	Rare (less than 10% of acute rheumatic fever cases); occurs in children and adolescents; more common in moderate-risk to high-risk populations; associated with carditis	Non-pruritic, evanescent, pink-to-red maculopapular rash with serpiginous (snake-like) borders and central clearing; appears on trunk and proximal extremities; spares face, palms, and soles; blanches with pressure; comes and goes over hours	Appears during acute phase of rheumatic fever; transient and migratory; individual lesions last hours; rash may persist for weeks during acute illness	Urticaria, erythema multiforme, erythema annulare centrifugum, viral exanthem	Clinical diagnosis as part of Jones criteria for acute rheumatic fever; evidence of preceding group A Streptococcus infection (throat culture, rapid antigen test, anti-streptolysin O titer); echocardiography to assess for carditis	Treat acute rheumatic fever with penicillin or amoxicillin; anti-inflammatory therapy with aspirin or corticosteroids; secondary prophylaxis with long-term penicillin to prevent recurrence	Y	https://www.uptodate.com/contents/acute-rheumatic-fever-clinical-manifestations-and-diagnosis																
Erythema Multiforme	Patient with target lesions on hands and feet after herpes simplex virus infection or Mycoplasma pneumoniae	Immune-mediated hypersensitivity reaction; T-cell mediated response to infectious antigens (especially herpes simplex virus DNA polymerase gene) or drugs; cytotoxic T-cell attack on keratinocytes	Prevalence 0.01-1%; peak incidence young adults (20-40 years); slight female predominance; herpes simplex virus most common trigger (17.9% in children), followed by Mycoplasma pneumoniae (15.7%)	Characteristic raised target (iris) lesions with three concentric zones: central dusky area, pale edematous ring, outer erythematous ring; symmetric distribution on acral surfaces (dorsal hands, feet, extensor surfaces); may have mucosal involvement (erythema multiforme major); pruritus or burning	Acute onset; individual lesions fixed for minimum 7 days (unlike urticaria which resolves within 24 hours); self-limited course lasting 1-2 weeks; can be recurrent	Urticaria, Stevens-Johnson syndrome, fixed drug eruption, bullous pemphigoid, Sweet syndrome, vasculitis	Clinical diagnosis based on characteristic target lesions; skin biopsy shows interface dermatitis with keratinocyte necrosis; herpes simplex virus PCR if recurrent; Mycoplasma serology or PCR if suspected	Symptomatic treatment with topical corticosteroids and antihistamines; treat underlying infection if identified; prophylactic antiviral therapy (acyclovir or valacyclovir) for recurrent herpes-associated erythema multiforme; hospitalization for severe mucosal involvement	N	https://www.aafp.org/pubs/afp/issues/2019/0715/p82.html																
Erythema Nodosum	Patient with tender red nodules on shins after streptococcal infection or starting oral contraceptives	Delayed hypersensitivity reaction in subcutaneous fat; septal panniculitis without vasculitis; triggered by infections (especially streptococcal, tuberculosis), drugs (oral contraceptives, antibiotics), sarcoidosis, inflammatory bowel disease	Most common form of panniculitis; female predominance (3-6:1); peak incidence 20-30 years; idiopathic in 30-50% of cases	Tender, erythematous, warm subcutaneous nodules (1-5 centimeters); bilateral and symmetric on anterior shins (pretibial); may occur on thighs, arms; no ulceration; associated systemic symptoms (fever, malaise, arthralgia) in 50%	Acute onset over days; individual lesions evolve from bright red to violaceous to yellow-brown (like a bruise) over 2-6 weeks; self-limited; total course 3-6 weeks	Cellulitis, superficial thrombophlebitis, erythema induratum, vasculitis, panniculitis from other causes	Clinical diagnosis; skin biopsy shows septal panniculitis without vasculitis; workup for underlying cause: throat culture, anti-streptolysin O titer, chest radiograph (sarcoidosis, tuberculosis, hilar adenopathy), complete blood count, erythrocyte sedimentation rate	Treat underlying cause; supportive care with rest, leg elevation, nonsteroidal anti-inflammatory drugs; potassium iodide for refractory cases; systemic corticosteroids rarely needed	N	https://www.uptodate.com/contents/erythema-nodosum																
Erythema Toxicum Neonatorum	Healthy newborn with blotchy red rash and pustules on day 2 of life	Benign self-limited condition; exact pathogenesis unknown; likely represents normal inflammatory response to new environment; eosinophil accumulation in hair follicles	Affects 40-70% of full-term newborns; onset typically 24-48 hours after birth (range 0-14 days); more common in full-term infants; rare in premature infants	Erythematous macules, papules, and pustules on erythematous base; "flea-bitten" appearance; distribution on face, trunk, extremities; spares palms and soles; infant otherwise well-appearing	Onset 24-48 hours after birth; individual lesions transient (lasting hours to days); new lesions may appear; resolves spontaneously within 5-14 days without treatment	Transient neonatal pustular melanosis, neonatal acne, miliaria, candidiasis, herpes simplex, bacterial infection	Clinical diagnosis; Wright or Giemsa stain of pustule contents shows eosinophils (not neutrophils); no cultures needed unless infant appears ill	Reassurance; no treatment needed; self-limited and benign	N	https://www.aafp.org/pubs/afp/issues/2024/0300/newborn-skin-part-1.html																
Erythrodermic Psoriasis	Patient with known psoriasis presenting with generalized erythema and scaling covering greater than 90% of body surface area	Severe form of psoriasis with widespread inflammation; triggered by abrupt withdrawal of systemic corticosteroids, infection, stress, or medications; T-cell mediated inflammation with excessive keratinocyte proliferation	Rare; affects less than 3% of psoriasis patients; can occur at any age; may be first presentation of psoriasis or complication of existing disease	Generalized erythema and scaling involving greater than 90% of body surface area; may have areas of indurated plaques with silvery scale; systemic symptoms (fever, chills, malaise); complications include hypothermia, high-output cardiac failure, hypoalbuminemia, secondary infection	Acute or subacute onset over days to weeks; chronic course without treatment; can be life-threatening	Atopic dermatitis, contact dermatitis, cutaneous T-cell lymphoma (Sezary syndrome), pityriasis rubra pilaris, drug reaction	Clinical diagnosis based on history of psoriasis and characteristic findings; skin biopsy shows psoriasiform hyperplasia; rule out infection; monitor electrolytes, albumin, complete blood count; consider HIV testing	Hospitalization for severe cases; supportive care (fluid and electrolyte management, temperature regulation); systemic therapy with methotrexate, cyclosporine, or biologics (tumor necrosis factor inhibitors, interleukin inhibitors); avoid abrupt corticosteroid withdrawal	Y	https://www.uptodate.com/contents/erythroderma-erythrodermic-psoriasis																
Extramammary Paget Disease	Elderly patient with chronic red plaque on genitals or perianal area that was treated as eczema for months to years	Rare adenocarcinoma arising from apocrine gland-rich skin; can be primary intraepithelial or associated with underlying visceral adenocarcinoma	Rare; predominantly affects older adults; most common on vulvar and penoscrotal skin, less frequently perianal region	Slowly growing erythematous plaque on apocrine-rich areas (genitals, perianal, axillae); often pruritic; mimics inflammatory dermatoses leading to delayed diagnosis	Chronic, slowly progressive over months to years	Eczema, psoriasis, lichen sclerosus, contact dermatitis, invasive squamous cell carcinoma, melanoma	Skin biopsy with histopathology showing Paget cells (large cells with pale cytoplasm in epidermis); immunohistochemistry supportive; workup for underlying malignancy required	Surgical excision (Mohs micrographic surgery preferred for lower recurrence); evaluate for associated internal malignancy; alternatives include topical therapy for intraepidermal disease when surgery is morbid	Y	https://www.uptodate.com/contents/extramammary-paget-disease																
Fixed Drug Eruption	Patient with round hyperpigmented plaque on lips or genitals that becomes red and inflamed with same medication each time	Type IV delayed hypersensitivity reaction; CD8 T-cell mediated inflammation at fixed anatomic sites; intraepidermal T cells remain dormant and reactivate upon drug re-exposure	Common drug reaction; affects all ages; no clear gender predominance	Well-demarcated round erythematous to violaceous plaques (typically less than 8 cm) that recur at identical sites; commonly on lips, genitals, hands; may blister; leaves residual hyperpigmentation; pruritus or burning sensation	Rapid onset within 1 to 24 hours of drug exposure; resolves in days to weeks after drug discontinuation; recurs at same sites with re-exposure	Erythema multiforme, contact dermatitis, herpes simplex, other drug eruptions, generalized bullous fixed drug eruption, Stevens-Johnson syndrome	Clinical diagnosis based on history of recurrence at same site; skin biopsy shows interface dermatitis with basal vacuolization; patch testing preferred over oral challenge	Discontinue offending drug; symptomatic relief with topical corticosteroids and antihistamines for pruritus; patient education to avoid causative agent	N	https://www.uptodate.com/contents/fixed-drug-eruption																
Folate (Vitamin B9) Deficiency	Patient with macrocytic anemia, glossitis, and history of alcoholism or malnutrition	Impaired DNA synthesis due to inadequate folate for one-carbon metabolism; affects rapidly dividing cells (bone marrow, gastrointestinal epithelium); folate is essential cofactor for nucleotide synthesis and methylation reactions	Rare in countries with mandatory folic acid fortification; higher rates in safety net populations, alcoholics, malabsorption syndromes, pregnancy, certain medications (methotrexate, trimethoprim, phenytoin)	Megaloblastic anemia with macrocytosis; glossitis (smooth, beefy red tongue); angular cheilitis; gastrointestinal symptoms; neurologic symptoms less common than B12 deficiency; fatigue, pallor	Develops over weeks to months depending on dietary intake and stores	Vitamin B12 deficiency, other causes of macrocytic anemia (alcohol, liver disease, hypothyroidism, myelodysplastic syndrome), hemolysis	Low serum folate (less than 3 ng/mL); low red blood cell folate (more reliable for chronic deficiency); elevated homocysteine; normal methylmalonic acid (distinguishes from B12 deficiency); macrocytic anemia on complete blood count; hypersegmented neutrophils on peripheral smear	Oral folic acid supplementation 1 to 5 mg daily; treat underlying cause; must rule out or treat concurrent B12 deficiency before folate replacement to avoid precipitating subacute combined degeneration	N	https://www.uptodate.com/contents/causes-and-pathophysiology-of-vitamin-b12-and-folate-deficiencies																
Folliculitis	Patient with multiple small pustules centered on hair follicles after hot tub use or shaving	Inflammation of hair follicle; most commonly infectious (Staphylococcus aureus most frequent); can be superficial (limited to epidermis) or deep (extends to dermis); also caused by Gram-negative bacteria, fungi, viruses, or non-infectious (mechanical, chemical)	Common; affects all ages; increased risk with occlusion, moisture, shaving, immunosuppression	Small erythematous papules and pustules (1 mm) centered on hair follicles; pruritus common; distribution varies by cause (hot tub folliculitis on trunk, pseudofolliculitis barbae on beard area)	Acute onset over days; typically self-limited if infectious cause removed	Acne vulgaris, keratosis pilaris, miliaria, insect bites, contact dermatitis, fungal folliculitis, pseudofolliculitis barbae	Clinical diagnosis; Gram stain and culture of pustule contents if severe or recurrent; cytology can identify bacterial, fungal, viral, or parasitic causes	Remove inciting factor; mild cases often self-resolve; topical antibiotics (mupirocin) or antiseptics for bacterial; oral antibiotics (cephalexin, doxycycline) for extensive or deep infection; antifungals if fungal etiology	N	https://www.uptodate.com/contents/bacterial-folliculitis																
Furuncles	Patient with painful red nodule on neck or buttocks that drains pus spontaneously	Deep infection of hair follicle caused by Staphylococcus aureus (often methicillin-resistant Staphylococcus aureus); suppuration extends through dermis into subcutaneous tissue forming abscess; carbuncle is coalescence of multiple furuncles	Common; increased in diabetes, obesity, immunosuppression, nasal Staphylococcus aureus carriage	Painful, tender, erythematous nodule with central pustule and hair emerging; fluctuance develops; may drain spontaneously; fever if systemic involvement; carbuncles are larger, deeper, drain from multiple follicular openings	Develops over days; may rupture and drain spontaneously or require incision and drainage	Folliculitis, abscess, inflamed epidermoid cyst, hidradenitis suppurativa, carbuncle, cellulitis	Clinical diagnosis; Gram stain and culture of purulent drainage recommended for carbuncles and abscesses but treatment without studies reasonable in typical cases	Incision and drainage is primary treatment; warm compresses may promote spontaneous drainage; antibiotics (targeting methicillin-resistant Staphylococcus aureus if prevalent) indicated if systemic inflammatory response syndrome, immunocompromised, or failed drainage alone; decolonization for recurrent cases	N	https://www.uptodate.com/contents/simple-cutaneous-abscesses-and-furuncles																
Giant Cell Arteritis	Woman over 70 with new headache, jaw claudication, and vision loss; elevated erythrocyte sedimentation rate over 50	Granulomatous vasculitis of large and medium arteries, particularly cranial branches of aorta; interleukin-6 and interferon-gamma mediated inflammation via JAK-STAT pathway	Most common primary vasculitis in adults; affects almost exclusively those 50 years or older; mean age over 70; more common in women; prevalence 51 per 100,000 persons over 50	New temporal headache, scalp tenderness, jaw or tongue claudication, sudden visual loss, temporal artery abnormality on exam; often associated with polymyalgia rheumatica (shoulder and neck morning stiffness); constitutional symptoms	Subacute onset over weeks; requires urgent diagnosis to prevent irreversible vision loss	Polymyalgia rheumatica, other vasculitides, temporal arteritis mimics (dental conditions, temporomandibular disorders, migraine, trigeminal neuralgia), malignancy, infection	Elevated erythrocyte sedimentation rate (typically over 50) or C-reactive protein (over 10 mg/L); temporal artery biopsy (gold standard but imperfect sensitivity) or temporal artery ultrasound showing halo sign; vascular imaging for large vessel involvement	High-dose glucocorticoids (prednisone 40 to 60 mg daily) tapered over 1 year or more; tocilizumab (interleukin-6 receptor inhibitor) is FDA-approved glucocorticoid-sparing agent; upadacitinib (JAK-1 inhibitor) recently FDA-approved	Y	https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-giant-cell-arteritis																
Granulomatosis with Polyangiitis	Patient with bloody nasal discharge, nasal crusting, pulmonary nodules, and glomerulonephritis; positive cytoplasmic antineutrophil cytoplasmic antibody	Necrotizing granulomatous inflammation of respiratory tract and necrotizing vasculitis of small and medium vessels; associated with antineutrophil cytoplasmic antibodies (primarily anti-proteinase 3)	Rare systemic disease; part of antineutrophil cytoplasmic antibody-associated vasculitis spectrum	Upper airway: bloody nasal discharge, crusting, sinonasal congestion, cartilaginous involvement, hearing loss; Pulmonary: nodules, cavitation; Renal: pauci-immune glomerulonephritis; constitutional symptoms	Progressive over weeks to months; can present as localized, early systemic, generalized, or severe disease	Microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, polyarteritis nodosa, other small vessel vasculitides, infection, malignancy	Positive cytoplasmic antineutrophil cytoplasmic antibody or anti-proteinase 3 antibody; tissue biopsy showing granuloma or giant cells; chest imaging showing nodules or cavitation; urinalysis and renal function for glomerulonephritis	Induction: cyclophosphamide or rituximab plus glucocorticoids; Maintenance: rituximab, azathioprine, or methotrexate; severity-based approach (localized, early systemic, generalized, severe)	Y	https://www.uptodate.com/contents/granulomatosis-with-polyangiitis-and-microscopic-polyangiitis-clinical-manifestations-and-diagnosis																
Granuloma Annulare	Child or young adult with asymptomatic annular ring of skin-colored to erythematous papules on dorsal hands or feet	Granulomatous disorder of uncertain etiology; histology shows palisading granulomas, collagen degeneration, mucin, and lymphohistiocytic infiltrate	Accounts for 0.1 to 0.4 percent of dermatology visits; most common in first 3 to 5 decades of life; female to male ratio approximately 2 to 1	Localized: annular groups of skin-colored to erythematous papules without epidermal change on dorsal hands or feet; Generalized: widespread papules or plaques; Subcutaneous: deep nodules; Perforating: umbilicated papules	Localized form often self-limited within 2 years; generalized form more chronic and recalcitrant	Tinea corporis, lichen planus, necrobiosis lipoidica, sarcoidosis, annular elastolytic giant cell granuloma	Clinical diagnosis confirmed by skin biopsy showing palisading granulomas with central collagen degeneration and mucin; no routine laboratory workup needed for localized disease	Localized: observation (often self-resolves), topical or intralesional corticosteroids; Generalized: challenging, over 30 treatments described with variable results including phototherapy, systemic immunosuppressants, biologics	N	https://www.uptodate.com/contents/granuloma-annulare																
Green Nails	Patient with artificial nails or chronic water exposure presenting with green discoloration of nail plate, proximal paronychia, and distal onycholysis	Pseudomonas aeruginosa infection of nail; bacteria produce pyocyanin and pyoverdin pigments causing characteristic green color; requires moisture and disruption of nail-nail bed seal	Occurs with predisposing factors: trauma, artificial nails, chronic wet exposure, preexisting nail conditions	Triad: green discoloration of nail plate (ranging from pale to dark green), proximal paronychia, distal onycholysis; typically painless unless superinfected	Develops over days to weeks with chronic exposure; resolves with treatment over weeks	Fungal nail infection, melanonychia, subungual hematoma, chloronychia from other causes	Clinical diagnosis based on characteristic green discoloration; bacterial culture of nail confirms Pseudomonas aeruginosa but not always necessary	Remove predisposing factor (artificial nails, wet exposure); trim affected nail; topical antibiotics (gentamicin, ciprofloxacin, or polymyxin B); chemical nail avulsion with urea for extensive involvement; oral antibiotics rarely needed	N	https://www.uptodate.com/contents/bacterial-nail-infections																
Guttate Psoriasis	Child or young adult with sudden onset of small droplike scaly papules on trunk 1 to 2 weeks after streptococcal pharyngitis	Immune-mediated inflammatory skin disease; often triggered by streptococcal infection; T-cell mediated with cytokine dysregulation similar to plaque psoriasis	Accounts for approximately 2 percent of psoriasis cases; typically affects children and young adults; can be first presentation of psoriasis	Diffuse small (less than 1 cm) erythematous scaly papules and plaques distributed over trunk and proximal extremities; spares palms and soles; may have preceding upper respiratory infection	Acute onset over days to weeks, typically 1 to 2 weeks post-streptococcal infection; may resolve spontaneously or progress to chronic plaque psoriasis	Pityriasis rosea (follows skin cleavage lines, herald patch), secondary syphilis (involves palms and soles), viral exanthem, drug eruption, lichen planus	Clinical diagnosis; skin biopsy if uncertain showing psoriasiform hyperplasia, parakeratosis, neutrophils in stratum corneum; throat culture or rapid strep test if recent pharyngitis	Treat streptococcal infection if present; topical corticosteroids and vitamin D analogs; phototherapy (narrowband ultraviolet B) for extensive disease; often self-limited; systemic therapy rarely needed	N	https://www.uptodate.com/contents/psoriasis-epidemiology-clinical-manifestations-and-diagnosis																
Hemangioma	Bright red strawberry birthmark appearing in first weeks of life; grows rapidly then involutes	Aberrant vasculogenesis and angiogenesis triggered by hypoxia; proliferation of GLUT1-positive endothelial cells forming syncytial masses, later forming capillary structures, then involuting to fibrofatty tissue	Most common benign tumor of infancy; affects up to 5% of infants; more common in premature infants, females, and Caucasians	Superficial: bright red papules/plaques; Deep: bluish subcutaneous masses; may have pale precursor lesion at birth; complications include ulceration, obstruction, functional impairment	Appears in first few weeks of life; rapid proliferation in first 3 months (80% of growth by 3 months); stabilization; spontaneous involution over months to years (90% complete by age 4 years)	Port wine stain, other vascular tumors, vascular malformations, pyogenic granuloma	Clinical diagnosis; GLUT1 immunohistochemistry positive; high-frequency ultrasound may help differentiate from other lesions	Observation for uncomplicated lesions; Propranolol 2-3 mg/kg/day for 6-12 months for high-risk lesions (periorbital, airway, large facial, ulcerated); topical timolol for small superficial lesions; surgery/laser for residual changes	N	https://www.ncbi.nlm.nih.gov/books/NBK537153/																
Herpes Simplex	Painful grouped vesicles on erythematous base; primary infection with systemic symptoms; recurrent episodes milder and shorter	HSV-1 or HSV-2 infection of epithelial cells; viral replication causes cell lysis and vesicle formation; establishes latency in sensory ganglia with periodic reactivation	HSV-1: 50-80% seroprevalence by adulthood; HSV-2: 12-16% in US adults; transmitted via direct contact with lesions or asymptomatic shedding	Primary: painful grouped vesicles, fever, malaise, lymphadenopathy; Recurrent: prodrome of tingling/burning, then vesicles that crust; orolabial (HSV-1) or genital (HSV-2) distribution	Primary: 7-10 days; Recurrent: 5-10 days; prodrome may precede lesions by hours to days; recurrences variable in frequency	Aphthous ulcers, syphilis, chancroid, Behcet disease, hand-foot-mouth disease, herpangina, varicella-zoster	NAAT/PCR from lesion swab (sensitivity 96.7-100%); viral culture (sensitivity 30-70%); type-specific IgG serology (detectable 2 weeks to 3 months after infection); Tzanck smear (low sensitivity)	Primary or severe: Acyclovir 400 mg PO three times daily, Valacyclovir 1 g PO twice daily, or Famciclovir 500 mg PO twice daily for 7-10 days; Recurrent: same agents for 5-10 days; Suppressive: same agents twice daily; IV acyclovir 5 mg/kg every 8 hours for severe mucocutaneous disease	N	https://www.cdc.gov/std/treatment-guidelines/herpes.htm																
Herpes Zoster	Painful unilateral vesicular rash in dermatomal distribution; "shingles"; may have prodrome of pain before rash	Reactivation of latent varicella-zoster virus from dorsal root ganglia; viral replication in sensory nerve and spread to dermatome; inflammation and nerve damage	Lifetime risk 30%; incidence increases with age; 1 million cases annually in US; risk increased 20-100 fold in immunocompromised	Prodrome: malaise, headache, fever, abnormal skin sensations 2-3 days before rash; unilateral dermatomal maculopapular rash progressing to vesicles that crust in 7-10 days; acute pain; postherpetic neuralgia in 20%	Prodrome 2-3 days; vesicular rash 7-10 days; acute pain during rash; postherpetic neuralgia defined as pain lasting greater than 90 days after rash onset	Herpes simplex, contact dermatitis, impetigo, cellulitis	Clinical diagnosis; PCR or direct fluorescent antibody testing if atypical presentation	Antiviral therapy within 72 hours of rash onset: Valacyclovir 1 g PO three times daily for 7 days, Famciclovir 500 mg PO three times daily for 7 days, or Acyclovir 800 mg PO five times daily for 7 days; pain management with opioids, gabapentin, pregabalin, or tricyclic antidepressants; ophthalmology referral for herpes zoster ophthalmicus	Y	https://www.cdc.gov/shingles/hcp/clinical-overview.html																
HHV6/HHV7	Roseola infantum (exanthem subitum): high fever for 3 days in infant, then rash as fever breaks; "fever then feels fine"	Primary infection with HHV-6B (most common) or HHV-7; viral replication in lymphocytes and other cells; establishes latency; can reactivate in immunocompromised	HHV-6B: nearly universal infection in early childhood (peak 6-15 months); HHV-7: infection occurs slightly later (mean 26 months); transmitted via saliva	High fever (38-40 degrees Celsius) for 2-5 days; child appears well despite fever; rash appears as fever resolves: pink maculopapular on trunk/face/extremities lasting 1-3 days; febrile seizures in 10-15%; may be asymptomatic	Fever 2-5 days; rash appears on day 3-4 of illness as fever breaks; rash lasts 1-3 days; total illness 5-7 days	Other viral exanthems, measles, rubella, drug eruption, scarlet fever	Clinical diagnosis; PCR from blood for confirmation; serology (IgM/IgG seroconversion); viral culture rarely needed	Supportive care; antipyretics for fever; seizure management if needed; antivirals (ganciclovir, foscarnet) reserved for severe disease in immunocompromised (encephalitis, post-transplant)	N	https://www.ncbi.nlm.nih.gov/books/NBK448190/																
HHV8 (Kaposi sarcoma)	Violaceous/purple vascular plaques or nodules in HIV-positive patient or immunosuppressed transplant recipient; may involve skin, oral mucosa, or viscera	HHV8 (KSHV) infection of endothelial cells; viral genes promote angiogenesis, proliferation, and cytokine production; immunosuppression allows viral reactivation and tumor development; lesions are multiclonal	Endemic in sub-Saharan Africa and Mediterranean; less than 5% seroprevalence in US general population; higher in men who have sex with men; most common AIDS-associated malignancy worldwide	Violaceous to purple macules, papules, plaques, or nodules on skin (especially lower extremities), oral mucosa, gastrointestinal tract, lungs, lymph nodes; may have lymphedema, pain, bleeding, or organ dysfunction	Variable: indolent in classic form; rapidly progressive in AIDS-related form; may develop IRIS after starting antiretroviral therapy; responds over months to immune reconstitution	Bacillary angiomatosis, pyogenic granuloma, melanoma, purpura, hematoma, other vascular tumors	Biopsy with histopathology showing spindle cells and abnormal vascularity; immunohistochemistry: HHV8 LANA-1 positive, CD31 positive, CD34 positive; staging with imaging if visceral involvement suspected	Limited cutaneous: antiretroviral therapy (for HIV-associated); observation; Advanced/symptomatic: liposomal doxorubicin or paclitaxel; avoid corticosteroids (promote progression); immune checkpoint inhibitors (pembrolizumab) emerging option	Y	https://www.cancer.gov/types/soft-tissue-sarcoma/patient/kaposi-treatment-pdq																
Hidradenitis Suppurativa	Recurrent painful boils in axillae, groin, or inframammary areas; "chronic boils in skin folds"; double-ended comedones	Follicular occlusion with perifollicular lymphocytic infiltrate and sebaceous gland loss; deregulation of local immune system with increased interleukin-1, tumor necrosis factor, interleukin-17; bacterial infection is secondary to inflammation; tissue destruction releases follicular content causing spread; healing produces tunnels and scarring	Prevalence 0.05-4.1%; onset typically in adolescence and young adulthood; more common in females; associated with smoking, obesity, metabolic syndrome	Painful deep-seated inflammatory nodules, abscesses, draining tunnels in axillae, inguinal, perianal, gluteal, inframammary areas; malodorous purulent discharge; hypertrophic scars; double-ended comedones; severe pain; may have associated acne, pilonidal cysts, dissecting cellulitis of scalp	Chronic recurrent disease; lesions emerge over at least 2 episodes within 6 months or persist for at least 3 months; progressive with tunnel formation and scarring over years without treatment	Furuncle, carbuncle, abscess from bacterial infection, folliculitis, acne conglobata, pilonidal cyst, Crohn disease with cutaneous manifestations, actinomycosis	Clinical diagnosis based on typical lesions in characteristic locations with recurrent course; Hurley staging (I: no scarring, II: recurrent abscesses with tunnels and scars, III: coalescent lesions); ultrasonography or magnetic resonance imaging for extent of tunnels; culture if secondary infection suspected	Hurley I: topical clindamycin, intralesional triamcinolone, laser therapy; Hurley II: systemic antibiotics (tetracyclines, rifampin plus clindamycin), adalimumab, hormonal therapy in females, surgical deroofing; Hurley III: adalimumab, secukinumab, bimekizumab, wide surgical excision; adjuncts: smoking cessation, weight loss, pain management	N	https://www.jaad.org/article/S0190-9622(19)30309-3/fulltext																
Hirsutism	Excessive terminal hair growth in androgen-dependent areas in women; "male-pattern hair growth in women"	Increased androgen production (ovarian or adrenal) or increased peripheral conversion to androgens or increased androgen receptor sensitivity; most commonly from polycystic ovary syndrome; hair follicles convert vellus hairs to terminal hairs in androgen-sensitive areas	Affects 5-10% of women of reproductive age; varies by ethnicity with higher prevalence in Mediterranean, Middle Eastern, South Asian populations	Excessive coarse dark terminal hair in male-pattern distribution: face (upper lip, chin), chest, abdomen (linea alba), back, inner thighs; may have associated acne, androgenic alopecia, menstrual irregularities, infertility, virilization signs if severe	Gradual onset over months to years; progressive without treatment; rapid onset or virilization suggests androgen-secreting tumor	Hypertrichosis (generalized non-androgen-dependent hair growth), polycystic ovary syndrome, congenital adrenal hyperplasia, Cushing syndrome, androgen-secreting tumor, medications (danazol, anabolic steroids, valproic acid)	Modified Ferriman-Gallwey score (9 body areas scored 0-4, score greater than 8 abnormal); total and free testosterone, dehydroepiandrosterone sulfate, 17-hydroxyprogesterone; luteinizing hormone to follicle-stimulating hormone ratio; consider pelvic ultrasound, dexamethasone suppression test if indicated	Cosmetic measures: shaving, waxing, laser hair removal, electrolysis; Pharmacologic: combined oral contraceptives (first-line), spironolactone 50-200 mg daily, finasteride 2.5-5 mg daily, eflornithine cream; treat underlying cause (polycystic ovary syndrome, congenital adrenal hyperplasia, tumor)	N	https://www.aafp.org/pubs/afp/issues/2012/0715/p373.html																
Herpes Simplex Virus type 1 and type 2	Painful grouped vesicles on erythematous base; primary infection with fever and systemic symptoms; recurrent episodes milder; "cold sores" (HSV-1) or "genital herpes" (HSV-2)	HSV-1 or HSV-2 infection of epithelial cells; viral replication causes cell lysis and vesicle formation; establishes latency in sensory ganglia (trigeminal for HSV-1, sacral for HSV-2) with periodic reactivation triggered by stress, illness, ultraviolet exposure, immunosuppression	HSV-1: 50-80% seroprevalence by adulthood; HSV-2: 12-16% in United States adults; transmitted via direct contact with lesions or asymptomatic viral shedding	Primary: painful grouped vesicles on erythematous base, fever, malaise, tender lymphadenopathy, dysuria (genital); gingivostomatitis (HSV-1 primary); Recurrent: prodrome of tingling or burning, then vesicles that crust; orolabial (HSV-1) or genital (HSV-2) distribution; asymptomatic shedding occurs	Primary: 7-10 days; Recurrent: 5-10 days; prodrome may precede lesions by hours to days; recurrences variable in frequency (average 4 per year for genital HSV-2)	Aphthous ulcers, syphilis, chancroid, Behcet disease, hand-foot-mouth disease, herpangina, varicella-zoster, impetigo	Nucleic acid amplification test or polymerase chain reaction from lesion swab (sensitivity 96.7-100%); viral culture (sensitivity 30-70%); type-specific immunoglobulin G serology (detectable 2 weeks to 3 months after infection); Tzanck smear shows multinucleated giant cells (low sensitivity)	Primary or severe: Acyclovir 400 mg orally three times daily, Valacyclovir 1 gram orally twice daily, or Famciclovir 500 mg orally twice daily for 7-10 days; Recurrent: same agents for 5-10 days; Suppressive: daily therapy reduces recurrences; intravenous acyclovir 5 mg/kg every 8 hours for severe mucocutaneous or disseminated disease	N	https://www.cdc.gov/std/treatment-guidelines/herpes.htm																
Ichthyosis Vulgaris	Dry scaly skin since early childhood; "fish scale skin"; spares flexures; associated with atopic dermatitis	Autosomal dominant or semidominant inheritance; loss-of-function mutations in filaggrin gene; defective keratinization with retention hyperkeratosis; impaired skin barrier function	Most common inherited disorder of keratinization; prevalence 1 in 250; onset in early childhood (first few months to years of life)	Fine white or gray scales on extensor surfaces of extremities, trunk, scalp; accentuated skin markings on palms and soles (hyperlinear palms); keratosis pilaris on upper arms and thighs; spares flexural areas; worse in winter, improves in summer; associated with atopic dermatitis, asthma, allergic rhinitis	Onset in early childhood; lifelong condition; improves with age and in humid environments; worsens in dry cold weather	Other ichthyoses (X-linked ichthyosis, lamellar ichthyosis, epidermolytic ichthyosis), atopic dermatitis, xerosis, asteatotic eczema	Clinical diagnosis; skin biopsy shows hyperkeratosis with reduced or absent granular layer; genetic testing for filaggrin mutations available but not routinely needed	Emollients and moisturizers (petrolatum, urea-containing creams, lactic acid lotions); keratolytics (salicylic acid, alpha-hydroxy acids); humidification; avoid harsh soaps and hot water; topical retinoids for severe cases	N	https://www.ncbi.nlm.nih.gov/books/NBK546574/																
Immunoglobulin A Vasculitis	Palpable purpura on lower extremities and buttocks in child after upper respiratory infection; "Henoch-Schonlein purpura"; triad of purpura, arthritis, abdominal pain	Small vessel leukocytoclastic vasculitis with immunoglobulin A immune complex deposition in vessel walls; often triggered by upper respiratory infection, medications, or malignancy; complement activation and neutrophil infiltration cause vessel wall damage	Most common systemic vasculitis in children; peak age 4-6 years; incidence 10-20 per 100,000 children; male to female ratio 1.5:1; more common in winter and spring	Palpable purpura on lower extremities and buttocks (100%); arthritis or arthralgia of knees and ankles (75%); colicky abdominal pain, nausea, vomiting, gastrointestinal bleeding (50-75%); renal involvement with hematuria and proteinuria (20-50%); scrotal or labial edema; may have fever, malaise	Acute onset over days; purpura appears in crops; typically self-limited over 4-6 weeks; may have recurrences in 33%; renal disease may develop months after initial presentation	Other vasculitides (hypersensitivity vasculitis, polyarteritis nodosa), thrombocytopenia, meningococcemia, Rocky Mountain spotted fever, hemolytic uremic syndrome, intussusception, acute abdomen	Clinical diagnosis; skin biopsy shows leukocytoclastic vasculitis with immunoglobulin A deposition on immunofluorescence; urinalysis for hematuria and proteinuria; complete blood count (platelets normal); stool guaiac; renal function tests; consider abdominal ultrasound if severe abdominal pain	Supportive care for mild disease; nonsteroidal anti-inflammatory drugs for arthritis; corticosteroids (prednisone 1-2 mg/kg/day) for severe abdominal pain, scrotal involvement, or significant renal disease; monitor urine for 6 months for renal involvement	Y	https://www.ncbi.nlm.nih.gov/books/NBK537252/																
Impetigo	Honey-colored crusted lesions on face in child; "honey-crusted lesions"; highly contagious	Bacterial infection of superficial epidermis; Staphylococcus aureus (most common, including methicillin-resistant Staphylococcus aureus) or Streptococcus pyogenes; direct inoculation through breaks in skin; exotoxins cause intraepidermal splitting in bullous form	Most common bacterial skin infection in children; peak age 2-5 years; more common in warm humid climates; associated with crowding, poor hygiene, skin trauma, atopic dermatitis	Nonbullous (70%): erythematous macules progressing to vesicles then pustules that rupture leaving honey-colored crusts on erythematous base; face and extremities; regional lymphadenopathy; Bullous (30%): flaccid bullae that rupture leaving collarette of scale; trunk and intertriginous areas; caused by Staphylococcus aureus exfoliative toxin	Acute onset; lesions develop over days; spreads rapidly; resolves in 2-3 weeks without treatment but faster with antibiotics; post-streptococcal glomerulonephritis may occur 10 days to 3 weeks after streptococcal impetigo	Herpes simplex, varicella, contact dermatitis, atopic dermatitis, bullous pemphigoid, dermatophyte infection, scabies	Clinical diagnosis; bacterial culture and sensitivity if extensive, recurrent, or not responding to treatment; consider methicillin-resistant Staphylococcus aureus; anti-streptolysin O titer or anti-DNase B if concern for post-streptococcal glomerulonephritis	Limited disease: topical mupirocin 2% ointment three times daily for 5 days or retapamulin 1% ointment twice daily for 5 days; Extensive disease: oral antibiotics (cephalexin, dicloxacillin, or if methicillin-resistant Staphylococcus aureus suspected: trimethoprim-sulfamethoxazole, clindamycin, doxycycline) for 7 days; hygiene measures; exclude from school until 24 hours after starting antibiotics	N	https://www.aafp.org/pubs/afp/issues/2014/0801/p229.html																
Incontinentia Pigmenti	Newborn female with linear vesicular rash following Blaschko lines; four stages: vesicular, verrucous, hyperpigmented, hypopigmented; "whorled hyperpigmentation in female infant"	X-linked dominant disorder; mutations in IKBKG (NEMO) gene; usually lethal in males; defect in nuclear factor kappa B signaling; abnormal melanin deposition in dermis	Rare; affects females almost exclusively (males usually die in utero); incidence 1 in 40,000 live births; sporadic mutations in 65-80% of cases	Four stages: Stage 1 (birth to 4 months): linear vesicles and bullae on erythematous base following Blaschko lines; Stage 2 (2-6 months): verrucous hyperkeratotic lesions; Stage 3 (6 months onward): whorled brown hyperpigmentation; Stage 4 (adolescence): linear hypopigmented atrophic streaks; may have dental anomalies, alopecia, nail dystrophy, ocular abnormalities (retinal detachment), central nervous system abnormalities (seizures, developmental delay)	Stage 1: birth to 4 months; Stage 2: 2-6 months; Stage 3: 6 months to adulthood; Stage 4: adolescence to adulthood; skin manifestations evolve through stages; hyperpigmentation fades over years to decades	Herpes simplex, epidermolysis bullosa, linear epidermal nevus, hypomelanosis of Ito, child abuse (for vesicular stage); other neurocutaneous syndromes	Clinical diagnosis based on characteristic skin findings; skin biopsy shows eosinophilic spongiosis in stage 1, dyskeratosis in stage 2, melanin incontinence in stage 3; genetic testing for IKBKG mutations; ophthalmologic examination (mandatory); neuroimaging if neurologic symptoms; dental evaluation	Supportive care for skin lesions; topical corticosteroids or antibiotics for secondary infection in vesicular stage; regular ophthalmologic examinations (every 3-6 months in first year, then annually) to monitor for retinal detachment; neurologic evaluation if developmental concerns; genetic counseling	Y	https://www.ncbi.nlm.nih.gov/books/NBK1472/																
Infantile Acropustulosis	Recurrent pruritic vesicles and pustules on palms and soles in infant; often follows scabies infestation; "itchy hands and feet after scabies"	Recurrent vesicopustular eruption of unclear etiology; may represent hypersensitivity reaction following scabies infestation or other infectious trigger; sterile pustules contain eosinophils and neutrophils	Onset typically 2-10 months of age; may persist until 2-3 years; more common in internationally adopted children from crowded living conditions; no clear gender or ethnic predominance	Intensely pruritic vesicles and pustules on palms (94%) and soles (100%); may extend to dorsal hands and feet; lesions appear in crops; often coexists with atopic dermatitis (over 50%); child otherwise well	Recurrent episodes lasting 7-14 days; cycles every 2-4 weeks; episodes decrease in frequency and severity over months to years; spontaneous resolution by age 2-3 years	Scabies, hand-foot-mouth disease, dyshidrotic eczema, pustular psoriasis, acropustulosis of infancy, erythema toxicum neonatorum	Clinical diagnosis based on characteristic distribution and recurrent pattern; skin biopsy shows intraepidermal or subcorneal pustules with eosinophils and neutrophils; scabies scraping to exclude active infestation	Mid- to high-potency topical corticosteroids (class 2-3) are first-line and effective; may use under occlusion; antihistamines for pruritus; dapsone for severe refractory cases; avoid unnecessary permethrin treatment for presumed recurrent scabies	N	https://www.ncbi.nlm.nih.gov/books/NBK559286/																
Intertrigo	Erythematous rash in skin folds; "red raw skin in body folds"; moist macerated appearance	Superficial inflammatory dermatitis caused by skin-on-skin friction, moisture retention, lack of ventilation, and maceration in skin folds; bodily secretions (perspiration, urine, feces) exacerbate inflammation; creates environment for secondary bacterial and fungal colonization	Common in all ages; increased risk with obesity, diabetes, incontinence, immobility; affects natural skin folds (axillae, inframammary, inguinal, intergluteal) and obesity-created folds	Erythema with peripheral scaling in opposing skin surfaces; moist, macerated appearance; burning and itching; satellite lesions suggest candidal superinfection; malodor suggests bacterial infection; well-demarcated borders	Acute to chronic; can develop within hours to days of moisture exposure; chronic cases persist without intervention; secondary infections develop over days	Candidiasis, inverse psoriasis, seborrheic dermatitis, erythrasma, tinea, allergic contact dermatitis, irritant contact dermatitis	Clinical diagnosis; potassium hydroxide preparation for fungal elements; Wood lamp examination (coral-red fluorescence for Corynebacterium minutissimum erythrasma); bacterial culture if suspected bacterial superinfection	Keep area dry and reduce friction; absorptive powders (cornstarch); barrier creams (zinc oxide); low-potency topical corticosteroids for inflammation; topical antifungals (nystatin, clotrimazole, ketoconazole) for candidal infection; topical mupirocin or oral penicillin for streptococcal infection; oral erythromycin for erythrasma; moisture-wicking textiles	N	https://www.aafp.org/pubs/afp/issues/2014/0401/p569.html																
Inverse Psoriasis	Well-demarcated erythematous plaques in skin folds without typical scale; "shiny red plaques in flexures"; may be mistaken for fungal infection	Psoriasis affecting intertriginous areas; same immune-mediated pathophysiology as plaque psoriasis with T-cell activation and cytokine release; occluded moist environment prevents typical scale formation	Affects 3-7% of psoriasis patients; can occur at any age; associated with obesity; often coexists with plaque psoriasis elsewhere	Well-demarcated erythematous shiny plaques in axillae, inframammary areas, inguinal folds, intergluteal cleft, groin, genitalia; minimal to absent scale due to moisture; pruritus; significant psychological impact especially with genital involvement	Chronic relapsing course; may be first manifestation of psoriasis or develop in patients with established disease; flares with friction, moisture, heat	Candidiasis, tinea, erythrasma, intertrigo, seborrheic dermatitis, contact dermatitis, extramammary Paget disease	Clinical diagnosis; potassium hydroxide preparation negative for fungal elements; skin biopsy shows psoriasiform hyperplasia with parakeratosis if needed for confirmation	Low- to mid-potency topical corticosteroids (avoid high-potency due to atrophy risk in occluded areas); calcineurin inhibitors (tacrolimus, pimecrolimus); vitamin D analogues (calcitriol less irritating than calcipotriene); topical corticosteroid-vitamin D combination; systemic therapy (biologics, apremilast, methotrexate) for extensive or refractory disease	N	https://www.jaad.org/article/S0190-9622(10)02173-0/fulltext																
Irritant Contact Dermatitis	Well-demarcated erythema and scaling at site of irritant exposure; "burning and stinging more than itching"; occupational hand dermatitis in healthcare workers or hairdressers	Direct cytotoxic damage to keratinocytes from chemical or physical irritants; innate immune activation with release of inflammatory cytokines; impaired skin barrier function; cumulative exposure to weak irritants accounts for 80% of cases	Most common form of contact dermatitis (80% of all contact dermatitis cases); accounts for 95% of occupational skin disorders; increased risk with atopic dermatitis, frequent hand washing, wet work	Burning and stinging sensation exceeding pruritus; well-demarcated erythema, scaling, fissuring at site of contact; hands most commonly affected; acute: erythema, edema, vesicles; chronic: lichenification, fissures; distribution corresponds to irritant exposure	Acute: develops within minutes to hours of exposure to strong irritants; Chronic cumulative: develops over weeks to months with repeated low-level exposure; improves with irritant avoidance	Allergic contact dermatitis, atopic dermatitis, dyshidrotic eczema, psoriasis, tinea manuum	Diagnosis of exclusion; detailed exposure history; patch testing to rule out allergic contact dermatitis (negative results support irritant contact dermatitis); skin prick testing to exclude type 1 hypersensitivity	Identify and avoid irritant; regular emollient use to restore skin barrier; protective gloves for wet work; low- to mid-potency topical corticosteroids for inflammation; severe cases may require short course of systemic corticosteroids	N	https://link.springer.com/article/10.1007/s12016-018-8713-0																
Kawasaki Disease	Child under 5 years with high fever for 5 days plus conjunctivitis, strawberry tongue, rash, hand/foot swelling, cervical lymphadenopathy; "CRASH and Burn: Conjunctivitis, Rash, Adenopathy, Strawberry tongue, Hands/feet, Burn (fever)"	Medium vessel vasculitis of unknown etiology; aggressive neutrophil-mediated panmural vascular necrosis without granuloma formation; primarily targets coronary arteries; intimal hyperplasia and lymphocytic inflammation in advanced disease	Incidence 25-50 per 100,000 children per year in United States; peak age under 5 years (80% of cases); more common in Asian populations; male to female ratio 1.5:1; most common cause of acquired heart disease in children in developed world	Fever at least 5 days plus at least 4 of: bilateral nonexudative conjunctival injection, polymorphic rash, oral changes (red cracked lips, strawberry tongue, oropharyngeal erythema), extremity changes (erythema and edema of hands/feet, periungual desquamation at 2-3 weeks), unilateral cervical lymphadenopathy at least 1.5 cm; irritability; may have Kawasaki shock syndrome with hypotension	Acute febrile phase: 1-2 weeks; subacute phase with desquamation and thrombocytosis: weeks 2-4; convalescent phase: weeks 4-8; coronary artery aneurysms develop in 25% untreated, 5% treated patients	Multisystem inflammatory syndrome in children, scarlet fever, measles, adenovirus, Epstein-Barr virus, toxic shock syndrome, Stevens-Johnson syndrome, drug reaction, juvenile idiopathic arthritis	Clinical diagnosis using American Heart Association criteria; elevated inflammatory markers (erythrocyte sedimentation rate, C-reactive protein); thrombocytosis (week 2); sterile pyuria; hypoalbuminemia; echocardiography to assess coronary arteries at diagnosis, 2 weeks, 6-8 weeks	Intravenous immunoglobulin 2 grams per kilogram as single infusion within 10 days of fever onset; high-dose aspirin 80-100 milligrams per kilogram per day divided four times daily until afebrile, then low-dose aspirin 3-5 milligrams per kilogram per day for 6-8 weeks; corticosteroids for intravenous immunoglobulin-resistant cases; infliximab for refractory cases; cardiology follow-up	Y	https://www.ahajournals.org/doi/10.1161/CIR.0000000000001295																
Keloids	Raised firm scar extending beyond original wound boundaries; "scar that grows beyond borders"; earlobes, chest, shoulders common sites; more common in darker skin	Abnormal wound healing with excessive collagen deposition and fibroblast proliferation; imbalance between collagen synthesis and degradation; transforming growth factor-beta pathway dysregulation; extends beyond original wound margins (unlike hypertrophic scars)	More common in individuals of African, Asian, and Hispanic descent; peak age 10-30 years; genetic predisposition with autosomal dominant inheritance pattern in some families; affects 5-16% of Black and Hispanic populations	Firm, rubbery, raised scar extending beyond original injury site; pink to dark brown color; may be pruritic or painful; continues to grow over months to years; does not regress spontaneously; common sites: earlobes, chest, shoulders, upper back; triggered by trauma, surgery, piercings, acne	Develops weeks to months after injury; continues to grow for months to years; does not spontaneously regress (unlike hypertrophic scars which may improve over 1-2 years)	Hypertrophic scar (stays within wound boundaries), dermatofibroma, dermatofibrosarcoma protuberans, scar sarcoid	Clinical diagnosis based on appearance and history of extending beyond original wound; skin biopsy shows thick collagen bundles, increased fibroblasts, minimal inflammation if diagnosis uncertain	Intralesional corticosteroid injections (triamcinolone 10-40 milligrams per milliliter every 4-6 weeks); silicone gel sheeting; pressure therapy; surgical excision with adjuvant therapy (high recurrence if excision alone); cryotherapy; laser therapy (pulsed dye laser, fractional laser); radiation therapy for refractory cases; 5-fluorouracil injections; combination therapies most effective	N	https://www.aad.org/public/diseases/a-z/keloids-overview																
Keratoacanthoma	Rapidly growing dome-shaped nodule with central keratin-filled crater on sun-exposed skin; "volcano-like lesion"; resembles molluscum contagiosum initially	Epithelial tumor with aberrant follicular keratinization; proliferation of well-differentiated squamous cells; possible role of human papillomavirus (beta-genus types) and ultraviolet radiation; shares molecular features with squamous cell carcinoma but distinct tendency for spontaneous regression	Annual incidence 104 per 100,000; peak age 65-71 years; more common in males; sun-exposed skin most affected (arms, hands, trunk); increased risk with immunosuppression	Begins as smooth, dome-shaped red papule; rapidly expands over weeks to 1-2 cm nodule with central keratin-filled crater; sun-exposed areas most common; may be tender; dermoscopy shows features overlapping with squamous cell carcinoma	Rapid growth phase over 6 weeks; stabilization; spontaneous regression over 2-12 months if untreated; some lesions may progress rather than regress	Squamous cell carcinoma (cannot reliably distinguish), basal cell carcinoma, molluscum contagiosum (early stage), prurigo nodularis	Clinical diagnosis difficult; dermoscopy cannot differentiate from squamous cell carcinoma; definitive diagnosis requires histopathology showing well-differentiated squamous proliferation with central keratin plug; complete excision preferred for diagnosis	Surgical excision with 5 mm margin (first-line); Mohs micrographic surgery for deep lesions or cosmetically sensitive areas (face, ear, periocular, perioral); alternatives after biopsy: electrodesiccation and curettage, intralesional fluorouracil or methotrexate, radiation, topical therapy	Y	https://www.ncbi.nlm.nih.gov/books/NBK482364/																
Keratosis Pilaris	Rough follicular papules on extensor arms and thighs; "chicken skin" or "goose bumps"; associated with atopic dermatitis	Follicular hyperkeratinization with keratin plugging of hair follicles; filaggrin gene mutations in many cases; impaired desquamation leads to follicular retention hyperkeratosis; perifollicular inflammation	Very common; prevalence 40-50% in adults, higher in children; onset in childhood; associated with atopic dermatitis, ichthyosis vulgaris, xerosis; no gender predominance	Small rough follicular papules on extensor surfaces of upper arms, thighs, buttocks, cheeks; may have perifollicular erythema (keratosis pilaris rubra); asymptomatic or mildly pruritic; worse in winter, improves in summer and with age	Onset in childhood; chronic lifelong condition; may improve with age and in humid environments; worsens in dry cold weather	Folliculitis, lichen spinulosus, pityriasis rubra pilaris, lichen nitidus, acne	Clinical diagnosis; skin biopsy shows follicular hyperkeratosis with keratin plugs and perifollicular lymphocytic infiltrate if needed	Topical keratolytics: lactic acid 12% (first-line), salicylic acid, urea, glycolic acid, alpha-hydroxy acids; topical retinoids; moisturizers; laser therapy (neodymium-doped yttrium aluminum garnet, carbon dioxide, erbium-doped yttrium aluminum garnet) for refractory cases; recurrence common within 3 months of stopping treatment	N	https://www.aad.org/public/diseases/a-z/keratosis-pilaris-overview																
Kwashiorkor Syndrome	Edematous malnourished child with "flaky paint" dermatosis, thin reddish hair, and hepatomegaly; "swollen belly with peeling skin"; protein deficiency with adequate calories	Severe protein deficiency in setting of adequate caloric intake; hypoalbuminemia causes edema; impaired protein synthesis affects multiple organ systems; free radical damage from antioxidant deficiency; fatty liver from impaired lipoprotein synthesis	Common in developing countries with famine; rare in developed countries; onset typically 6 months to 3 years (after weaning); can occur in developed countries from severe dietary restriction by well-intentioned parents	Pitting edema (especially legs, feet, face giving "moon face" or "bull-dog face"); growth retardation; muscle wasting; apathy and irritability; dermatosis with hyperpigmentation, desquamation, erythema ("flaky paint" dermatosis); thin, sparse, reddish-brown hair that is easily pluckable; hepatomegaly with fatty liver; diarrhea; hypoalbuminemia	Develops over weeks to months of protein deficiency; acute presentation when brought to medical attention; recovery rapid with refeeding but initial weight loss from fluid mobilization; anemia may develop during recovery	Marasmus (total calorie deficiency), nephrotic syndrome, congestive heart failure, liver disease, other causes of edema and malnutrition	Low serum albumin (less than 25 grams per liter); characteristic plasma amino acid pattern (low essential amino acids, normal to high non-essential amino acids); anemia; electrolyte abnormalities; low total protein; dietary history reveals adequate calories but insufficient protein	Gradual refeeding with balanced diet containing adequate protein; correct electrolyte abnormalities; treat infections; multivitamin supplementation; monitor for refeeding syndrome; initial rapid weight loss from edema mobilization followed by weight gain; address underlying cause (dietary restriction, poverty, neglect)	Y	https://www.ncbi.nlm.nih.gov/books/NBK507876/																
Lamellar Ichthyosis	Newborn encased in tight collodion membrane; later develops large dark plate-like scales; "armored baby"; autosomal recessive	Autosomal recessive disorder; mutations in transglutaminase-1 (TGM1) gene most common (27% of cases); also ABCA12, ALOX12B, ALOXE3, NIPAL4, PNPLA1, CYP4F22; defective cornified cell envelope formation; retention hyperkeratosis with impaired barrier function	Rare; incidence 1 in 200,000 births; autosomal recessive inheritance; consanguinity increases risk; no gender predominance	Collodion membrane at birth (87% of cases): tight, shiny, parchment-like membrane causing ectropion and eclabium; membrane sheds revealing large, dark, plate-like scales in generalized distribution; mild erythroderma; ectropion, eclabium; scarring alopecia of scalp and eyebrows; palmoplantar keratoderma; heat intolerance from sweat duct occlusion; recurrent ear infections from scale accumulation	Present at birth with collodion membrane; membrane sheds over days to weeks; lifelong condition with persistent scaling; does not improve significantly with age	Other ichthyoses (congenital ichthyosiform erythroderma, harlequin ichthyosis, X-linked ichthyosis), collodion baby from other causes	Clinical diagnosis; skin biopsy shows hyperkeratosis with reduced or absent granular layer; genetic testing identifies mutations in TGM1 or other causative genes; prenatal diagnosis available	Intensive emollients and moisturizers (petrolatum-based, urea, lactic acid); keratolytics (salicylic acid, alpha-hydroxy acids); topical retinoids; oral retinoids (acitretin) for severe cases; humidification; avoid overheating; treat secondary infections; ophthalmology for ectropion; lifelong management required	Y	https://www.ncbi.nlm.nih.gov/books/NBK1420/																
Lentigo	Well-circumscribed brown macule; "age spot" or "liver spot"; sun-exposed areas in older adults; benign	Increased number of melanocytes at dermal-epidermal junction; increased melanin production; chronic ultraviolet radiation exposure causes melanocyte proliferation; benign proliferation without atypia	Very common; increases with age; more common in fair-skinned individuals; sun-exposed areas; solar lentigo prevalence increases after age 40	Well-circumscribed, uniformly pigmented brown to dark brown macule; round to oval; 2-20 mm diameter; sun-exposed areas (face, dorsal hands, upper back, shoulders); asymptomatic; multiple lesions common	Develops gradually over years; increases in number and size with continued sun exposure; stable once formed; does not regress spontaneously	Seborrheic keratosis, solar keratosis, lentigo maligna, melanocytic nevus, melanoma (if atypical features), ephelis (freckle)	Clinical diagnosis; dermoscopy shows uniform pigmentation, sharp borders, fingerprint-like pattern; biopsy if atypical features: shows increased melanocytes at basal layer, elongated rete ridges, increased melanin	No treatment required; cosmetic options: cryotherapy, laser therapy (Q-switched, intense pulsed light), chemical peels, topical hydroquinone, tretinoin; sun protection to prevent new lesions	N	https://www.aad.org/public/diseases/a-z/age-spots-overview																
Lentigo Maligna	Slowly enlarging tan-brown macule with irregular borders on chronically sun-damaged facial skin in elderly; "melanoma in situ on the face"; "Hutchinson melanotic freckle"	Melanoma in situ; proliferation of atypical melanocytes along dermal-epidermal junction; chronic ultraviolet radiation damage; mutations in BRAF, NRAS, NF1 genes; may progress to invasive lentigo maligna melanoma; subclinical spread beyond visible margins common	Incidence increasing; peak age seventh to eighth decade; more common in males; fair-skinned individuals; chronic sun exposure; head and neck (especially face) in over 90% of cases	Slowly enlarging tan to dark brown macule or patch; irregular, indistinct borders; variegated pigmentation; asymmetric; chronically sun-damaged skin (face, neck, scalp); may have areas of regression; subclinical extension beyond visible margins	Slow growth over months to years; may remain in situ for years before progressing to invasive melanoma; progression to lentigo maligna melanoma in 5-50% of cases if untreated	Solar lentigo, seborrheic keratosis, pigmented actinic keratosis, melanocytic nevus, lichen planus-like keratosis	Dermoscopy shows asymmetric pigmented follicular openings, rhomboidal structures, obliterated hair follicles; reflectance confocal microscopy for margin assessment; excisional biopsy or multiple punch biopsies for diagnosis; histology shows atypical melanocytes at dermal-epidermal junction; immunostains: HMB-45, MART-1, Melan-A, S-100	Surgical excision with margin assessment (first-line); Mohs micrographic surgery for margin control on cosmetically sensitive areas; 5-10 mm clinical margins; topical imiquimod 5% for nonsurgical candidates; radiation therapy for poor surgical candidates; close surveillance for recurrence	Y	https://www.jaad.org/article/S0190-9622(24)02893-9/fulltext																
Lice (Pediculosis Capitis)	Itchy scalp in school-aged child; nits firmly attached to hair shaft near scalp; "sesame seed-sized bugs"; posterior hairline and behind ears	Pediculus humanus capitis infestation; louse feeds by injecting saliva with vasodilatory and anticoagulative properties into scalp and sucking blood; pruritus results from sensitization to saliva components; takes 4-6 weeks for sensitization with first infestation	Common in school-aged children; no predilection for socioeconomic status or hygiene level; spread by direct head-to-head contact; adult louse is 2-3 mm long, tan to grayish-white; female lives 3-4 weeks and lays up to 10 eggs per day	Pruritus of scalp (may not develop for 4-6 weeks with first infestation); nits (eggs and empty casings) firmly attached to hair shaft within 1 cm of scalp; viable eggs camouflaged to match hair color; adult lice visible but avoid light and crawl quickly; excoriations from scratching; cervical and posterior auricular lymphadenopathy	Eggs hatch in 8-9 days; nymph passes through 3 stages over 9-12 days before reaching adult stage; female can mate and lay eggs 1.5 days after becoming adult; cycle repeats every 3 weeks if untreated; lice survive less than 1 day away from scalp	Seborrheic dermatitis, atopic dermatitis, psoriasis, dandruff, hair casts (pseudonits), piedra (fungal infection of hair shaft), other debris (hairspray droplets, dirt)	Clinical diagnosis by identifying nits, nymphs, or adult lice with naked eye or handheld magnification; louse comb more efficient than standard comb for diagnosis; nits firmly attached to hair shaft (unlike dandruff); nits more than 1 cm from scalp unlikely to be viable	First-line: permethrin 1% cream rinse or pyrethrin-based products; Second-line: malathion 0.5% lotion, benzyl alcohol 5% lotion, ivermectin 0.5% lotion, spinosad 0.9% suspension; oral ivermectin for resistant cases; manual removal of nits with fine-toothed comb; treat all household contacts with active infestation; environmental measures (wash bedding, clothing in hot water)	N	https://publications.aap.org/pediatrics/article/150/4/e2022059282/189757/Head-Lice																
Lichen Planus	Purple polygonal pruritic papules and plaques on wrists and ankles; "6 P's: pruritic, purple, polygonal, planar, papules, plaques"; Wickham striae (white lacy network); oral involvement common	T-cell mediated autoimmune disorder; liquefactive degeneration of basal keratinocytes; bandlike lymphocytic infiltrate at dermal-epidermal junction; cytotoxic T-cell attack on basal keratinocytes; associated with hepatitis C virus infection	Prevalence 0.5-1% of population; cutaneous: 0.3% in men, 0.1% in women; oral: 1.5% in men, 2.3% in women; peak age 30-60 years; no clear gender predominance for cutaneous form	Cutaneous: flat-topped violaceous papules on flexor wrists, ankles, lumbar region; intense pruritus; Wickham striae (white lacy lines); Oral: bilateral symmetric white lacy network (reticular), erythematous patches, or painful erosions on buccal mucosa, gingiva, tongue; Genital: white network or erosions; Nail: longitudinal ridging, thinning, distal splitting; Scalp: scarring alopecia	Cutaneous: acute to chronic; may resolve spontaneously in 1-2 years; residual hyperpigmentation common; Oral: chronic relapsing course, less likely to resolve than cutaneous form; erosive forms persist longer	Drug-induced lichenoid eruption, psoriasis, lichen simplex chronicus, secondary syphilis, pityriasis rosea, graft-versus-host disease, lupus erythematosus; Oral: leukoplakia, candidiasis, squamous cell carcinoma	Clinical diagnosis; skin or mucosal biopsy shows orthokeratosis, accentuated granular layer, liquefactive degeneration of basal layer, bandlike lymphocytic infiltrate; screen for hepatitis C virus with enzyme-linked immunosorbent assay; biopsy persistent lesions to rule out dysplasia or squamous cell carcinoma	Cutaneous: high-potency topical corticosteroids (clobetasol 0.05% ointment once daily); oral corticosteroids (prednisone 0.5-1 mg/kg/day for 4-6 weeks) for severe disease; Oral: topical clobetasol 0.05% ointment three times daily on erosions; Systemic options: tofacitinib, apremilast, methotrexate, cyclosporine, acitretin; avoid triggers (hepatitis C treatment if positive)	N	https://www.nejm.org/doi/full/10.1056/NEJMcp1103641																
Lichen Sclerosus	White atrophic patches in anogenital area; "cigarette paper" or "porcelain white" appearance; figure-of-eight distribution around vulva and anus; associated with autoimmune diseases	Unknown etiology; genetic predisposition; immune-mediated with T-helper 1-specific interferon-gamma-induced phenotype; tissue remodeling gene dysregulation; oxidative stress with lipid and DNA peroxidation; autoantibodies against extracellular matrix protein 1 and hemidesmosome components	Postmenopausal women predominantly affected; also affects men, prepubertal children, adolescents; underdiagnosed condition; associated with autoimmune diseases (thyroid disease, vitiligo, alopecia areata); increased risk of squamous cell carcinoma	Chronic whitish atrophic patches with "cigarette paper" or "porcelain white" appearance; intense pruritus and soreness; vulvar, perianal, penile involvement; figure-of-eight distribution in females; dyspareunia; dysuria; genital scarring (labial fusion, clitoral hood adhesions, vaginal stenosis, phimosis); fissuring; purpura; extragenital involvement rare	Chronic progressive course; may lead to architectural changes and scarring; sexual and urinary dysfunction develop over time; 4-6% risk of progression to squamous cell carcinoma in vulvar lichen sclerosus	Vitiligo, morphea, lichen simplex chronicus, lichen planus, vulvar intraepithelial neoplasia, squamous cell carcinoma, candidiasis, psoriasis	Clinical diagnosis; skin biopsy if unclear clinical picture, treatment failure, or suspicion of neoplasm; histology shows hyperkeratosis, epidermal atrophy, homogenization of collagen in upper dermis, bandlike lymphocytic infiltrate	Ultrapotent or potent topical corticosteroids (clobetasol propionate 0.05% ointment) applied daily for 1-3 months, then tapered; long-term maintenance therapy; topical calcineurin inhibitors (tacrolimus, pimecrolimus) as alternatives; surgical intervention for complications (labial adhesions, vaginal stenosis); regular surveillance for malignancy	Y	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988819/																
Lichen Simplex Chronicus	Localized intensely pruritic lichenified plaque from chronic scratching; "thickened leathery skin from scratching"; common sites: nape of neck, ankles, vulva, scrotum	Chronic localized pruritus with secondary dermatitis; itch-scratch cycle perpetuates condition; neuroimmune-driven pathogenesis; type 2 inflammation; dysregulated sensory pathways; may be secondary to underlying dermatologic, systemic, or psychological triggers	Affects more than 10% of general population; more common in adults; female predominance; associated with psychological stress, anxiety, depression; common sites: posterior neck, ankles, wrists, vulva, scrotum, extensor forearms	Intense localized pruritus; initial erythematous well-defined plaques with excoriations; chronic scratching leads to thickened, lichenified, violaceous patches with accentuated skin markings; single or few plaques; sleep disruption; emotional distress; functional impairment	Chronic course; develops over weeks to months of repeated scratching; persists as long as scratching continues; improves with cessation of scratching but recurrence common	Psoriasis, atopic dermatitis, contact dermatitis, lichen planus, tinea, nummular eczema, prurigo nodularis	Clinical diagnosis based on characteristic lichenified appearance and history of chronic scratching; skin biopsy shows hyperkeratosis, acanthosis, hypergranulosis, vertical collagen bundles in papillary dermis; evaluate for underlying triggers (atopic dermatitis, contact allergens, psychological factors)	Break itch-scratch cycle: mid- to high-potency topical corticosteroids under occlusion; topical calcineurin inhibitors (tacrolimus, pimecrolimus); antihistamines for pruritus; neuromodulators (gabapentin, pregabalin); Janus kinase inhibitors (topical or systemic); intralesional corticosteroids; procedural: cryotherapy, fractional laser, botulinum toxin; address underlying psychological factors; behavioral modification	N	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613593/																
Linear Immunoglobulin A Bullous Dermatosis	Tense bullae arranged in "string of pearls" or "cluster of jewels" pattern; severe pruritus; children and adults affected; drug-induced form in adults	Autoimmune subepidermal blistering disorder; linear immunoglobulin A deposits at basement membrane zone; circulating immunoglobulin A antibodies to basement membrane zone antigens (BP180/LAD-1, BP230, type VII collagen, laminin 332, p200); drug-induced cases associated with vancomycin, penicillins, cephalosporins, nonsteroidal anti-inflammatory drugs	Rare; incidence 0.5-2.3 per million per year; bimodal distribution: children (peak under 5 years) and adults (peak over 60 years); children: equal gender distribution; adults: slight female predominance	Tense bullae on erythematous or normal skin; "string of pearls" or "cluster of jewels" arrangement (new bullae at periphery of older lesions); severe pruritus; trunk, extremities, face involvement; mucosal involvement variable (more common in adults); children: often self-limited; adults: chronic course; drug-induced form resolves with drug discontinuation	Children: often self-limited, resolves within 2-3 years; Adults: chronic relapsing course; Drug-induced: resolves weeks to months after drug discontinuation	Bullous pemphigoid, dermatitis herpetiformis, epidermolysis bullosa acquisita, pemphigus, bullous lupus erythematosus, bullous drug eruption	Direct immunofluorescence shows linear immunoglobulin A deposits at basement membrane zone (diagnostic); indirect immunofluorescence may show circulating immunoglobulin A antibodies; salt-split skin shows immunoglobulin A on roof (lamina lucida antigens) or floor (type VII collagen); enzyme-linked immunosorbent assay for specific antigens; skin biopsy shows subepidermal blister with neutrophils	First-line: dapsone 50-200 mg daily (test for glucose-6-phosphate dehydrogenase deficiency and HLA-B*1301 before starting); alternatives: sulfasalazine, sulfapyridine, colchicine; severe cases: systemic corticosteroids, immunosuppressants (mycophenolate mofetil, azathioprine); emerging: dupilumab for severe pruritus; discontinue offending drug if drug-induced	N	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11321936/																
Lipoma	Soft, mobile, painless subcutaneous mass; "doughy" feel; slow-growing; head, neck, shoulders, back common sites	Benign adipose tumor; proliferation of mature adipocytes in subcutaneous tissue; encapsulated; variants include angiolipoma (with vascular component), spindle cell lipoma, pleomorphic lipoma; rarely associated with syndromes (hereditary multiple lipomatosis, Gardner syndrome, Madelung disease, adiposis dolorosa)	Common; usually first appear between ages 40-60 years; can occur at any age; slight male predominance; 1% of population; solitary in 80% of cases; multiple lipomas in 5-10%	Soft, mobile, painless, round or oval subcutaneous mass; characteristic soft "doughy" feel; well-circumscribed; slow-growing; size ranges from 1-10 cm (most less than 5 cm); head, neck, shoulders, back, extremities; usually asymptomatic; angiolipomas may be tender	Slow growth over months to years; stable once formed; rarely regress spontaneously; rapid growth should raise concern for liposarcoma	Epidermoid cyst, lipoblastoma (in children), hibernoma, atypical lipomatous tumor, well-differentiated liposarcoma, other soft tissue tumors	Clinical diagnosis for typical presentation; imaging (ultrasound, magnetic resonance imaging, computed tomography) if atypical features or deep location; magnetic resonance imaging: homogeneous fat signal intensity; excisional biopsy if diagnostic uncertainty; histology shows mature adipocytes; must distinguish from atypical lipomatous tumor/well-differentiated liposarcoma (size greater than 11 cm, deep location, thick septa greater than 2 mm, enhancement, lipoblasts suggest malignancy)	Observation for asymptomatic lipomas; excision for cosmetic concerns, pain, rapid growth, functional impairment, or diagnostic uncertainty; steroid injection for small lipomas (causes atrophy); liposuction for selected cases; complete excision to prevent recurrence	N	https://www.aafp.org/pubs/afp/issues/2002/0301/p901.html																
Livedo Racemosa	Irregular, broken, branching violaceous network on trunk and extremities; does not resolve with warming; associated with systemic disease; "broken net pattern that stays"	Pathologic vascular occlusion or inflammation; vessel wall damage from vasculitis, thrombosis, or emboli; permanent structural changes in dermal vessels; associated with antiphospholipid syndrome, polyarteritis nodosa, cholesterol emboli, calciphylaxis	Less common than livedo reticularis; associated with serious underlying systemic disease; occurs in adults; no gender predominance; requires investigation for underlying pathology	Irregular, broken, branching violaceous to reddish-blue network that does not blanch with warming; persistent pattern; may have skin ulceration, necrosis, or nodules; associated systemic symptoms depend on underlying cause (fever, weight loss, organ dysfunction); trunk and extremities affected	Persistent and does not resolve with rewarming; chronic course; may worsen with progression of underlying disease; ulceration and necrosis develop over weeks to months	Livedo reticularis, cutis marmorata, vasculitis, cholesterol emboli syndrome, calciphylaxis, disseminated intravascular coagulation	Clinical diagnosis based on persistent pattern that does not resolve with warming; skin biopsy shows vascular occlusion, thrombosis, or vasculitis; workup for underlying cause: antiphospholipid antibodies, antinuclear antibodies, cryoglobulins, hepatitis serologies, complete blood count, comprehensive metabolic panel, urinalysis; imaging as indicated	Treat underlying cause; antiphospholipid syndrome: anticoagulation; vasculitis: immunosuppression (corticosteroids, cyclophosphamide); cholesterol emboli: supportive care, statin therapy; wound care for ulceration; pain management; avoid further vascular injury	Y	https://www.jaad.org/article/S0190-9622(04)02644-9/fulltext																
Livedo Reticularis	Regular, symmetric, net-like violaceous pattern on extremities; resolves with warming; "fishnet stockings"; often benign and physiologic	Benign vasospasm or sluggish blood flow in dermal venous plexus; deoxygenated blood visible through skin creates net-like pattern; physiologic form related to cold exposure; secondary form associated with autoimmune diseases, hypercoagulable states, medications	Common; affects all ages; more common in young to middle-aged women; physiologic form very common with cold exposure; secondary form associated with systemic lupus erythematosus, antiphospholipid syndrome, polyarteritis nodosa	Regular, symmetric, net-like violaceous to reddish-blue pattern on extremities (legs more than arms); blanches and resolves with warming in physiologic form; asymptomatic in most cases; may have associated Raynaud phenomenon; secondary form may have systemic symptoms	Physiologic: appears with cold exposure, resolves with rewarming within minutes; Secondary: persistent but may improve with warming; chronic relapsing course in secondary forms	Livedo racemosa, cutis marmorata (in infants), erythema ab igne, vasculitis, cholesterol emboli	Clinical diagnosis; physiologic form resolves completely with rewarming; secondary form: evaluate for underlying disease if persistent, young patient, or associated symptoms; antiphospholipid antibodies, antinuclear antibodies, complete blood count, comprehensive metabolic panel; skin biopsy rarely needed	Physiologic form: reassurance, avoid cold exposure, keep extremities warm; Secondary form: treat underlying condition; aspirin for antiphospholipid syndrome; immunosuppression for autoimmune diseases; discontinue offending medications	N	https://www.jaad.org/article/S0190-9622(04)02644-9/fulltext																
Localized Scleroderma (Morphea)	Well-demarcated sclerotic plaques with ivory-colored center and violaceous border (lilac ring); skin and subcutaneous tissue involvement without systemic sclerosis; "morphea"	Autoimmune-mediated fibrosis of skin and subcutaneous tissue; T-helper 1 interferon-gamma-induced phenotype; excessive collagen deposition by activated fibroblasts; tissue remodeling gene dysregulation; does not progress to systemic sclerosis	Incidence 0.4-2.7 per 100,000; more common in females (female to male ratio 2.6:1); bimodal age distribution: childhood (peak 7-11 years) and middle age (peak 40-50 years); associated with autoimmune diseases (thyroid disease 14.8%, vitiligo, rheumatoid arthritis)	Circumscribed (plaque-type): oval sclerotic plaques with ivory center and violaceous border (lilac ring); Linear: band-like sclerosis on extremities or face (en coup de sabre); Generalized: four or more plaques larger than 3 cm or involvement of two or more body sites; Pansclerotic: circumferential involvement of limbs and trunk; may have joint contractures, limb length discrepancy, facial hemiatrophy, extracutaneous manifestations (arthritis, uveitis, central nervous system involvement more common in children)	Active inflammatory phase: violaceous border, expansion over months; Sclerotic phase: hardening and thickening; Atrophic phase: softening with residual hyperpigmentation or hypopigmentation; disease duration typically 3-6 years; 50% have disease activity at 5 years	Systemic sclerosis (has Raynaud phenomenon, internal organ involvement, specific autoantibodies), lichen sclerosus, eosinophilic fasciitis, nephrogenic systemic fibrosis, graft-versus-host disease	Clinical diagnosis; skin biopsy shows dermal sclerosis with thickened collagen bundles, loss of adnexal structures, lymphocytic infiltrate at dermal-subcutaneous junction; antinuclear antibodies positive in 40-80%; modified Rodnan skin score or Localized Scleroderma Cutaneous Assessment Tool for disease activity; magnetic resonance imaging for deep tissue involvement	Limited plaque-type: topical corticosteroids (class 1-2), topical calcineurin inhibitors, phototherapy (ultraviolet A1, narrowband ultraviolet B); Active or extensive disease: methotrexate 15-25 mg weekly plus corticosteroids (prednisone 0.5-1 mg/kg/day tapered over 3 months); alternatives: mycophenolate mofetil, Janus kinase inhibitors; physical therapy for contractures; multidisciplinary care for extracutaneous manifestations	N	https://www.ncbi.nlm.nih.gov/books/NBK513370/																
Lyme Disease	Erythema migrans (expanding red rash with central clearing creating "bull's-eye" or target lesion) at tick bite site; history of tick exposure in endemic area; "bull's-eye rash after tick bite"	Infection with Borrelia burgdorferi spirochete transmitted by Ixodes tick bite; spirochete disseminates hematogenously from skin to multiple organs; immune-mediated inflammation in joints, nervous system, heart; persistent infection despite immune response	Most common vector-borne disease in United States; 476,000 cases annually; endemic in Northeast (Virginia to Maine), upper Midwest (Wisconsin, Minnesota), northern California; peak incidence May through August; all ages affected, peak 5-9 years and 45-54 years	Early localized (3-30 days): erythema migrans (70-80% of cases): expanding erythematous macule or papule at tick bite site, often with central clearing (bull's-eye), typically 5 cm or larger, warm but not painful; flu-like symptoms (fever, headache, myalgia, arthralgia); Early disseminated (days to weeks): multiple erythema migrans lesions, cranial nerve palsy (especially facial nerve palsy), meningitis, carditis (atrioventricular block); Late (months): monoarticular or oligoarticular arthritis (especially knee), encephalopathy, polyneuropathy	Erythema migrans appears 3-30 days after tick bite (median 7 days); expands over days to weeks; early disseminated manifestations develop days to weeks after initial infection; late manifestations develop months after infection; untreated erythema migrans resolves spontaneously in 3-4 weeks	Southern tick-associated rash illness, cellulitis, erythema multiforme, granuloma annulare, tinea corporis, fixed drug eruption, spider bite reaction	Clinical diagnosis for erythema migrans in endemic area (do not delay treatment for serology); Two-tier serologic testing for disseminated disease: enzyme-linked immunosorbent assay followed by Western blot if positive or equivocal (often negative in early disease, becomes positive 2-6 weeks after infection); polymerase chain reaction of synovial fluid for Lyme arthritis; cerebrospinal fluid analysis for neuroborreliosis	Early localized or early disseminated without neurologic or cardiac involvement: Doxycycline 100 mg orally twice daily for 10 days (adults), Amoxicillin 500 mg orally three times daily for 14 days, or Cefuroxime 500 mg orally twice daily for 14 days; Neurologic involvement: Ceftriaxone 2 grams intravenously daily for 14-28 days; Carditis: oral regimen for mild, intravenous ceftriaxone for advanced heart block; Lyme arthritis: oral regimen for 28 days; Prophylaxis: single dose doxycycline 200 mg within 72 hours of tick removal in endemic area	N	https://www.cdc.gov/lyme/index.html																
Malignant Melanoma	Asymmetric pigmented lesion with irregular borders, color variation, diameter greater than 6 mm, and evolution; "ABCDE: Asymmetry, Border, Color, Diameter, Evolving"; may arise de novo or from existing nevus	Malignant transformation of melanocytes; uncontrolled proliferation with potential for local invasion and distant metastasis; mutations in BRAF (40-50%), NRAS (15-20%), NF1, KIT; ultraviolet radiation-induced DNA damage; radial growth phase followed by vertical growth phase with metastatic potential	Incidence 22.8 per 100,000 in United States; lifetime risk 1 in 27 for men, 1 in 40 for women; median age at diagnosis 66 years; more common in fair-skinned individuals; risk factors: ultraviolet exposure, family history, multiple nevi, atypical nevi, immunosuppression	Asymmetric pigmented macule, papule, or nodule; irregular or notched borders; color variation (tan, brown, black, red, white, blue); diameter typically greater than 6 mm; evolving size, shape, or color; may have ulceration, bleeding, or pruritus; subtypes: superficial spreading (70%), nodular (15-30%), lentigo maligna, acral lentiginous; "ugly duckling" sign (lesion different from other nevi)	Develops over months to years; superficial spreading melanoma has prolonged radial growth phase; nodular melanoma has rapid vertical growth phase; metastatic potential increases with Breslow depth	Atypical nevus, seborrheic keratosis, pigmented basal cell carcinoma, dermatofibroma, blue nevus, solar lentigo, pigmented actinic keratosis	Dermoscopy improves diagnostic accuracy; excisional biopsy with 1-3 mm margin for diagnosis (shave biopsy acceptable if lesion can be completely removed); histopathology: atypical melanocytes, pagetoid spread, mitoses; Breslow depth (tumor thickness) most important prognostic factor; sentinel lymph node biopsy for tumors greater than 0.8 mm or with high-risk features; staging with imaging (positron emission tomography, computed tomography, magnetic resonance imaging of brain) for stage IIB and higher	Wide local excision with margins based on Breslow depth: in situ (0.5-1 cm), less than 1 mm (1 cm), 1-2 mm (1-2 cm), greater than 2 mm (2 cm); Sentinel lymph node biopsy for staging; Adjuvant therapy for stage IIB-IV: immune checkpoint inhibitors (nivolumab, pembrolizumab), targeted therapy for BRAF-mutated tumors (dabrafenib plus trametinib); Metastatic disease: immunotherapy, targeted therapy, radiation; Regular surveillance based on stage	Y	https://www.aad.org/public/diseases/skin-cancer/melanoma																
Marasmus	Severe wasting and emaciation in child; "skin and bones" appearance; total calorie and protein deficiency; alert but irritable; no edema	Severe calorie and protein deficiency; body consumes muscle and fat for energy; loss of subcutaneous fat and muscle mass; metabolic adaptations to starvation; impaired immune function; micronutrient deficiencies	Common in developing countries with famine and food insecurity; rare in developed countries; onset typically under 1 year of age; can occur at any age with severe malnutrition; may result from chronic illness, malabsorption, neglect	Severe wasting with loss of subcutaneous fat and muscle mass; "old man" facies; prominent ribs and bones; weight less than 60% of expected for age; alert but irritable (unlike kwashiorkor); no edema (unlike kwashiorkor); thin, dry skin; sparse, thin hair; hypothermia; bradycardia; hypotension; may have diarrhea, dehydration, infections	Develops over weeks to months of inadequate caloric intake; chronic progressive course; acute decompensation with infection or stress; recovery requires weeks to months of nutritional rehabilitation	Kwashiorkor (has edema, adequate calories but protein deficiency), chronic illness (malignancy, tuberculosis, human immunodeficiency virus), malabsorption syndromes, neglect or abuse	Low weight-for-height (less than 70% of median or less than negative 3 standard deviations); low mid-upper arm circumference; low serum albumin (but less severe than kwashiorkor); anemia; electrolyte abnormalities (hypokalemia, hypophosphatemia, hypomagnesemia); hypoglycemia; hypothermia; dietary history reveals inadequate total caloric intake	Gradual refeeding with balanced diet; initial phase: rehydration, correct electrolyte abnormalities, treat infections, provide micronutrients; rehabilitation phase: gradual increase in calories (start 80-100 kcal/kg/day, advance to 150-220 kcal/kg/day); monitor for refeeding syndrome (hypophosphatemia, hypokalemia, hypomagnesemia, fluid overload, cardiac failure); therapeutic feeding formulas (F-75 for stabilization, F-100 for rehabilitation); address underlying cause	Y	https://www.ncbi.nlm.nih.gov/books/NBK507826/																
Measles	Fever, cough, coryza, conjunctivitis (3 Cs) followed by maculopapular rash spreading from face to trunk to extremities; Koplik spots (bluish-white spots on buccal mucosa); "3 Cs and Koplik spots"	Infection with measles virus (paramyxovirus); virus targets CD150-positive lymphocytes (T and B memory cells); causes immune suppression lasting weeks to months; direct cytopathic effects and immune-mediated inflammation cause clinical manifestations	Highly contagious; incubation period 7-10 days (range 7-21 days); rash appears approximately 14 days after exposure; contagious from 4 days before to 4 days after rash appears; vaccine-preventable disease; resurgence in areas with low vaccination rates	Prodrome: fever, malaise, cough, coryza, conjunctivitis for 2-4 days; Koplik spots appear 1-2 days before rash (present in up to 70%); erythematous maculopapular rash appears 2-4 days after fever onset, starts on face and head, spreads to trunk and extremities, may be confluent on face and upper body; complications: otitis media (7-9%), pneumonia (1-6%), diarrhea (8-10%), encephalitis (1 per 1000), death (1-3 per 1000 in developed countries)	Incubation 7-10 days; prodrome 2-4 days; rash appears day 14 after exposure; rash fades in order of appearance over 3-5 days; full recovery within 7 days after rash onset in uncomplicated cases; immune suppression persists for weeks to months	Rubella, roseola, scarlet fever, drug eruption, Kawasaki disease, infectious mononucleosis, Rocky Mountain spotted fever	Clinical diagnosis based on fever, 3 Cs, and characteristic rash; confirmation: reverse transcription polymerase chain reaction from nasopharyngeal swab, throat swab, or urine; serology: measles-specific immunoglobulin M antibody (appears 3-4 days after rash onset); viral culture; notify public health authorities immediately	Supportive care: hydration, antipyretics, rest; vitamin A supplementation (200,000 international units for 2 days) for children 6 months to 2 years, especially in developing countries or vitamin A deficiency; isolation: airborne precautions from 4 days before to 4 days after rash onset; post-exposure prophylaxis: measles-mumps-rubella vaccine within 72 hours of exposure or immunoglobulin within 6 days for contraindications to vaccine	Y	https://www.cdc.gov/measles/index.html																
Melasma	Symmetric hyperpigmented patches on face (cheeks, forehead, upper lip, chin) in women of reproductive age; "mask of pregnancy"; worsens with sun exposure	Multifactorial: ultraviolet radiation exposure, hormonal influences (pregnancy, oral contraceptives), genetic predisposition; increased melanin production and deposition in epidermis and/or dermis; vascular component with increased vessel density and diameter; disrupted basement membrane allows melanin to drop into dermis	Highly prevalent in Latin America and populations with darker skin phototypes (Fitzpatrick III-VI); more common in women (90%); peak age 20-40 years; triggered by pregnancy (chloasma), oral contraceptives, sun exposure; chronic relapsing condition	Symmetric brown to gray-brown macules and patches on sun-exposed areas of face; centrofacial pattern (63%): forehead, cheeks, nose, upper lip; malar pattern (21%): cheeks and nose; mandibular pattern (16%): jawline; no scale or textural change; significant psychosocial impact on quality of life	Chronic relapsing course; develops over weeks to months; worsens with sun exposure and hormonal triggers; may improve after pregnancy or discontinuation of oral contraceptives but often persists; high recurrence rate even with treatment	Post-inflammatory hyperpigmentation, solar lentigo, drug-induced hyperpigmentation, ochronosis, nevus of Ota, lichen planus pigmentosus	Clinical diagnosis; Wood lamp examination to determine depth: epidermal (enhancement under Wood lamp), dermal (no enhancement), mixed; skin biopsy rarely needed; assess severity with Melasma Area and Severity Index; evaluate quality of life impact	Photoprotection: broad-spectrum sunscreen (SPF 30 or higher, reapply every 2 hours) is essential; First-line topical: triple combination cream (hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%) applied nightly; alternatives: azelaic acid 15-20%, kojic acid, tranexamic acid cream; Systemic: oral tranexamic acid 250 mg twice daily for 3-6 months; Procedural adjuncts: chemical peels, microneedling; lasers reserved for refractory cases; maintenance therapy essential to prevent recurrence	N	https://www.jaad.org/article/S0190-9622(17)32583-9/fulltext																
Milia	Small white or yellow dome-shaped papules on face, especially around eyes and cheeks; "tiny white bumps"; common in newborns (neonatal milia)	Retention of keratin in dermal cysts arising from vellus hair follicles or eccrine sweat ducts; primary milia arise spontaneously; secondary milia develop after trauma, blistering diseases, or skin resurfacing procedures	Very common; neonatal milia affects 40-50% of newborns; primary milia common in children and adults; no gender predominance; secondary milia occur after skin injury or certain genodermatoses	Small (1-2 mm) white to yellow dome-shaped firm papules; most commonly on face (eyelids, cheeks, nose, forehead); asymptomatic; neonatal milia typically on nose, cheeks, forehead; may occur on trunk, extremities, oral mucosa (Epstein pearls on palate); secondary milia at sites of previous trauma or blistering	Neonatal milia: appear at birth or within first few weeks; spontaneously resolve within first few months of life; Primary milia in older children and adults: persist indefinitely without treatment; Secondary milia: develop weeks to months after inciting event	Closed comedones, sebaceous hyperplasia, syringomas, trichoepitheliomas, molluscum contagiosum, flat warts	Clinical diagnosis based on characteristic appearance; dermoscopy shows white to yellow round structures; histopathology (rarely needed): small keratin-filled cyst in superficial dermis lined by stratified squamous epithelium	Neonatal milia: observation (spontaneous resolution); Primary and secondary milia: observation if asymptomatic; removal for cosmetic concerns: extraction with sterile needle or blade, electrodesiccation, laser ablation (carbon dioxide or erbium-doped yttrium aluminum garnet), chemical peels; topical retinoids may help prevent new lesions	N	https://www.aad.org/public/diseases/a-z/milia-overview																
Molluscum Contagiosum	Discrete, dome-shaped, waxy, skin-colored papules with central umbilication; "pearly papules with belly button"; common in children; can express white cheesy material	Poxvirus infection (molluscum contagiosum virus); direct inoculation into epidermis through breach in skin barrier; viral replication in keratinocytes causes characteristic lesions; spreads by autoinoculation, direct contact, fomites; more severe in immunocompromised and atopic dermatitis	Common in children (peak age 1-4 years) and sexually active adults; prevalence 5-11% in children; transmitted by direct skin contact, fomites, sexual contact (genital lesions), autoinoculation; increased prevalence in atopic dermatitis and immunosuppression	Discrete dome-shaped waxy skin-colored to pink papules, 2-5 mm diameter (range 1-10 mm); central umbilication (dell); number typically fewer than 20 in immunocompetent hosts, but can exceed 100; any body site except palms and soles; children: trunk, extremities, face; adults: genital area if sexually transmitted; creamy white material can be expressed; surrounding eczematous dermatitis common; pruritus may lead to autoinoculation	Incubation period 2-7 weeks (range 1 week to 6 months); individual lesions last 2-4 months; total disease duration typically 6-18 months; spontaneous resolution usually within 2 years in immunocompetent hosts; may persist for years in immunocompromised	Warts, closed comedones, basal cell carcinoma, keratoacanthoma, cryptococcosis (in immunocompromised), histoplasmosis, varicella, folliculitis	Clinical diagnosis based on characteristic appearance; dermoscopy shows central pore with white to yellow amorphous structures; skin biopsy (rarely needed): intracytoplasmic inclusion bodies (molluscum bodies or Henderson-Patterson bodies) in keratinocytes	Observation for spontaneous resolution is acceptable; active treatment for cosmetic concerns, prevent spread, or patient preference: physical destruction (cryotherapy, curettage, cantharidin), topical therapies (imiquimod 5%, podophyllotoxin, tretinoin, salicylic acid), oral cimetidine; avoid scarring with aggressive treatment; treat surrounding eczema with topical corticosteroids	N	https://www.aad.org/public/diseases/a-z/molluscum-contagiosum-overview																
Monkeypox (Mpox)	Prodrome of fever and lymphadenopathy followed by vesiculopustular rash; lesions in same stage of development; may have genital or perianal involvement; "pox with painful lymph nodes"; 2022 outbreak: genital lesions in men who have sex with men	Orthopoxvirus infection (monkeypox virus); transmitted by close contact with infected humans or animals, respiratory droplets, fomites, sexual contact; virus replicates at inoculation site then disseminates; two clades: clade I (Central Africa, higher mortality) and clade II (West Africa, lower mortality); 2022 outbreak caused by clade IIb	Endemic to Central and West Africa; 2022 global outbreak primarily affected men who have sex with men in non-endemic countries; incubation period 5-21 days (usually 7-14 days); contagious from symptom onset until all lesions crusted and healed (2-4 weeks)	Classic form: fever, headache, myalgia, lymphadenopathy (distinguishes from smallpox), followed by rash starting on face and extremities with centrifugal distribution; 2022 outbreak form: genital or perianal lesions often first sign, fewer lesions (39% had fewer than 5), proctitis, pharyngitis, painful inguinal lymphadenopathy; rash progresses from macules to papules to vesicles to pustules to crusts; all lesions typically in same stage; complications: secondary bacterial infection, scarring (5-40%), ocular involvement, encephalitis	Incubation 5-21 days; prodrome 1-4 days; rash appears 1-3 days after fever onset; lesions evolve over 2-4 weeks; contagious until all lesions crusted and new skin formed; scarring may be permanent	Varicella (lesions in different stages), herpes simplex, syphilis, chancroid, lymphogranuloma venereum, impetigo, folliculitis, insect bites, molluscum contagiosum	Polymerase chain reaction from lesion swab (vesicular or pustular fluid, crust) is diagnostic; orthopoxvirus-specific testing followed by monkeypox-specific confirmation; serology not useful for acute diagnosis; notify public health authorities	Supportive care for most cases; tecovirimat (TPOXX) for severe disease, immunocompromised patients, or high-risk complications; pain management; wound care; isolation until all lesions healed; vaccination: JYNNEOS vaccine for pre-exposure prophylaxis (high-risk individuals) or post-exposure prophylaxis within 4 days of exposure; treat secondary bacterial infections	Y	https://www.cdc.gov/poxvirus/mpox/index.html																
Microscopic Polyangiitis	Rapidly progressive glomerulonephritis with pulmonary hemorrhage; pauci-immune necrotizing vasculitis; perinuclear antineutrophil cytoplasmic antibody and anti-myeloperoxidase antibody positive; "pulmonary-renal syndrome with positive perinuclear antineutrophil cytoplasmic antibody"	Small vessel necrotizing vasculitis without granulomatous inflammation; antineutrophil cytoplasmic antibody-mediated neutrophil activation causes endothelial injury; pauci-immune (little to no immune complex deposition); affects arterioles, capillaries, venules; commonly involves kidneys (glomerulonephritis) and lungs (alveolar hemorrhage)	Prevalence 0-66 per million in European countries, 86 per million in Japan; peak age 50-60 years; slight male predominance; associated with perinuclear antineutrophil cytoplasmic antibody and anti-myeloperoxidase antibody in 50-75%	Rapidly progressive glomerulonephritis: hematuria with dysmorphic red blood cells, red cell casts, proteinuria (usually 1-3 grams per day), acute kidney injury; pulmonary hemorrhage (10%): hemoptysis, dyspnea, diffuse alveolar infiltrates; constitutional symptoms: fever, weight loss, malaise; other manifestations: purpura, peripheral neuropathy, arthralgia, myalgia; no upper airway involvement (distinguishes from granulomatosis with polyangiitis)	Acute to subacute onset over days to weeks; rapidly progressive glomerular filtration rate decline without treatment; pulmonary hemorrhage can be life-threatening; requires prompt diagnosis and treatment to prevent irreversible organ damage	Granulomatosis with polyangiitis (has upper airway involvement and granulomas), eosinophilic granulomatosis with polyangiitis, anti-glomerular basement membrane disease (Goodpasture syndrome), systemic lupus erythematosus, immunoglobulin A vasculitis, other causes of pulmonary-renal syndrome	Antineutrophil cytoplasmic antibody testing: perinuclear pattern on immunofluorescence, anti-myeloperoxidase antibody by enzyme-linked immunosorbent assay; urinalysis: hematuria, red cell casts, proteinuria; elevated creatinine; chest imaging: diffuse alveolar infiltrates if pulmonary involvement; kidney biopsy: pauci-immune focal segmental necrotizing and crescentic glomerulonephritis; elevated inflammatory markers	Induction therapy: glucocorticoids (methylprednisolone 500-1000 mg intravenously daily for 3 days, then prednisone 1 mg/kg/day orally) plus rituximab (375 mg/m2 weekly for 4 weeks or 1000 mg on days 1 and 15) or cyclophosphamide (2 mg/kg/day orally or 15 mg/kg intravenously every 2-3 weeks); plasma exchange for severe disease (dialysis-dependent, pulmonary hemorrhage); Maintenance therapy: rituximab or azathioprine for 18-24 months; gradual steroid taper	Y	https://www.kidney.org/atoz/content/vasculitis																
Necrobiosis Lipoidica	Yellow-brown atrophic plaques with telangiectasias on pretibial shins; "shiny yellow plaques on shins"; 58% have diabetes mellitus	Granulomatous inflammation with collagen degeneration; microangiopathic changes with vessel wall thickening; immune-mediated process; unclear exact pathogenesis; associated with diabetes but occurs in non-diabetics	Rare; 0.3-1.2 per 1000 diabetic patients; female to male ratio 3:1; median age 50 years; 58.5% have diabetes; 97.8% involve lower legs	Well-demarcated yellow-brown atrophic plaques with waxy appearance and prominent telangiectasias on pretibial shins bilaterally; central atrophy with raised violaceous border; ulceration in 12.7%; pain in 25.5%; pruritus in 26.8%; associated with obesity, hypertension, dyslipidemia, thyroid disease	Chronic progressive course; develops over months to years; lesions expand slowly; ulceration may develop; does not resolve spontaneously; persists indefinitely without treatment	Granuloma annulare, sarcoidosis, diabetic dermopathy, pretibial myxedema, morphea, lipodermatosclerosis	Clinical diagnosis in typical cases; skin biopsy shows palisading granulomas with necrobiosis (collagen degeneration), thickened blood vessel walls, plasma cells; screen for diabetes with hemoglobin A1c and fasting glucose	First-line: high-potency topical corticosteroids under occlusion; intralesional corticosteroids; Second-line: phototherapy (psoralen plus ultraviolet A, narrowband ultraviolet B); Systemic: Janus kinase inhibitors, biologics (ustekinumab, secukinumab), tapinarof, fumaric acid esters; wound care for ulceration; optimize glycemic control if diabetic	N	https://www.jaad.org/article/S0190-9622(17)32583-9/fulltext																
Necrotizing Fasciitis	Rapidly progressive soft tissue infection with pain out of proportion to exam findings; skin necrosis, crepitus, systemic toxicity; "pain worse than exam suggests"; surgical emergency	Bacterial invasion of fascia and subcutaneous tissue; polymicrobial (type 1: mixed aerobic and anaerobic) or monomicrobial (type 2: group A Streptococcus, Staphylococcus aureus); bacterial toxins and enzymes cause tissue necrosis; thrombosis of vessels leads to ischemia and gangrene; systemic inflammatory response	Incidence 0.4-15.5 per 100,000; affects extremities (57-73%), perineum (13-40% Fournier gangrene), trunk (13-26%); risk factors: diabetes (22-59%), obesity, immunosuppression, intravenous drug use, peripheral arterial disease	Pain out of proportion to physical findings; rapidly progressive erythema, edema, warmth; skin changes: dusky, violaceous, bullae, necrosis; crepitus (gas in tissues); systemic toxicity: fever, tachycardia, hypotension, altered mental status; Laboratory Risk Indicator for Necrotizing Fasciitis score greater than or equal to 6 suggests necrotizing fasciitis	Rapid progression over hours to days; early phase may resemble cellulitis; skin necrosis develops within 24-72 hours; high mortality (20-40%) without prompt treatment; septic shock can develop within hours	Cellulitis, erythema, abscess, pyomyositis, gas gangrene, deep vein thrombosis	Clinical diagnosis; Laboratory Risk Indicator for Necrotizing Fasciitis score: white blood cells, hemoglobin, sodium, creatinine, glucose, C-reactive protein; imaging (computed tomography, magnetic resonance imaging) shows fascial thickening, gas, fluid collections but should not delay surgery; definitive diagnosis: surgical exploration with necrotic fascia; Gram stain and culture of tissue	Immediate surgical debridement (within 6 hours); repeat debridement as needed; broad-spectrum antibiotics: vancomycin plus piperacillin-tazobactam or carbapenem; add clindamycin for toxin suppression; intravenous immunoglobulin for streptococcal toxic shock; intensive care support; hyperbaric oxygen as adjunct	Y	https://www.ncbi.nlm.nih.gov/books/NBK430756/																
Neurofibroma	Soft, rubbery, skin-colored to pink papules or nodules; "bag of worms" feel; may be pedunculated; associated with neurofibromatosis type 1	Benign peripheral nerve sheath tumor; proliferation of Schwann cells, fibroblasts, perineural cells, mast cells; loss of neurofibromin (tumor suppressor) in neurofibromatosis type 1 leads to uncontrolled cell growth; sporadic or associated with neurofibromatosis type 1	Cutaneous neurofibromas: 99% of adults with neurofibromatosis type 1; rare in general population; subcutaneous neurofibromas: 15% of adults with neurofibromatosis type 1; plexiform neurofibromas: 30% on exam, 50% on whole-body magnetic resonance imaging	Cutaneous: soft, sessile or pedunculated papules/nodules, 1 mm to few cm, skin-colored to pink/brown; "buttonhole sign" (invagination with pressure); Subcutaneous: rubbery nodules under skin, mobile; Plexiform: diffuse, bag of worms texture, may cause disfigurement, pain; may be tender or pruritic; continue to develop throughout life	Cutaneous neurofibromas: rare in children, develop in adolescence, increase throughout adulthood; Plexiform neurofibromas: present from infancy or early childhood; may grow rapidly during puberty or pregnancy; 8-13% lifetime risk of malignant transformation to malignant peripheral nerve sheath tumor	Lipoma, skin tag, dermatofibroma, schwannoma, leiomyoma, angiolipoma	Clinical diagnosis; skin biopsy shows spindle cells in myxoid stroma with wavy nuclei; S-100 positive; magnetic resonance imaging for deep or plexiform neurofibromas; whole-body magnetic resonance imaging for neurofibromatosis type 1 surveillance; positron emission tomography if malignant transformation suspected	Observation for asymptomatic lesions; surgical excision for symptomatic, cosmetically concerning, or suspicious lesions; MEK inhibitors (selumetinib) for symptomatic inoperable plexiform neurofibromas in neurofibromatosis type 1; monitor for malignant transformation (rapid growth, pain, neurologic symptoms)	N	https://www.ncbi.nlm.nih.gov/books/NBK1109/																
Neurofibromatosis Type 1	Multiple café-au-lait macules, axillary/inguinal freckling, neurofibromas, Lisch nodules; "café-au-lait spots plus freckling plus bumps"; autosomal dominant	Autosomal dominant disorder; mutation in NF1 gene on chromosome 17q11.2; loss of neurofibromin (tumor suppressor and RAS-GTPase activating protein); uncontrolled RAS signaling leads to increased cell proliferation; 50% de novo mutations	Birth incidence 1 in 2000-2500; affects all ethnicities equally; autosomal dominant with complete penetrance; 50% inherited, 50% de novo; no gender predominance	Café-au-lait macules greater than 99% (6 or more, greater than 5 mm prepubertal or greater than 15 mm postpubertal); axillary/inguinal freckling 85%; Lisch nodules (iris hamartomas) greater than 95%; cutaneous neurofibromas 99% in adults; plexiform neurofibromas 30-50%; optic pathway glioma 15-20%; learning disabilities 50-60%; skeletal abnormalities: scoliosis, tibial dysplasia, sphenoid wing dysplasia; increased cancer risk: malignant peripheral nerve sheath tumor 8-13%, breast cancer, leukemia, brain tumors	Café-au-lait macules: present at birth or early infancy, increase in first years; Freckling: early childhood; Lisch nodules: childhood; Neurofibromas: adolescence to adulthood; Complications develop throughout life; lifelong condition	Legius syndrome (café-au-lait macules without neurofibromas), McCune-Albright syndrome, Noonan syndrome, multiple café-au-lait macules without syndrome	Clinical diagnosis using revised diagnostic criteria: 2 or more of café-au-lait macules, freckling, neurofibromas, optic pathway glioma, Lisch nodules/choroidal abnormalities, bone dysplasia, heterozygous pathogenic NF1 variant, or parent with neurofibromatosis type 1; genetic testing confirms NF1 mutation; ophthalmologic exam; whole-body magnetic resonance imaging for tumor surveillance	Multidisciplinary care; annual comprehensive exam; ophthalmology surveillance; whole-body magnetic resonance imaging every 2-3 years in children; MEK inhibitors (selumetinib) for symptomatic plexiform neurofibromas; surgical excision of symptomatic neurofibromas; treat complications (optic pathway glioma, malignant peripheral nerve sheath tumor, scoliosis); educational support for learning disabilities; genetic counseling	Y	https://www.ncbi.nlm.nih.gov/books/NBK1109/																
Nevus (Melanocytic Nevus)	Benign pigmented macule, papule, or nodule; "mole"; uniform color and borders; common acquired or congenital	Benign proliferation of melanocytes; junctional (melanocytes at dermal-epidermal junction), compound (junctional plus dermal), or intradermal (dermal only); congenital nevi present at birth; acquired nevi develop in childhood and adolescence; genetic mosaicism in some cases	Very common; average adult has 10-40 nevi; more common in fair-skinned individuals; sun exposure increases number; congenital nevi: 1-6% of newborns	Junctional: flat, tan to brown macule; Compound: slightly raised, tan to brown papule; Intradermal: dome-shaped, skin-colored to tan papule; uniform color; symmetric; well-defined borders; typically less than 6 mm; asymptomatic; congenital nevi present at birth, may be large	Acquired nevi: appear in childhood, peak in adolescence and young adulthood, may fade or disappear in older age; Congenital nevi: present at birth, grow proportionally with child, persist throughout life	Melanoma (asymmetry, irregular borders, color variation, diameter greater than 6 mm, evolution), seborrheic keratosis, lentigo, dermatofibroma, blue nevus	Clinical diagnosis; dermoscopy improves accuracy; biopsy if atypical features (asymmetry, irregular borders, color variation, diameter greater than 6 mm, evolution); histopathology shows nests of melanocytes; molecular testing (comparative genomic hybridization, fluorescence in situ hybridization, quantitative reverse transcription polymerase chain reaction) if ambiguous for melanoma	Observation for typical benign nevi; excision for cosmetic concerns, irritation, or atypical features concerning for melanoma; sun protection to prevent new nevi; monitor for changes (asymmetry, border, color, diameter, evolution)	N	https://www.aad.org/public/diseases/a-z/moles-overview																
Nevus Simplex	Flat pink to red vascular patch on glabella, eyelids, or nape; "salmon patch," "angel kiss" (facial), "stork bite" (nape); blanches with pressure; very common in newborns	Capillary malformation; dilated dermal capillaries; immature vascular development; not true nevus (not genetic mosaicism); represents persistent fetal circulation pattern	Affects 40-50% of newborns; most common vascular birthmark; no gender or ethnic predominance; typical sites: glabella 77.8%, nape 59.3%, eyelids 55.6%; extensive involvement (nevus simplex complex) less common	Flat, pink to red, irregular vascular patch; blanches with pressure; typical sites: glabella (between eyebrows), upper eyelids, nape of neck; may also involve nose, lip, scalp, lumbosacral area; becomes more prominent with crying, straining, temperature changes; asymptomatic	Facial lesions: fade over first 1-2 years of life, most resolve by age 3; Nape lesions: persist in 50% of adults; may become more prominent with crying or Valsalva throughout life	Port-wine stain (darker, does not fade, associated with Sturge-Weber syndrome if in trigeminal V1 distribution), hemangioma (raised, proliferative), capillary malformation	Clinical diagnosis based on characteristic appearance and location; no imaging or biopsy needed; differentiate from port-wine stain (darker, does not fade, may be associated with syndromes)	Observation; facial lesions typically fade spontaneously; nape lesions often persist but benign; pulsed dye laser for persistent cosmetically concerning lesions; reassurance to parents	N	https://www.jaad.org/article/S0190-9622(09)01464-X/fulltext																
Newborn Desquamation	Peeling skin in first few weeks of life, especially on hands and feet; "normal newborn skin shedding"; more prominent in post-term infants	Physiologic shedding of stratum corneum; transition from intrauterine aqueous environment to dry extrauterine environment; vernix caseosa loss exposes immature stratum corneum to air; increased desquamation in post-term infants due to prolonged amniotic fluid exposure	Affects nearly all newborns to some degree; more prominent in post-term infants (greater than 42 weeks gestation); typically begins in first few days of life	Superficial peeling and flaking of skin, most prominent on hands, feet, ankles, wrists; underlying skin appears normal; no erythema or inflammation; infant otherwise well-appearing; may have fine, dry, cracked appearance	Begins within first few days of life; peaks at 1-2 weeks; resolves spontaneously within 2-4 weeks without intervention	Congenital ichthyosis, collodion baby, transient neonatal pustular melanosis (has pigmented macules after pustule rupture), congenital candidiasis, congenital syphilis	Clinical diagnosis in well-appearing newborn with typical presentation; skin biopsy or potassium hydroxide preparation if concern for infectious or ichthyotic process; rule out congenital infections if atypical features present	Observation and reassurance; gentle moisturizers if desired for comfort; avoid harsh soaps; no specific treatment required; resolves spontaneously	N	https://www.aafp.org/pubs/afp/issues/2024/0300/p212.html																
Niacin (Vitamin B3) Deficiency	Pellagra: "4 Ds: Diarrhea, Dermatitis, Dementia, Death"; photosensitive dermatitis in sun-exposed areas; Casal necklace (hyperpigmented rash around neck)	Deficiency of niacin (vitamin B3) or its precursor tryptophan; niacin required for NAD and NADP synthesis (essential for cellular metabolism); deficiency impairs energy production, DNA repair, cell signaling; causes in developed countries: alcoholism, malabsorption, carcinoid syndrome (tryptophan diverted to serotonin), Hartnup disease (impaired tryptophan absorption), isoniazid therapy	Rare in developed countries; common in areas with maize-based diets (niacin in maize poorly bioavailable without alkali treatment); alcoholism most common cause in developed countries; Hartnup disease mimics pellagra	Dermatitis: symmetric photosensitive dermatitis on sun-exposed areas (face, neck, hands, feet); Casal necklace (broad collar of hyperpigmented dermatitis around neck); glossitis with bright red tongue; Diarrhea: watery diarrhea, abdominal pain; Dementia: confusion, memory loss, psychosis, depression; may have ataxia, peripheral neuropathy	Acute to subacute onset over weeks to months of deficiency; symptoms progress without treatment; dermatitis worsens with sun exposure; neurologic symptoms may become irreversible if prolonged	Hartnup disease (genetic disorder with identical presentation), zinc deficiency, riboflavin deficiency, pyridoxine deficiency, photosensitive drug eruption, systemic lupus erythematosus	Low urinary N1-methyl-nicotinamide plus N1-methyl-2-pyridone-5-carboxamide (less than 5.8 micromoles per day indicates deficiency); clinical diagnosis based on classic triad; response to niacin supplementation confirms diagnosis; evaluate for underlying cause (dietary history, alcoholism, malabsorption)	Niacin (nicotinic acid or nicotinamide) 300-1000 mg per day orally in divided doses until symptoms resolve; maintenance 50-100 mg per day; treat underlying cause; multivitamin supplementation (often multiple deficiencies); dietary counseling; symptoms improve within days to weeks; dermatitis resolves first, followed by gastrointestinal and neurologic symptoms	N	https://www.nejm.org/doi/full/10.1056/NEJMra2314150																
Non-purulent Cellulitis	Erythema, warmth, tenderness, swelling without purulence or abscess; "red, hot, swollen skin without pus"; typically unilateral lower extremity	Bacterial infection of deep dermis and subcutaneous tissue; beta-hemolytic Streptococcus (most common) and methicillin-sensitive Staphylococcus aureus; breach in skin barrier allows bacterial entry; inflammatory response causes erythema, edema, warmth; spreads along tissue planes	Estimated 14.5 million cases annually in United States; accounts for over 650,000 hospitalizations per year; lower extremity most common site; risk factors: obesity, lymphedema, venous insufficiency, tinea pedis, prior cellulitis	Expanding erythema, warmth, tenderness, swelling; typically unilateral; lower extremity most common; no purulence, fluctuance, or abscess; may have fever, malaise; regional lymphadenopathy; predisposing factors: tinea pedis, trauma, edema	Acute onset; symptoms develop over hours to days; erythema expands without treatment; improvement expected within 24-48 hours of appropriate antibiotics; complete resolution over 7-10 days	Purulent cellulitis with abscess, erysipelas (more superficial, raised borders), deep vein thrombosis, necrotizing fasciitis, stasis dermatitis, contact dermatitis, lipodermatosclerosis	Clinical diagnosis based on history and physical examination; blood cultures and tissue cultures unnecessary for typical cases; consider blood cultures if severe systemic features, immunocompromised, or unusual exposures; imaging if concern for abscess or necrotizing fasciitis	Oral antibiotics covering Streptococcus and methicillin-sensitive Staphylococcus aureus: cephalexin 500 mg four times daily, dicloxacillin 500 mg four times daily, or clindamycin 300-450 mg three times daily for 5 days; extend if not improved by day 5; intravenous antibiotics for severe systemic features; address predisposing factors (treat tinea pedis, compression for edema)	N	https://jamanetwork.com/journals/jama/fullarticle/2532513																
Nummular Dermatitis	Coin-shaped (discoid) eczematous plaques on extremities; "coin-shaped itchy patches"; chronic relapsing course	Variant of atopic dermatitis with codominant type 2 and type 17 immune response; impaired epidermal barrier function; microbial colonization (often Staphylococcus aureus); spongiosis with eosinophil and neutrophil infiltration; upregulation of type 2 cytokines (interleukin-13, CCL17, CCL18) and neutrophil-attracting cytokines (interleukin-19, CXCL8)	Common chronic inflammatory skin disease; affects all ages; slight male predominance; more common in winter months; associated with dry skin, atopic dermatitis, venous insufficiency	Well-demarcated, coin-shaped (discoid), erythematous, scaly, eczematous plaques; intense pruritus; typically 1-10 cm diameter; lower extremities most common (shins, dorsal feet), also upper extremities, trunk; may have crusting, weeping, or lichenification; often multiple lesions	Chronic relapsing course; individual lesions develop over days to weeks; persist for weeks to months without treatment; may resolve with post-inflammatory hyperpigmentation; recurrences common, especially in winter	Psoriasis (thicker scale, less pruritic), tinea corporis (active scaly border, central clearing, potassium hydroxide positive), contact dermatitis, atopic dermatitis (more flexural), lichen simplex chronicus (single plaque, more lichenified)	Clinical diagnosis; potassium hydroxide preparation to exclude tinea; skin biopsy if uncertain: shows spongiosis, acanthosis, eosinophils, neutrophils; bacterial culture if secondary infection suspected	High-potency topical corticosteroids (class 1-2) twice daily for 2-4 weeks, then taper; topical calcineurin inhibitors (tacrolimus, pimecrolimus) for maintenance; emollients and moisturizers; treat secondary bacterial infection with antibiotics; severe or refractory cases: phototherapy (narrowband ultraviolet B), dupilumab, systemic immunosuppressants; address xerosis and environmental triggers	N	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165693/																
Onychomycosis	Discolored, thickened, brittle nails with subungual debris; "thick yellow crumbly nails"; toenails more than fingernails; chronic progressive course	Fungal infection of nail plate and nail bed; dermatophytes (Trichophyton rubrum most common 70-90%), yeasts (Candida), non-dermatophyte molds; fungal invasion causes nail plate thickening, discoloration, onycholysis; keratin degradation by fungal enzymes	Affects 10% of general population, 20% of those over 60 years, 50% of those over 70 years; toenails affected more than fingernails; risk factors: older age, diabetes, peripheral arterial disease, immunosuppression, tinea pedis, trauma, family history	Distal lateral subungual onychomycosis (most common): yellow-brown discoloration starting at distal or lateral nail, subungual hyperkeratosis, onycholysis; White superficial onychomycosis: white patches on nail surface; Proximal subungual onychomycosis: white discoloration at proximal nail fold (associated with immunosuppression); nail thickening, brittleness, dystrophy; usually painless unless secondary paronychia	Chronic progressive course; develops over months to years; spreads from distal to proximal nail; may involve multiple nails; does not resolve spontaneously; 25% recurrence rate after treatment	Psoriasis (nail pitting, oil drop sign), lichen planus (longitudinal ridging, pterygium), traumatic dystrophy, onychogryphosis, melanonychia	Potassium hydroxide preparation with microscopy (sensitivity 80%); fungal culture (gold standard for species identification but high false-negative rate); periodic acid-Schiff stain of nail clipping (sensitivity 80-92%); polymerase chain reaction (highest sensitivity and specificity); confirm diagnosis before treatment	Oral terbinafine 250 mg daily for 6 weeks (fingernails) or 12 weeks (toenails) is first-line (mycologic cure 76%); alternatives: itraconazole pulse therapy 200 mg twice daily for 1 week per month for 2-3 months (fingernails) or 3-4 months (toenails); Topical therapy for mild disease: efinaconazole 10% daily, tavaborole 5% daily, ciclopirox 8% daily; nail debridement improves cure rates; monitor liver function with oral agents	N	https://www.aafp.org/pubs/afp/issues/2021/1000/p359.html																
Polyarteritis Nodosa	Systemic necrotizing vasculitis with multiple mononeuropathies, livedo reticularis, testicular pain, abdominal pain, hypertension; "medium vessel vasculitis sparing lungs and kidneys"; antineutrophil cytoplasmic antibody negative	Necrotizing inflammation of medium-sized arteries without granulomas or glomerulonephritis; may be triggered by hepatitis B virus (now rare) or remain idiopathic; vessel wall necrosis leads to aneurysm formation, thrombosis, organ ischemia	Rare; prevalence lower than other systemic vasculitides; affects all ages with peak 40-60 years; male to female ratio 1.5:1; hepatitis B association now uncommon due to vaccination; may be associated with genetic syndromes and malignancy	Constitutional symptoms: fever, weight loss, malaise; Peripheral neuropathy (75%): multiple mononeuropathies, asymmetric sensory and motor deficits; Skin (50-60%): livedo reticularis, nodules, ulcers, digital ischemia; Gastrointestinal: abdominal pain, mesenteric ischemia, hemorrhage; Renal: hypertension, renal artery aneurysms (not glomerulonephritis); Cardiac: coronary arteritis, myocardial infarction; Orchitis (rare but specific); no pulmonary involvement	Acute to subacute onset over weeks to months; progressive without treatment; life-threatening complications (mesenteric ischemia, myocardial infarction, stroke) can develop rapidly; mortality high without treatment	Microscopic polyangiitis (has glomerulonephritis, antineutrophil cytoplasmic antibody positive), granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis, other systemic vasculitides, cholesterol emboli syndrome	Elevated inflammatory markers (erythrocyte sedimentation rate, C-reactive protein); antineutrophil cytoplasmic antibody negative; hepatitis B surface antigen testing; Tissue biopsy of symptomatic organ (skin, muscle plus nerve, testis): necrotizing arteritis of medium vessels; Visceral angiography (mesenteric, renal): multiple microaneurysms, vessel irregularity, stenosis	Severe disease: intravenous pulse glucocorticoids (methylprednisolone 500-1000 mg daily for 3-5 days) followed by high-dose oral glucocorticoids (prednisone 1 mg/kg/day) plus cyclophosphamide; Nonsevere disease: glucocorticoids plus non-glucocorticoid immunosuppressive agents (azathioprine, methotrexate); Cutaneous polyarteritis nodosa: colchicine first-line, glucocorticoids plus azathioprine for refractory cases; Hepatitis B-associated: antivirals plus plasma exchange	Y	https://www.ncbi.nlm.nih.gov/books/NBK544253/																
Paronychia	Painful, erythematous, swollen nail fold; acute (bacterial, often Staphylococcus aureus) or chronic (Candida, irritant exposure); "red swollen cuticle with pus"	Acute: bacterial infection (Staphylococcus aureus most common) following trauma, nail biting, hangnails; abscess formation in lateral or proximal nail fold; Chronic: multifactorial with Candida colonization, irritant contact dermatitis from moisture exposure, loss of cuticle seal allows irritants and microbes to enter	Very common; acute paronychia affects all ages; chronic paronychia more common in adults with occupational wet work (dishwashers, bartenders, healthcare workers, food handlers); diabetes increases risk	Acute: sudden onset pain, erythema, warmth, swelling of nail fold; purulent drainage; may have fluctuance indicating abscess; Chronic: gradual onset erythema, swelling, tenderness of proximal and lateral nail folds; loss of cuticle; nail plate changes (transverse ridging, discoloration, onycholysis); intermittent drainage; affects multiple fingers	Acute: develops over hours to days; resolves with drainage and antibiotics over days to weeks; Chronic: develops over weeks to months; persists without treatment; improves over weeks to months with avoidance of moisture and appropriate therapy	Acute: felon, herpetic whitlow, cellulitis; Chronic: psoriasis, lichen planus, contact dermatitis, squamous cell carcinoma (if single digit, non-healing)	Acute: clinical diagnosis; culture of purulent drainage if not responding to empiric therapy; Chronic: potassium hydroxide preparation and fungal culture for Candida; bacterial culture; patch testing if contact dermatitis suspected; biopsy if concern for malignancy	Acute: warm soaks; incision and drainage if abscess present; oral antibiotics covering Staphylococcus aureus (cephalexin, dicloxacillin, clindamycin) for 5-10 days; Chronic: avoid moisture and irritants, wear cotton-lined gloves for wet work; topical antifungals (clotrimazole, ketoconazole) and topical corticosteroids; systemic antifungals (fluconazole, itraconazole) for refractory cases	N	https://www.aafp.org/pubs/afp/issues/2017/0701/p44.html																
Parvovirus Infection (Fifth Disease)	"Slapped cheek" rash in child followed by lacy reticular rash on trunk and extremities; "slapped cheeks then lace-like rash"; may have arthralgia in adults	Infection with parvovirus B19; virus targets erythroid progenitor cells via P antigen receptor; causes transient cessation of red blood cell production; immune complex-mediated rash appears as viremia clears; can cause aplastic crisis in patients with hemolytic anemias, hydrops fetalis in pregnant women	Common childhood infection; 50% of adults seropositive; peak age 5-15 years; outbreaks in schools and daycare; transmitted by respiratory droplets; incubation period 4-14 days (range 4-21 days)	Prodrome: mild fever, malaise, headache for 2-3 days; Rash phase: bright red "slapped cheek" facial erythema (pathognomonic), followed 1-4 days later by lacy reticular erythema on trunk and extremities; rash may recur with triggers (heat, exercise, stress) for weeks; Adults: polyarthralgia and arthritis (especially hands, wrists, knees) more common than rash; Complications: transient aplastic crisis in hemolytic anemias, chronic anemia in immunocompromised, hydrops fetalis in pregnancy	Prodrome 2-3 days; facial rash appears as prodrome resolves; body rash 1-4 days after facial rash; rash fades over 1-3 weeks but may recur for weeks to months; arthralgia in adults may persist for weeks to months	Rubella, measles, roseola, scarlet fever, drug eruption, Kawasaki disease, systemic lupus erythematosus (in adults with arthritis)	Clinical diagnosis in typical presentation; Serology: parvovirus B19-specific immunoglobulin M (acute infection), immunoglobulin G (past infection or immunity); Polymerase chain reaction for immunocompromised or aplastic crisis; Complete blood count: reticulocytopenia during aplastic crisis	Supportive care: antipyretics, hydration; nonsteroidal anti-inflammatory drugs for arthralgia; Immunoglobulin for chronic infection in immunocompromised; transfusion support for aplastic crisis; pregnant women with exposure require monitoring for hydrops fetalis	N	https://www.cdc.gov/parvovirusb19/about/index.html																
Pemphigus Vulgaris	Flaccid bullae and painful oral erosions; positive Nikolsky sign; "fragile blisters that break easily leaving erosions"; autoimmune blistering disease	Autoimmune disease with immunoglobulin G autoantibodies against desmoglein 3 (mucosal) and desmoglein 1 (cutaneous); antibodies disrupt keratinocyte adhesion causing acantholysis (loss of cell-cell adhesion); intraepidermal blister formation above basal layer	Rare; incidence 0.1-0.5 per 100,000 per year; peak age 40-60 years; more common in Ashkenazi Jews and people of Mediterranean descent; slight female predominance	Oral erosions (90-100%): painful, slow-healing erosions on buccal mucosa, palate, gingiva, lips; often first manifestation; Cutaneous: flaccid bullae on normal or erythematous skin that rupture easily leaving painful erosions; scalp, face, trunk, intertriginous areas; positive Nikolsky sign (lateral pressure causes blister extension or skin sloughing); may have laryngeal, esophageal, genital involvement; significant pain interferes with eating and daily activities	Chronic relapsing course; oral lesions typically precede skin lesions by weeks to months; progressive without treatment; high mortality (75-90%) before corticosteroids; now mortality 5-10% with treatment	Bullous pemphigoid (tense bullae, older patients, negative Nikolsky), mucous membrane pemphigoid, paraneoplastic pemphigus, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, aphthous stomatitis	Direct immunofluorescence of perilesional skin: intercellular immunoglobulin G and complement C3 deposition in epidermis (fishnet or chicken-wire pattern); Indirect immunofluorescence: circulating anti-desmoglein antibodies; Enzyme-linked immunosorbent assay: anti-desmoglein 3 and anti-desmoglein 1 antibodies; Skin biopsy: suprabasal acantholysis with tombstone appearance of basal cells	Systemic corticosteroids (prednisone 1-2 mg/kg/day) are first-line; Steroid-sparing agents: rituximab (now preferred first-line adjunct), azathioprine, mycophenolate mofetil, cyclophosphamide; Adjunctive: intravenous immunoglobulin, plasmapheresis for severe refractory disease; Topical corticosteroids for oral lesions; Wound care; Pain management; Monitor for infections	Y	https://www.ncbi.nlm.nih.gov/books/NBK560860/																
Photosensitivity Disorders	Exaggerated sunburn reaction or rash in sun-exposed areas; drug-induced (thiazides, tetracyclines, fluoroquinolones) or porphyrias (blistering on hands with fragile skin); "bad sunburn from minimal sun" or "blisters on hands after sun"	Drug-induced: phototoxic (direct cellular damage from drug plus ultraviolet A) or photoallergic (immune-mediated from drug plus ultraviolet A creating hapten); Porphyrias: enzyme defects in heme synthesis pathway cause porphyrin accumulation; porphyrins absorb light (400-410 nm) generating reactive oxygen species causing skin damage	Drug-induced very common; porphyria cutanea tarda most common porphyria (1 in 10,000); variegate porphyria and hereditary coproporphyria rare; erythropoietic protoporphyria 1 in 75,000-200,000	Drug-induced phototoxic: exaggerated sunburn (erythema, edema, blistering) in sun-exposed areas within hours; Drug-induced photoallergic: eczematous eruption in sun-exposed areas, may spread beyond exposed areas; Porphyria cutanea tarda: skin fragility, blisters, erosions, milia, scarring, hypertrichosis on sun-exposed areas (dorsal hands, face); Variegate porphyria and hereditary coproporphyria: similar skin findings plus acute neurovisceral attacks; Erythropoietic protoporphyria: burning pain within minutes of sun exposure, erythema, edema	Drug-induced: develops hours (phototoxic) to days (photoallergic) after sun exposure while on medication; resolves days to weeks after drug discontinuation; Porphyria cutanea tarda: chronic course with seasonal variation (worse summer); blisters heal over weeks leaving scars; Acute porphyrias: attacks last days to weeks	Polymorphic light eruption, solar urticaria, systemic lupus erythematosus, dermatomyositis, phytophotodermatitis, sunburn, contact dermatitis	Drug-induced: clinical history of temporal relationship; photopatch testing for photoallergic; Porphyria cutanea tarda: elevated urine porphyrins (uroporphyrin, coproporphyrin), plasma fluorescence peak at 619-620 nm; Variegate porphyria: elevated fecal protoporphyrin and coproporphyrin, plasma fluorescence peak at 626 nm; Erythropoietic protoporphyria: elevated erythrocyte protoporphyrin, plasma fluorescence peak at 634 nm	Drug-induced: discontinue offending medication, sun protection, topical corticosteroids; Porphyria cutanea tarda: phlebotomy (remove 450 mL every 1-2 weeks until ferritin low-normal) or low-dose hydroxychloroquine 100 mg twice weekly; Variegate porphyria and hereditary coproporphyria: avoid triggers, heme therapy for acute attacks; Erythropoietic protoporphyria: afamelanotide (alpha-melanocyte-stimulating hormone analogue), sun protection, beta-carotene	N	https://www.ncbi.nlm.nih.gov/books/NBK519558/																
Pilar Cyst	Smooth, firm, mobile subcutaneous nodule on scalp; "scalp bump that moves"; no central punctum (unlike epidermoid cyst)	Benign cyst arising from outer root sheath of hair follicle; keratin-filled cyst without granular layer in cyst wall; autosomal dominant inheritance in some families	Common; 5-10% of population; more common in middle-aged adults; female predominance; 90% occur on scalp; often multiple; familial clustering	Smooth, firm, mobile, dome-shaped subcutaneous nodule on scalp; skin-colored; typically 0.5-5 cm; no central punctum; asymptomatic unless inflamed or ruptured; may have multiple lesions	Slow growth over months to years; stable once formed; may become inflamed or rupture with trauma; persist indefinitely without treatment	Epidermoid cyst (has central punctum, occurs on face and trunk), lipoma (softer, doughy feel), dermoid cyst, proliferating trichilemmal cyst (rapidly growing, may ulcerate)	Clinical diagnosis based on location and characteristics; excisional biopsy if diagnostic uncertainty; histopathology shows cyst lined by stratified squamous epithelium without granular layer, dense eosinophilic keratin	Observation for asymptomatic cysts; excision for cosmetic concerns, recurrent inflammation, or diagnostic uncertainty; complete excision with intact cyst wall to prevent recurrence; incision and drainage for acutely inflamed cysts followed by delayed excision	N	https://www.aafp.org/pubs/afp/issues/2007/0401/p1025.html																
Pityriasis Alba	Hypopigmented patches on face in children with darker skin; "white patches on cheeks"; associated with atopic dermatitis; more noticeable in summer	Mild chronic dermatitis with post-inflammatory hypopigmentation; reduced melanin transfer to keratinocytes; associated with atopic dermatitis in many cases; exact pathogenesis unclear; may involve Malassezia colonization	Very common in children; affects 5% of children worldwide; more common and noticeable in children with darker skin (Fitzpatrick types III-VI); peak age 3-16 years; slight male predominance	Hypopigmented, ill-defined patches with fine scale on face (especially cheeks), upper arms, trunk; typically 0.5-5 cm; minimal to no pruritus; more noticeable after sun exposure or in summer; may have associated xerosis or atopic dermatitis	Develops over weeks; individual patches persist for months to years; spontaneous resolution typical by adolescence or early adulthood; new patches may develop	Vitiligo (complete depigmentation, well-demarcated), tinea versicolor (potassium hydroxide positive, trunk distribution), post-inflammatory hypopigmentation, pityriasis lichenoides chronica, mycosis fungoides (hypopigmented variant)	Clinical diagnosis; Wood lamp examination shows enhancement of hypopigmentation; potassium hydroxide preparation negative for fungal elements; skin biopsy rarely needed: shows mild spongiosis, reduced melanin in basal layer	Reassurance that condition is benign and self-limited; emollients and moisturizers; low-potency topical corticosteroids (hydrocortisone 1%) for inflammation; topical calcineurin inhibitors (tacrolimus, pimecrolimus); sun protection to prevent contrast with surrounding skin; repigmentation occurs gradually over months	N	https://www.aad.org/public/diseases/a-z/pityriasis-alba-overview																
Pityriasis Rosea	Herald patch followed 1-2 weeks later by generalized rash in "Christmas tree" distribution along Langer lines; "herald patch then tree pattern"; self-limited	Likely viral etiology (human herpesvirus 6 and 7 reactivation); herald patch represents initial site of viral reactivation; subsequent viremia causes generalized eruption; immune response leads to rash resolution	Common; affects all ages with peak in adolescents and young adults (10-35 years); slight female predominance; more common in spring and fall; 2% of dermatology visits	Herald patch: solitary oval erythematous plaque with collarette scale, typically on trunk, 2-10 cm; Secondary eruption 1-2 weeks later: smaller oval salmon-colored papules and plaques with collarette scale on trunk and proximal extremities in "Christmas tree" distribution along Langer lines; mild pruritus in 50%; may have prodrome of malaise, headache, fever	Herald patch appears first; secondary eruption 1-2 weeks later; total duration 6-8 weeks (range 2-12 weeks); spontaneous resolution without scarring; recurrence rare (2%)	Secondary syphilis (palms and soles involved, serology positive), guttate psoriasis (no herald patch, thicker scale), nummular eczema, tinea corporis, drug eruption, viral exanthem, lichen planus	Clinical diagnosis based on herald patch and characteristic distribution; serologic testing for syphilis (rapid plasma reagin or venereal disease research laboratory) to exclude secondary syphilis; potassium hydroxide preparation if concern for tinea; skin biopsy rarely needed	Observation for mild cases (self-limited); topical corticosteroids or oral antihistamines for pruritus; oral acyclovir 800 mg five times daily for 7 days may shorten duration if started early; ultraviolet B phototherapy for severe pruritus; avoid in pregnancy (associated with spontaneous abortion in first 15 weeks)	N	https://www.aafp.org/pubs/afp/issues/2018/0101/p38.html																
Plaque Psoriasis	Well-demarcated erythematous plaques with silvery scale on extensor surfaces (elbows, knees), scalp, and sacrum; "thick scaly plaques on elbows and knees"; Auspitz sign (pinpoint bleeding when scale removed)	Immune-mediated inflammatory disease; T-helper 17 and T-helper 1 pathways drive keratinocyte hyperproliferation; genetic susceptibility (HLA-Cw6 association); environmental triggers (stress, infection, trauma, medications); epidermal hyperproliferation with shortened keratinocyte turnover (3-5 days versus normal 28 days)	Affects 2-3% of population; bimodal age distribution: peak 20-30 years and 50-60 years; equal gender distribution; more common in Caucasians; 30% have family history; 30% develop psoriatic arthritis	Well-demarcated erythematous plaques with thick silvery-white scale on extensor surfaces (elbows, knees), scalp, lower back, intergluteal cleft; Auspitz sign (pinpoint bleeding when scale removed); Koebner phenomenon (new lesions at sites of trauma); nail changes (pitting, onycholysis, oil drop sign) in 50%; pruritus variable; psoriatic arthritis in 30%	Chronic relapsing course; individual plaques develop over days to weeks; persist indefinitely without treatment; flares triggered by stress, infection, medications (beta-blockers, lithium, antimalarials), trauma	Seborrheic dermatitis (greasy scale, less well-demarcated), nummular eczema (more pruritic, less well-demarcated), tinea corporis (active border, potassium hydroxide positive), cutaneous T-cell lymphoma, pityriasis rosea, lichen planus	Clinical diagnosis; skin biopsy if uncertain: shows parakeratosis, acanthosis, elongated rete ridges, Munro microabscesses, dilated dermal capillaries; screen for psoriatic arthritis, metabolic syndrome, cardiovascular disease	Mild (less than 3% body surface area): topical corticosteroids, vitamin D analogues (calcipotriene), combination calcipotriene-betamethasone; Moderate to severe (greater than 3% body surface area or impaired quality of life): phototherapy (narrowband ultraviolet B), systemic therapy (methotrexate, cyclosporine, acitretin, apremilast), biologics (tumor necrosis factor inhibitors, interleukin-17 inhibitors, interleukin-23 inhibitors); lifestyle modifications (weight loss, smoking cessation, alcohol reduction)	N	https://www.aad.org/public/diseases/a-z/psoriasis-overview																
Polymyalgia Rheumatica	Bilateral shoulder and hip girdle pain and stiffness in patient over 50 years; "can't lift arms or get out of chair"; morning stiffness greater than 45 minutes; elevated erythrocyte sedimentation rate and C-reactive protein	Inflammatory condition of unknown etiology; synovitis and bursitis of shoulder and hip girdles; cytokine-mediated inflammation (interleukin-6, interleukin-1); genetic predisposition (HLA-DR4 association); may represent spectrum with giant cell arteritis	Incidence 50 per 100,000 in those over 50 years; almost exclusively affects those over 50 years; peak age 70-80 years; female to male ratio 2-3:1; more common in Northern European descent; 16-21% have concurrent giant cell arteritis	Bilateral shoulder and hip girdle pain and stiffness; morning stiffness greater than 45 minutes; difficulty with overhead activities, rising from chair, getting out of bed; constitutional symptoms (fatigue, malaise, low-grade fever, weight loss); no muscle weakness on examination; may have peripheral synovitis (knees, wrists) in 50%	Subacute onset over 2 weeks to 3 months; symptoms worse in morning; dramatic response to low-dose corticosteroids within 24-72 hours; relapsing course common during steroid taper; average treatment duration 1-2 years	Rheumatoid arthritis (positive rheumatoid factor and anti-cyclic citrullinated peptide, symmetric small joint involvement), rotator cuff disease, adhesive capsulitis, osteoarthritis, statin-induced myopathy, hypothyroidism, malignancy, infection	Elevated erythrocyte sedimentation rate (typically greater than 40 mm/hour) and C-reactive protein; normocytic anemia; normal creatine kinase; rheumatoid factor and anti-cyclic citrullinated peptide negative; consider temporal artery biopsy or imaging if giant cell arteritis suspected	Prednisone 12.5-25 mg daily; dramatic response within 24-72 hours confirms diagnosis; gradual taper over 12-24 months; monitor for giant cell arteritis symptoms (headache, jaw claudication, vision changes); methotrexate or tocilizumab as steroid-sparing agents; calcium and vitamin D supplementation; bone density screening	Y	https://www.aafp.org/pubs/afp/issues/2022/1000/p420.html																
Porokeratosis	Annular plaques with raised keratotic ridge and central atrophy; "ridge around the edge"; multiple variants; risk of malignant transformation	Clonal expansion of abnormal keratinocytes; defect in keratinization with formation of cornoid lamella (column of parakeratotic cells); genetic mutations in mevalonate pathway genes; triggered by ultraviolet radiation, immunosuppression	Rare; disseminated superficial actinic porokeratosis most common variant; affects adults; more common in fair-skinned individuals; increased prevalence in immunosuppressed patients; autosomal dominant inheritance in some families	Annular plaques with characteristic raised keratotic ridge (thread-like border) and central atrophy; Disseminated superficial actinic porokeratosis: multiple small lesions on sun-exposed areas (arms, legs); Linear porokeratosis: unilateral linear distribution; Porokeratosis of Mibelli: larger solitary or few lesions; asymptomatic or mildly pruritic; 7.5-11% risk of malignant transformation (squamous cell carcinoma, basal cell carcinoma)	Chronic progressive course; new lesions develop over years; individual lesions slowly enlarge; persist indefinitely; malignant transformation may occur after years to decades	Actinic keratosis, Bowen disease, superficial basal cell carcinoma, tinea corporis, granuloma annulare, lichen planus	Clinical diagnosis; dermoscopy shows double white track sign; skin biopsy shows cornoid lamella (diagnostic): column of parakeratotic cells with absent or decreased granular layer beneath; monitor for malignant transformation	Sun protection; topical therapies: 5-fluorouracil, imiquimod, retinoids, vitamin D analogues; cryotherapy; laser therapy (carbon dioxide, erbium-doped yttrium aluminum garnet); photodynamic therapy; systemic retinoids for extensive disease; regular surveillance for malignant transformation; excision of suspicious lesions	N	https://www.ncbi.nlm.nih.gov/books/NBK544364/																
Porphyria Cutanea Tarda	Skin fragility, blisters, and scarring on sun-exposed areas (dorsal hands); hypertrichosis; hyperpigmentation; "blisters on hands after sun"; associated with hepatitis C, alcohol, iron overload	Deficiency of uroporphyrinogen decarboxylase (acquired or inherited); accumulation of uroporphyrin in liver and plasma; porphyrins absorb light (400-410 nm) generating reactive oxygen species causing skin damage; susceptibility factors: hepatitis C virus (67%), alcohol, smoking, estrogens, iron overload, HFE mutations	Most common porphyria; prevalence 1 in 10,000; peak age 50-60 years; slight male predominance; 67% have hepatitis C virus infection; 80% have type I (sporadic acquired), 20% have type II (familial with UROD mutation)	Skin fragility and blistering on sun-exposed areas (dorsal hands, forearms, face); erosions and crusts; milia; scarring; hypertrichosis (especially face); hyperpigmentation; sclerodermoid changes; may have mild liver enzyme elevations; advanced fibrosis or cirrhosis in some; increased risk of hepatocellular carcinoma	Chronic course; blisters develop days after sun exposure; heal over weeks leaving scars and milia; new blisters continue to develop without treatment; remission achieved with treatment over months	Pseudoporphyria (drug-induced, dialysis-associated), variegate porphyria, hereditary coproporphyria, epidermolysis bullosa acquisita, bullous pemphigoid, bullous lupus erythematosus	Elevated urine porphyrins (uroporphyrin and 7-carboxyl porphyrin); plasma fluorescence emission peak at 619-620 nm; elevated serum ferritin; hepatitis C virus testing; liver function tests; consider liver biopsy if cirrhosis suspected; genetic testing for UROD mutations in familial cases	Phlebotomy: remove 450 mL every 1-2 weeks until serum ferritin low-normal (approximately 20 ng/mL); typically 3-8 phlebotomies; Alternative: low-dose hydroxychloroquine 100 mg twice weekly; both equally effective; treat hepatitis C virus if present; avoid alcohol, smoking, estrogens; sun protection; monitor for hepatocellular carcinoma if cirrhosis present	N	https://www.nejm.org/doi/full/10.1056/NEJMra1608634																
Post-Inflammatory Hyperpigmentation	Irregular hyperpigmented macules or patches at sites of prior inflammation or injury; "dark spots after acne or rash"; more prominent in darker skin types	Reactive hypermelanosis following inflammation or injury; increased melanin production and deposition in epidermis and/or dermis; melanocyte activation by inflammatory mediators; epidermal hyperpigmentation resolves better than dermal	Affects 65% of individuals with skin of color; 90% of cases occur in Fitzpatrick skin types III-VI; common after acne (47.4-65.3%), pseudofolliculitis barbae, atopic dermatitis, lichen planus, psoriasis; also follows procedures (chemical peels, cryotherapy, laser)	Irregular hyperpigmented macules or patches at sites of previous inflammation or trauma; tan to dark brown color; well-demarcated or diffuse; asymptomatic; face, neck, trunk, extremities depending on inciting cause; no scale or textural change	Develops days to weeks after inflammatory insult; persists for months to years; epidermal pigmentation may fade over 6-12 months; dermal pigmentation persists longer (years); chronic and unpredictable course	Melasma (symmetric facial distribution, hormonal triggers), solar lentigines (chronic sun exposure, older age), café au lait macules (present from birth or early childhood), tinea versicolor (potassium hydroxide positive)	Clinical diagnosis based on history of preceding inflammation; Wood lamp examination: epidermal pigment enhances, dermal pigment does not enhance; skin biopsy rarely needed: shows increased melanin in epidermis and/or dermis	Treat underlying inflammatory condition first; broad-spectrum sunscreen (SPF 30 or higher, iron oxide for visible light protection); First-line topical: hydroquinone 4% once or twice daily for 3 months; Triple combination therapy (fluocinolone 0.01%/hydroquinone 4%/tretinoin 0.05%) more effective than hydroquinone alone; Alternatives: tretinoin 0.1%, azelaic acid 15%, chemical peels, laser therapy	N	https://www.aafp.org/pubs/afp/issues/2023/0100/p26.html																
Post-Inflammatory Hypopigmentation	Hypopigmented patches at sites of prior inflammation; "white spots after rash heals"; more noticeable in darker skin types	Decreased melanin production and transfer to keratinocytes following inflammation; melanocyte damage or dysfunction; inflammatory mediators inhibit melanogenesis; may result from cutaneous inflammation, infectious dermatoses, or dermatologic procedures	More prominent in skin of color; common after atopic dermatitis, pityriasis alba, seborrheic dermatitis, psoriasis, tinea versicolor, laser procedures	Hypopigmented (not depigmented) patches at sites of previous inflammation; ill-defined borders; lighter than surrounding skin but not completely white; asymptomatic; distribution corresponds to prior inflammatory process	Develops weeks to months after inflammatory insult; most cases resolve spontaneously over months to years; duration depends on depth of pigment loss and underlying cause	Vitiligo (complete depigmentation, well-demarcated, progressive), tinea versicolor (potassium hydroxide positive, fine scale), pityriasis alba (facial distribution in children), idiopathic guttate hypomelanosis	Clinical diagnosis based on history of preceding inflammation; Wood lamp examination shows hypopigmentation (not complete depigmentation as in vitiligo); potassium hydroxide preparation to exclude tinea versicolor; skin biopsy if uncertain: shows reduced melanin in basal layer	Treat underlying inflammatory condition; most cases resolve spontaneously; sun protection to prevent contrast with surrounding skin; topical corticosteroids or calcineurin inhibitors for residual inflammation; phototherapy (narrowband ultraviolet B, excimer laser) may accelerate repigmentation; cosmetic camouflage	N	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916351/																
Pressure Ulcers	Localized skin and tissue damage over bony prominence in immobilized patient; "bedsore"; sacrum, heels, hips most common; staged I-IV plus unstageable and deep tissue injury	Prolonged pressure exceeding capillary perfusion pressure (32 mm Hg) causes tissue ischemia and necrosis; shear forces and friction contribute; moisture from incontinence macerates skin; malnutrition impairs healing	Prevalence 2.5 million annually in United States; affects 2.5-3% of hospitalized patients; higher in long-term care (2-28%), spinal cord injury (25-85%); risk factors: immobility, advanced age, malnutrition, incontinence, diabetes, vascular disease	Stage 1: non-blanchable erythema of intact skin; Stage 2: partial-thickness skin loss with exposed dermis; Stage 3: full-thickness skin loss with visible subcutaneous fat; Stage 4: full-thickness tissue loss with exposed muscle, tendon, or bone; Unstageable: obscured by slough or eschar; Deep tissue injury: persistent non-blanchable purple or maroon discoloration; most common sites: sacrum, heels, ischial tuberosities, greater trochanters	Develops over hours to days of sustained pressure; Stage 1 may progress to deeper stages within hours without intervention; healing time varies: Stage 2 (weeks), Stage 3-4 (months to years); 60% mortality within 1 year for Stage 4	Moisture-associated skin damage (incontinence-associated dermatitis), skin tears, arterial or venous ulcers, pyoderma gangrenosum, calciphylaxis, malignancy (Marjolin ulcer in chronic wounds)	Clinical diagnosis with staging based on depth of tissue loss; assess wound size, depth, exudate, odor, surrounding skin; evaluate for infection (erythema, warmth, purulent drainage, fever); imaging (radiography, magnetic resonance imaging) if concern for osteomyelitis; nutritional assessment (albumin, prealbumin)	Prevention: repositioning every 2 hours, pressure-redistributing surfaces, skin care, moisture management, nutritional support; Treatment: relieve pressure, wound care (debridement of necrotic tissue, moisture balance, infection control), nutritional optimization (protein 1.25-1.5 grams/kg/day, calories 30-35 kcal/kg/day, vitamin C, zinc); surgical debridement and flap closure for Stage 3-4 ulcers not healing with conservative management	Y	https://www.ncbi.nlm.nih.gov/books/NBK553107/																
Pseudofolliculitis Barbae	Inflammatory papules and pustules in beard area from ingrown hairs; "razor bumps"; common in individuals with tightly coiled hair; African American males predominantly affected	Tightly coiled or curly hair re-enters skin after shaving causing foreign body inflammatory reaction; extrafollicular penetration (transfollicular) or intrafollicular penetration; chronic inflammation leads to post-inflammatory hyperpigmentation and scarring	Affects 45-83% of African American males who shave; also affects other individuals with tightly coiled hair; onset typically in adolescence when shaving begins; occupational impact (military, food service requiring clean-shaven appearance)	Erythematous or hyperpigmented firm papules and pustules in beard distribution (jaw, upper neck); may have visible ingrown hairs; post-inflammatory hyperpigmentation common; keloid formation in severe cases; pruritus and tenderness; significant psychosocial impact	Develops days after shaving; chronic relapsing course with continued shaving; improves within weeks of shaving cessation; post-inflammatory hyperpigmentation persists for months	Bacterial folliculitis (culture positive), acne vulgaris (comedones present), tinea barbae (potassium hydroxide positive), contact dermatitis, keratosis pilaris	Clinical diagnosis based on characteristic appearance and history of shaving; bacterial culture if concern for secondary infection; potassium hydroxide preparation to exclude tinea barbae	First-line: shaving cessation for at least 8 weeks; if shaving required: use single-blade razor or electric clippers, shave in direction of hair growth, avoid close shaves, use pre-shave oils and lubricating shaving gel; Topical: benzoyl peroxide, salicylic acid, topical retinoids, topical antibiotics (clindamycin, erythromycin), eflornithine 13.9% cream (slows hair growth); chemical depilatories; laser hair removal (most effective long-term solution)	N	https://www.aafp.org/pubs/afp/issues/2023/0100/p26.html																
Purulent Cellulitis	Erythema, warmth, tenderness, swelling with purulent drainage or abscess; "cellulitis with pus"; methicillin-resistant Staphylococcus aureus most common	Bacterial infection of deep dermis and subcutaneous tissue with abscess formation; methicillin-resistant Staphylococcus aureus most common pathogen; purulent collections require drainage; systemic inflammatory response in severe cases	Common; methicillin-resistant Staphylococcus aureus accounts for majority of purulent skin infections; risk factors: prior methicillin-resistant Staphylococcus aureus infection, close contact with infected individuals, incarceration, intravenous drug use, contact sports, men who have sex with men	Erythema, warmth, tenderness, swelling with purulent drainage or fluctuant abscess; may have fever, malaise; regional lymphadenopathy; lower extremity, buttocks, groin common sites	Acute onset over hours to days; abscess formation over 3-7 days; improvement expected within 48-72 hours of drainage and appropriate antibiotics	Non-purulent cellulitis (no abscess), furuncle, carbuncle, hidradenitis suppurativa, necrotizing fasciitis (severe pain, systemic toxicity, rapid progression)	Clinical diagnosis; incision and drainage with culture and sensitivity testing; blood cultures if severe systemic features or immunocompromised; imaging if concern for deeper infection or necrotizing fasciitis	Incision and drainage is primary treatment for abscess; Antibiotics covering methicillin-resistant Staphylococcus aureus: trimethoprim-sulfamethoxazole 1-2 double-strength tablets twice daily, doxycycline 100 mg twice daily, or clindamycin 300-450 mg three times daily for 5-10 days; intravenous vancomycin or linezolid for severe systemic features; decolonization (mupirocin nasal ointment, chlorhexidine body washes) for recurrent infections	N	https://jamanetwork.com/journals/jama/fullarticle/2532513																
Pustular Psoriasis	Sterile pustules on erythematous base; generalized (von Zumbusch) or localized (palmoplantar); "sheets of pustules"; may have systemic symptoms; can be life-threatening	Autoinflammatory disease; mutations in IL36RN gene (encodes interleukin-36 receptor antagonist) in generalized pustular psoriasis; dysregulated interleukin-36 and interleukin-17 pathways; neutrophil accumulation forms sterile pustules; triggers include infection, pregnancy, medications (systemic corticosteroid withdrawal, lithium), hypocalcemia	Rare; generalized pustular psoriasis prevalence 1-2 per million; localized palmoplantar pustulosis more common; generalized form affects all ages; female predominance in palmoplantar form; may occur with or without plaque psoriasis	Generalized (von Zumbusch): acute onset of widespread erythema with sheets of sterile pustules; fever, malaise, arthralgia; may have hypocalcemia, hypoalbuminemia; life-threatening; Palmoplantar pustulosis: sterile pustules on palms and soles with erythema and scaling; painful, disabling; Acrodermatitis continua of Hallopeau: pustules on fingers and toes with nail dystrophy	Generalized: acute onset over hours to days; pustules coalesce and desquamate in waves; may be recurrent; Palmoplantar: chronic relapsing course; pustules evolve to brown macules over 7-10 days; new crops develop	Acute generalized exanthematous pustulosis (drug-induced, resolves with drug discontinuation), subcorneal pustular dermatosis, impetigo, pustular drug eruption, infection	Clinical diagnosis; skin biopsy shows spongiform pustules of Kogoj (neutrophils in epidermis), acanthosis, parakeratosis; bacterial culture to exclude infection; complete blood count, comprehensive metabolic panel (hypocalcemia, hypoalbuminemia in generalized form); genetic testing for IL36RN mutations	Generalized pustular psoriasis: hospitalization for severe cases; acitretin 25-50 mg daily, cyclosporine 3-5 mg/kg/day, methotrexate, biologics (interleukin-17 inhibitors: secukinumab, ixekizumab; interleukin-23 inhibitors: guselkumab, risankizumab; spesolimab for acute flares); supportive care (fluid resuscitation, electrolyte correction); Palmoplantar: high-potency topical corticosteroids, acitretin, phototherapy, biologics	Y	https://www.ncbi.nlm.nih.gov/books/NBK537127/																
Pyoderma Gangrenosum	Rapidly enlarging painful ulcer with violaceous undermined border; "pathergy" (new lesions at trauma sites); 50% associated with inflammatory bowel disease, rheumatoid arthritis, hematologic malignancy	Neutrophilic dermatosis; dysregulated innate immune response with excessive neutrophil activation; pathergy (lesions at sites of trauma); associated with systemic diseases (inflammatory bowel disease 50%, rheumatoid arthritis, hematologic malignancy); mutations in PSTPIP1, MEFV genes in some cases	Incidence 3-10 per million per year; affects all ages with peak 40-60 years; slight female predominance; 50% have associated systemic disease (inflammatory bowel disease most common, also rheumatoid arthritis, hematologic malignancy)	Begins as painful pustule or nodule that rapidly breaks down into enlarging ulcer; violaceous undermined border; purulent base; severe pain out of proportion to size; pathergy (new lesions at trauma sites); lower extremities most common (70%); may have systemic symptoms if associated disease	Rapid progression over days to weeks; ulcer expands centrifugally; may stabilize or continue to enlarge without treatment; healing occurs slowly over months with cribriform (sieve-like) scarring	Venous ulcer, arterial ulcer, vasculitis, infection (ecthyma, atypical mycobacteria), malignancy (squamous cell carcinoma), factitial ulcer, calciphylaxis	Diagnosis of exclusion; skin biopsy from ulcer edge shows neutrophilic infiltrate, but not specific; exclude infection with bacterial, fungal, mycobacterial cultures; evaluate for associated diseases: colonoscopy for inflammatory bowel disease, complete blood count for hematologic malignancy, rheumatoid factor and anti-cyclic citrullinated peptide for rheumatoid arthritis	Avoid debridement (causes pathergy); Localized: high-potency topical corticosteroids, intralesional corticosteroids, topical tacrolimus; Moderate to severe: systemic corticosteroids (prednisone 0.5-1 mg/kg/day), cyclosporine 3-5 mg/kg/day, biologics (tumor necrosis factor inhibitors: infliximab, adalimumab; interleukin-12/23 inhibitor: ustekinumab; interleukin-17 inhibitor: secukinumab); wound care; pain management; treat underlying associated disease	N	https://www.ncbi.nlm.nih.gov/books/NBK482247/																
Pyogenic Granuloma	Rapidly growing friable red papule that bleeds easily; "raspberry-like lesion"; often follows minor trauma; common in pregnancy	Benign vascular tumor (lobular capillary hemangioma); rapid proliferation of capillaries; triggered by trauma, pregnancy, medications (retinoids, protease inhibitors); not infectious despite name	Affects all ages; children: head and neck most common; adults: trunk and extremities; pregnancy-associated (granuloma gravidarum) on gingiva; slight male predominance in children	Solitary friable red to purple papule or nodule; bleeds easily with minor trauma; rapid growth over weeks to months; typically less than 2 cm; often surrounded by collarette of scale; may ulcerate; most common sites: fingers, lips, oral mucosa, face	Rapid growth over weeks to months; stabilizes at less than 2 cm; may regress spontaneously but most persist without treatment; recurrence in 0-15% after treatment	Cherry angioma (does not bleed easily, multiple), amelanotic melanoma, Spitz nevus, squamous cell carcinoma, basal cell carcinoma, bacillary angiomatosis (in immunocompromised)	Clinical diagnosis; dermoscopy shows homogeneous red-white areas with white collarette; skin biopsy shows lobular capillary proliferation if diagnosis uncertain	Surgical excision with margin (lowest recurrence rate); alternatives: shave excision with electrodesiccation of base, cryotherapy, laser therapy (pulsed dye laser, carbon dioxide); topical beta-blockers (timolol, propranolol) with occlusion for small lesions, especially in children	N	https://www.aafp.org/pubs/afp/issues/2024/1000/p353.html																
Pyridoxine (Vitamin B6) Deficiency	Seborrheic dermatitis, glossitis, cheilosis, peripheral neuropathy, seizures (especially in infants); "dermatitis plus neuropathy"; associated with isoniazid therapy	Deficiency of pyridoxine (vitamin B6); pyridoxal phosphate is cofactor for over 100 enzymes in amino acid metabolism, neurotransmitter synthesis (serotonin, dopamine, gamma-aminobutyric acid), heme synthesis; causes: inadequate intake, alcoholism, malabsorption, medications (isoniazid, penicillamine, cycloserine)	Uncommon in developed countries; approximately 20% of United States population has plasma pyridoxal phosphate less than 30 nmol/L; risk factors: alcoholism, malabsorption, chronic kidney disease, medications (isoniazid most common)	Dermatologic: seborrheic dermatitis, cheilosis, glossitis; Neurologic: peripheral neuropathy (sensory greater than motor), seizures (especially pyridoxine-dependent epilepsy in infants), confusion, depression; Hematologic: microcytic or sideroblastic anemia; may have hyperhomocysteinemia	Develops over weeks to months of deficiency; neurologic symptoms may become irreversible if prolonged; symptoms improve within days to weeks of supplementation	Riboflavin deficiency (similar dermatologic findings), niacin deficiency (pellagra), other causes of peripheral neuropathy, seborrheic dermatitis from other causes	Plasma pyridoxal phosphate less than 20 nmol/L indicates deficiency (less than 30 nmol/L more commonly used); elevated homocysteine; evaluate for underlying cause (medication history, alcoholism, malabsorption)	Pyridoxine 50-100 mg orally daily for deficiency; higher doses (100-200 mg daily) for isoniazid-induced deficiency; prophylaxis: pyridoxine 25-50 mg daily with isoniazid therapy; treat underlying cause; avoid doses greater than 200 mg/day (risk of sensory neuropathy)	N	https://www.nejm.org/doi/full/10.1056/NEJMra2314150																
Raynaud Phenomenon	Episodic digital color changes (white, blue, red) triggered by cold or stress; "triphasic color change in fingers"; primary (benign) versus secondary (associated with connective tissue disease)	Exaggerated vasospasm of digital arteries in response to cold or emotional stress; primary: functional abnormality without underlying disease; secondary: structural vascular damage from connective tissue diseases (especially systemic sclerosis), medications, occupational exposure	Affects 3-5% of general population; primary: onset age 15-30 years, female to male ratio 9:1; secondary: onset after age 30, associated with systemic sclerosis (90% of patients), systemic lupus erythematosus, mixed connective tissue disease	Episodic triphasic color changes: pallor (white from vasospasm), cyanosis (blue from deoxygenation), rubor (red from reperfusion); triggered by cold exposure or emotional stress; fingers most common, toes less common; primary: symmetric, spares thumbs, no tissue damage; secondary: asymmetric, may include thumbs, digital ulcers or pitting scars, abnormal nailfold capillaries	Episodes last minutes to hours; primary: lifelong but benign course; secondary: progressive with risk of digital ulceration, gangrene; 37.2% with presumed primary develop connective tissue disease over time	Primary versus secondary Raynaud; acrocyanosis (persistent blue discoloration without pallor phase), chilblains (pernio), thromboangiitis obliterans, cryoglobulinemia, thoracic outlet syndrome	Clinical diagnosis based on biphasic color change; nailfold capillaroscopy: normal in primary, enlarged capillary loops and dropout in secondary (especially systemic sclerosis); antinuclear antibody, erythrocyte sedimentation rate, complete blood count; specific autoantibodies if positive antinuclear antibody	Avoid cold exposure, smoking cessation, stress management; calcium channel blockers (nifedipine extended-release 30-90 mg daily) first-line for moderate to severe symptoms; alternatives: phosphodiesterase-5 inhibitors (sildenafil, tadalafil), topical nitroglycerin, prostacyclin analogues (iloprost) for severe secondary; treat underlying disease	N	https://www.nejm.org/doi/full/10.1056/NEJMra1507638																
Rheumatoid Nodules	Firm subcutaneous nodules over pressure points (elbows, fingers) in patient with rheumatoid arthritis; "bumps on elbows"; associated with positive rheumatoid factor and severe disease	Granulomatous inflammation with central fibrinoid necrosis surrounded by palisading epithelioid macrophages; pathogenesis unclear; associated with high rheumatoid factor titers, anti-citrullinated protein antibodies, severe erosive disease, smoking	Most common extra-articular manifestation of rheumatoid arthritis; affects 20-35% of rheumatoid arthritis patients; more common in males; associated with rheumatoid factor positivity (87.7% high-positive), anti-citrullinated protein antibodies, bone erosion (77.2%), disease-modifying anti-rheumatic drug use (98.2%)	Firm, usually painless subcutaneous nodules 5 mm to several cm; most common sites: extensor surfaces (elbows, fingers), pressure points (sacrum, occiput, Achilles tendon); may occur in lungs, heart valves, vocal cords; mobile or fixed; skin-colored to erythematous; may ulcerate or become infected	Develop average 11.6 years after rheumatoid arthritis onset; chronic and persistent; may wax and wane with disease activity; can develop or worsen with methotrexate therapy (paradoxical)	Gouty tophi, xanthomas, granuloma annulare, sarcoidosis, necrobiosis lipoidica, subcutaneous calcifications, infection (abscess)	Clinical diagnosis in patient with rheumatoid arthritis; skin biopsy shows central fibrinoid necrosis surrounded by palisading epithelioid macrophages and outer layer of chronic inflammation; imaging if concern for internal nodules	Optimize rheumatoid arthritis treatment; surgical excision if symptomatic, infected, or cosmetically concerning; intralesional corticosteroids; hydroxychloroquine may reduce nodules; consider discontinuing methotrexate if nodules develop or worsen on therapy	N	https://www.aafp.org/pubs/afp/issues/2024/1100/p515.html																
Riboflavin (Vitamin B2) Deficiency	Angular cheilosis, glossitis, seborrheic dermatitis, normocytic anemia; "sore mouth and lips"; often coexists with other B vitamin deficiencies	Deficiency of riboflavin (vitamin B2); flavin adenine dinucleotide and flavin mononucleotide are cofactors for energy metabolism, antioxidant reactions, metabolism of other B vitamins (folate, pyridoxine, niacin); causes: inadequate intake (dairy avoidance), alcoholism, malabsorption, phototherapy in neonates	Prevalence uncertain in United States but high in Europe if dairy avoided; severe deficiency rare in developed countries; subclinical deficiency may be widespread; risk factors: alcoholism, malabsorption, vegan diet, phototherapy in neonates	Orofacial: angular cheilosis (cracks at mouth corners), glossitis (magenta tongue), seborrheic dermatitis (nasolabial folds, scrotum); Ocular: photophobia, lacrimation, decreased visual acuity; Hematologic: normocytic anemia; may have pharyngitis, peripheral neuropathy	Develops over weeks to months of deficiency; symptoms improve within days to weeks of supplementation; dermatologic manifestations resolve first	Niacin deficiency (pellagra), pyridoxine deficiency, iron deficiency anemia, other causes of angular cheilosis (candidiasis, contact dermatitis)	Erythrocyte glutathione reductase activity coefficient: 1.2-1.4 considered low, greater than 1.4 deficient; red blood cell riboflavin less than 170 nmol/L detects 92% of cases with activity coefficient 1.4 or higher; no reliable plasma assay	Riboflavin 5-30 mg orally daily until symptoms resolve; maintenance 1.1-1.3 mg daily (recommended dietary allowance); treat underlying cause; multivitamin supplementation (often multiple deficiencies); dietary counseling (dairy products, eggs, lean meats, green vegetables)	N	https://www.nejm.org/doi/full/10.1056/NEJMra2314150																
Rocky Mountain Spotted Fever	Fever, headache, myalgia followed by petechial rash starting on wrists and ankles spreading centrally including palms and soles; "rash on palms and soles after tick bite"; can be fatal if untreated	Infection with Rickettsia rickettsii transmitted by tick bite (Dermacentor variabilis, Dermacentor andersoni); rickettsiae invade endothelial cells causing vasculitis; increased vascular permeability leads to edema, hypovolemia, end-organ damage	Incidence 6-7 per million in United States; 60% of cases in 5 southern states (North Carolina, Oklahoma, Arkansas, Tennessee, Missouri); peak April to September; all ages affected; 50% do not recall tick exposure	Early (days 1-4): high fever, severe headache, malaise, myalgia, nausea, vomiting; Rash (days 2-5): maculopapular rash on wrists, forearms, ankles spreading to trunk, palms, soles; Late (day 6 and beyond): petechial rash (severe disease), altered mental status, pulmonary edema, acute respiratory distress syndrome, multiorgan failure; 10-15% never develop rash	Incubation 3-12 days; rash appears 2-5 days after fever onset; petechiae after day 6 indicate severe disease; mortality 20-25% untreated, less than 5% with prompt treatment; delay beyond 5 days increases fatality	Ehrlichiosis, anaplasmosis, meningococcemia, measles, typhus, thrombotic thrombocytopenic purpura, immune thrombocytopenic purpura, viral exanthem	Clinical diagnosis; do not delay treatment for laboratory confirmation; thrombocytopenia, hyponatremia, elevated hepatic transaminases; serology: 4-fold increase in immunoglobulin G by indirect immunofluorescence assay in paired samples (acute and convalescent 2-4 weeks later); polymerase chain reaction or immunohistochemistry of skin biopsy	Doxycycline 100 mg orally or intravenously twice daily for adults; doxycycline 2.2 mg/kg twice daily for children (regardless of age); start immediately on clinical suspicion; treat minimum 5-7 days and at least 3 days after fever subsides; chloramphenicol alternative in pregnancy (higher mortality)	Y	https://www.cdc.gov/rmsf/index.html																
Rosacea	Central facial erythema, flushing, telangiectasias, papules and pustules; "red face with bumps"; spares nasolabial folds; adults 30-50 years	Chronic inflammatory skin disease; dysregulated innate immunity; neurovascular dysregulation; Demodex folliculorum proliferation; genetic predisposition; triggers include sun, heat, alcohol, spicy foods, stress	Affects 5% of population; peak age 30-50 years; more common in fair-skinned individuals; female predominance but more severe in males; underdiagnosed in skin of color	Fixed central facial erythema in characteristic pattern (cheeks, nose, chin, forehead); flushing; telangiectasias; papules and pustules without comedones; phymatous changes (skin thickening, rhinophyma); ocular involvement (dry eyes, blepharitis); burning and stinging	Chronic relapsing course; onset typically in 30s-40s; progressive without treatment; flares triggered by heat, sun, alcohol, spicy foods, stress; individual lesions develop over days	Acne vulgaris (has comedones), seborrheic dermatitis (affects scalp and hairline), lupus (spares nasolabial folds), perioral dermatitis, photodamage, carcinoid syndrome	Clinical diagnosis using 2017 National Rosacea Society criteria: requires one diagnostic feature (fixed erythema or phymatous changes) or two major features (papules/pustules, flushing, telangiectasias); skin biopsy rarely needed	Trigger avoidance; daily broad-spectrum sunscreen SPF 30 or higher; gentle skin care; Erythema/flushing: topical alpha-adrenergic agonists (brimonidine, oxymetazoline), oral beta-blockers; Papules/pustules: topical ivermectin, metronidazole, azelaic acid; oral doxycycline 40 mg daily for moderate-severe; isotretinoin for severe refractory cases	N	https://www.aafp.org/pubs/afp/issues/2024/0600/p533.html																
Roseola (Exanthem Subitum)	High fever for 3-4 days in infant, then rash appears as fever breaks; "fever then feels fine"; caused by human herpesvirus 6 or 7	Primary infection with human herpesvirus 6B (most common) or human herpesvirus 7; viral replication in lymphocytes; viremia causes fever; rash appears as immune response clears virus	Peak age 6-15 months; nearly universal infection by age 2 years; human herpesvirus 7 infection occurs slightly later (mean 26 months); transmitted via saliva	High fever (38-40 degrees Celsius) for 3-5 days; child appears well despite fever; rash appears as fever resolves: pink maculopapular on trunk, face, extremities lasting 1-3 days; febrile seizures in 10-15%; may have mild upper respiratory symptoms, diarrhea	Incubation 5-15 days; fever 3-5 days; rash appears on day 3-4 as fever breaks; rash lasts 1-3 days; total illness 5-7 days; full recovery typical	Rubella, measles, scarlet fever, drug eruption, other viral exanthems	Clinical diagnosis based on characteristic fever pattern followed by rash; polymerase chain reaction from blood for confirmation if needed; serology shows immunoglobulin M or immunoglobulin G seroconversion	Supportive care: antipyretics for fever, hydration; seizure management if needed; antivirals (ganciclovir, foscarnet) reserved for severe disease in immunocompromised	N	https://www.ncbi.nlm.nih.gov/books/NBK448190/																
Rubella (German Measles)	Mild fever, posterior auricular and suboccipital lymphadenopathy, maculopapular rash starting on face; "3 Ls: low-grade fever, lymphadenopathy, light rash"; arthralgia in adults; congenital rubella syndrome if maternal infection	Infection with rubella virus (togavirus); virus replicates in nasopharynx and regional lymph nodes; viremia causes rash and systemic symptoms; transplacental transmission causes congenital rubella syndrome	Rare in vaccinated populations; incubation 12-23 days (average 17 days); 25-50% of infections asymptomatic; congenital rubella syndrome risk highest (greater than 90%) if maternal infection in first trimester	Prodrome: low-grade fever, headache, malaise, mild conjunctivitis, sore throat, cough; posterior auricular, posterior cervical, suboccipital lymphadenopathy (characteristic); maculopapular rash starts on face, spreads to trunk and extremities over 24 hours, lasts 3 days; arthralgia/arthritis in 70% of adult women; Congenital rubella syndrome: cataracts, cardiac defects (patent ductus arteriosus, pulmonary stenosis), sensorineural deafness, microcephaly, developmental delay	Incubation 12-23 days; prodrome up to 5 days before rash; lymphadenopathy starts before rash; rash lasts median 3 days; arthralgia lasts days to weeks	Measles (more severe, Koplik spots), scarlet fever (sandpaper rash, strawberry tongue), roseola, parvovirus B19, drug eruption	Rubella-specific immunoglobulin M antibody by enzyme immunoassay (peak 5 days after rash onset); 4-fold increase in immunoglobulin G between acute and convalescent samples; reverse transcription polymerase chain reaction from nasopharyngeal swab; notify public health authorities	Supportive care: antipyretics, hydration; isolation until 7 days after rash onset; post-exposure prophylaxis: measles-mumps-rubella vaccine within 72 hours if not immune; immunoglobulin for pregnant women; prevention: measles-mumps-rubella vaccination	Y	https://www.cdc.gov/rubella/index.html																
Sarcoidosis	Bilateral hilar lymphadenopathy with or without pulmonary infiltrates; erythema nodosum; lupus pernio; "non-caseating granulomas everywhere"	Multisystem granulomatous disease of unknown etiology; exaggerated cellular immune response to unknown antigen; non-caseating granulomas in affected organs; genetic susceptibility; environmental triggers suspected	Incidence 10-20 per 100,000; peak age 20-40 years; more common in African Americans (3-4 times) and Northern Europeans; female predominance; Lofgren syndrome (acute sarcoidosis with erythema nodosum, bilateral hilar lymphadenopathy, arthritis) has good prognosis	Pulmonary (90%): dyspnea, cough, chest pain; bilateral hilar lymphadenopathy; Skin (25%): erythema nodosum (acute), lupus pernio (chronic violaceous plaques on nose, cheeks, ears), papules, plaques, scars; Eyes (25%): uveitis, dry eyes; Cardiac (5%): arrhythmias, heart block, cardiomyopathy; Neurologic (5%): cranial neuropathies (especially facial nerve), meningitis; Hypercalcemia; Constitutional symptoms	Acute (Lofgren syndrome): self-limited over months; Chronic: insidious onset, progressive over years; spontaneous remission in 60-70% within 2 years; 10-30% develop chronic progressive disease	Tuberculosis (caseating granulomas), fungal infections, lymphoma, berylliosis, hypersensitivity pneumonitis, other granulomatous diseases	Chest radiography: bilateral hilar lymphadenopathy (stage I), pulmonary infiltrates (stage II-III), fibrosis (stage IV); elevated angiotensin-converting enzyme (60%); hypercalcemia; tissue biopsy showing non-caseating granulomas; exclude infections with cultures, stains	Asymptomatic: observation; Symptomatic: systemic corticosteroids (prednisone 20-40 mg daily, taper over 6-12 months); steroid-sparing agents: methotrexate, azathioprine, hydroxychloroquine; biologics (tumor necrosis factor inhibitors) for refractory disease; treat specific organ involvement (cardiac, neurologic, ocular)	Y	https://www.ncbi.nlm.nih.gov/books/NBK448194/																
Scabies	Intense pruritus worse at night; burrows in web spaces, wrists, genitals; "itchy rash between fingers"; caused by Sarcoptes scabiei mite	Infestation with Sarcoptes scabiei mite; female mite burrows into stratum corneum laying eggs; hypersensitivity reaction to mite, eggs, feces causes pruritus and rash; transmitted by prolonged skin-to-skin contact	Common; estimated 200 million cases worldwide; affects all socioeconomic groups; outbreaks in nursing homes, hospitals, prisons; incubation 2-6 weeks for first infestation, 1-3 days for re-infestation	Intense pruritus worse at night; burrows (pathognomonic): linear or S-shaped ridges in web spaces, wrists, elbows, axillae, waistline, genitals, buttocks; excoriated papules; secondary bacterial infection common; crusted (Norwegian) scabies in immunocompromised: thick crusts with millions of mites	Incubation 2-6 weeks for first infestation; pruritus and rash develop as hypersensitivity reaction; pruritus may persist 2-4 weeks after successful treatment; re-infestation causes symptoms within 1-3 days	Atopic dermatitis, contact dermatitis, insect bites, folliculitis, impetigo, dermatitis herpetiformis	Clinical diagnosis based on pruritus and distribution; dermoscopy may reveal mites or burrows; skin scraping with mineral oil: identify mites, eggs, or feces under microscopy (sensitivity 50%); burrow ink test	Permethrin 5% cream applied neck down, wash off after 8-14 hours, repeat in 1 week; alternative: ivermectin 200 micrograms/kg orally, repeat in 2 weeks; treat all household and close contacts simultaneously; wash bedding and clothing in hot water; antihistamines for pruritus; topical corticosteroids for inflammation	N	https://www.cdc.gov/parasites/scabies/index.html																
Scarlet Fever	Sandpaper-like rash, strawberry tongue, circumoral pallor in child with strep throat; "sandpaper rash with strawberry tongue"; Pastia lines in flexural creases	Group A Streptococcus (Streptococcus pyogenes) pharyngitis with erythrogenic toxin production; toxin causes diffuse erythematous rash; immune-mediated complications include rheumatic fever, post-streptococcal glomerulonephritis	Peak age 5-15 years; more common in children than adults; winter and spring predominance; transmitted by respiratory droplets; incubation 2-5 days	Prodrome: fever, sore throat, headache, vomiting; Pharyngitis: exudative tonsillitis, palatal petechiae; Rash (12-48 hours after fever): diffuse erythematous blanching sandpaper-like rash starting on neck and chest, spreading to trunk and extremities; spares palms and soles; circumoral pallor; Pastia lines (accentuation in flexural creases); strawberry tongue (white then red); desquamation 1-2 weeks after rash onset	Incubation 2-5 days; rash appears 12-48 hours after fever onset; rash lasts 4-5 days; desquamation begins as rash fades and lasts 1-2 weeks	Kawasaki disease (younger age, conjunctivitis, no pharyngitis), staphylococcal toxic shock syndrome, viral exanthems (measles, rubella), drug eruption	Clinical diagnosis; rapid antigen detection test for group A Streptococcus; throat culture (gold standard); antistreptolysin O titer or anti-DNase B for post-streptococcal complications	Penicillin V 250 mg orally three times daily for 10 days (children) or 500 mg twice daily (adults); amoxicillin 50 mg/kg/day divided twice daily for 10 days; alternatives: cephalexin, azithromycin, clindamycin; antipyretics; monitor for complications (rheumatic fever, post-streptococcal glomerulonephritis)	N	https://www.cdc.gov/groupastrep/diseases-public/scarlet-fever.html																
Scarring (Cicatricial) Alopecia	Permanent hair loss with smooth, shiny scalp lacking follicular openings; "shiny scalp with no pores"; may have inflammation, scaling, or pustules; central centrifugal cicatricial alopecia common in African American women	Primary destruction of hair follicles with replacement by fibrous tissue; lymphocytic (lichen planopilaris, frontal fibrosing alopecia, central centrifugal cicatricial alopecia) or neutrophilic/mixed (folliculitis decalvans, dissecting cellulitis) inflammation; follicular stem cells destroyed leading to permanent hair loss	Affects all ages and ethnicities; central centrifugal cicatricial alopecia most common in African American women; lichen planopilaris more common in middle-aged women; frontal fibrosing alopecia increasing in postmenopausal women	Permanent patches of hair loss with smooth, shiny scalp; absence of follicular openings; may have erythema, scaling, pustules, or crusting at active margins; pruritus, burning, or tenderness; scarring visible on close examination; central centrifugal cicatricial alopecia: starts at vertex, expands centrifugally; frontal fibrosing alopecia: band-like recession of frontal hairline and eyebrows	Progressive over months to years; active inflammatory phase followed by burnt-out scarred phase; early treatment critical to prevent further follicle destruction; hair loss is permanent and irreversible	Non-scarring alopecia (androgenetic alopecia, alopecia areata, telogen effluvium), tinea capitis, traction alopecia (early stages may be reversible), discoid lupus erythematosus	Clinical diagnosis with dermoscopy showing absence of follicular openings; scalp biopsy from active margin (two 4-mm punch biopsies: one for vertical sectioning, one for horizontal sectioning) shows follicular destruction with fibrosis and inflammatory infiltrate; direct immunofluorescence if lupus suspected	Early treatment essential; high-potency topical corticosteroids; intralesional triamcinolone 5-10 mg/mL monthly; systemic therapy for progressive disease: hydroxychloroquine 200-400 mg daily, doxycycline 100 mg twice daily, mycophenolate mofetil, oral corticosteroids; antibiotics for neutrophilic types; hair transplantation only after disease inactive for 1-2 years	N	https://www.aafp.org/pubs/afp/issues/2024/0900/p243.html																
Sebaceous Gland Hyperplasia	Dome-shaped yellow papules with central umbilication on forehead and cheeks in older adults; "yellow bumps with belly buttons on face"; multiple lesions common	Benign enlargement of sebaceous glands; increased sebocyte proliferation; associated with aging, sun exposure, immunosuppression, cyclosporine therapy; represents hyperplasia not neoplasia	Common in middle-aged and older adults; more common in men; affects 1% of general population, increases with age; associated with chronic sun exposure	Multiple small (1-4 mm) dome-shaped, soft, yellow to skin-colored papules with central umbilication; primarily on forehead, cheeks, nose; asymptomatic; may have telangiectasias on surface; dermoscopy shows crown vessels at base of follicle and between yellow lobules	Develops in middle age and increases with aging; lesions persist indefinitely; may slowly increase in number; stable once formed	Basal cell carcinoma (more pink, enlarges over time, arborizing vessels on dermoscopy), molluscum contagiosum (younger patients, different distribution), sebaceous adenoma (solitary, larger), nevus sebaceus	Clinical diagnosis; dermoscopy shows hair follicles surrounded by yellow lobules with crown vessels; biopsy if uncertain: shows enlarged sebaceous glands with multiple lobules opening into central dilated duct	No treatment required; cosmetic options: cryotherapy, shave excision, electrodesiccation and curettage, laser ablation (carbon dioxide, pulsed dye), chemical cautery, photodynamic therapy; oral isotretinoin for widespread lesions; lesions may recur after treatment	N	https://www.aafp.org/pubs/afp/issues/2024/1000/p353.html																
Sebaceous Nevus of Jadassohn	Yellow-orange hairless plaque on scalp or face present at birth; "bald yellow patch on baby's head"; becomes verrucous at puberty; risk of secondary neoplasms	Congenital hamartoma with abnormal sebaceous glands, hair follicles, apocrine glands; hormonal changes at puberty cause lesion to become more prominent and verrucous; secondary neoplasms develop in 10-30% (mostly benign trichoblastoma, syringocystadenoma papilliferum; basal cell carcinoma rare)	Affects 0.3% of newborns; no gender predominance; sporadic; may be associated with epidermal nevus syndrome (central nervous system, skeletal, ocular abnormalities) if extensive	Congenital hairless yellow-orange plaque on scalp (50-75%) or face; smooth surface in infancy; becomes thickened, verrucous, nodular at puberty; typically solitary, well-demarcated, oval or linear; 1-9 cm; asymptomatic; secondary tumors appear as nodules within lesion	Present at birth; relatively flat and smooth in childhood; becomes raised, verrucous, and more prominent at puberty due to hormonal stimulation; secondary neoplasms develop in adulthood (average age 30-40 years)	Aplasia cutis congenita, juvenile xanthogranuloma, mastocytoma, epidermal nevus, congenital melanocytic nevus	Clinical diagnosis based on characteristic appearance and location; skin biopsy shows immature hair follicles, sebaceous glands, apocrine glands in dermis; biopsy any nodular areas to exclude secondary neoplasm	Prophylactic excision recommended before or during puberty to prevent secondary neoplasms and for cosmetic reasons; complete excision with primary closure or tissue expansion; observation acceptable with close monitoring for nodular changes; excise any suspicious nodules	N	https://www.ncbi.nlm.nih.gov/books/NBK470172/																
Seborrheic Dermatitis	Greasy yellow scales with erythema on scalp, nasolabial folds, eyebrows, chest; "dandruff plus greasy scales on face"; associated with Parkinson disease and HIV	Chronic inflammatory condition; Malassezia yeast colonization triggers inflammatory response in genetically susceptible individuals; sebaceous gland activity contributes; immune dysregulation; neurologic diseases (Parkinson) and immunosuppression (HIV) increase severity	Affects 1-3% of general population; infantile form (cradle cap) affects up to 70% of infants in first 3 months; adult form: prevalence 11.6% overall, 2.8% clinically significant; peak age 35-44 years; more common and severe in Parkinson disease (30-80%) and HIV (34-83%)	Scalp: greasy yellow scales (dandruff) to thick crusts with erythema; Face: erythematous patches with greasy scales on eyebrows, glabella, nasolabial folds, beard area; Chest: petaloid pattern with circinate patches; Intertriginous areas: erythema with fissuring; mild to moderate pruritus; blepharitis common; severe in HIV patients	Infantile form: appears first 3 months of life, resolves by 1 year; Adult form: chronic relapsing course; flares in winter, with stress, illness; improves in summer	Psoriasis (thicker scale, well-demarcated, extensor surfaces), atopic dermatitis (more pruritic, flexural), tinea capitis (potassium hydroxide positive), rosacea, systemic lupus erythematosus	Clinical diagnosis; potassium hydroxide preparation to exclude tinea; skin biopsy if uncertain: shows parakeratosis, spongiosis, perivascular lymphocytic infiltrate	Scalp: antifungal shampoos (ketoconazole 2%, selenium sulfide 2.5%, zinc pyrithione 1-2%) twice weekly; Face/body: topical antifungals (ketoconazole 2% cream), topical corticosteroids (low to mid-potency), topical calcineurin inhibitors (pimecrolimus 1%, tacrolimus 0.1%); maintenance with antifungal shampoos or creams 1-2 times weekly	N	https://www.aafp.org/pubs/afp/issues/2025/0800/p166.html																
Seborrheic Keratosis	Stuck-on waxy brown papules and plaques; "looks like it was stuck on with glue"; common in older adults; "barnacles of aging"	Benign epidermal tumor; clonal proliferation of keratinocytes; mutations in FGFR3, PIK3CA genes; not premalignant; sign of Leser-Trelat (sudden eruption of multiple seborrheic keratoses) may indicate internal malignancy	Very common; increases with age; affects more than 90% of adults over 60 years; equal gender distribution; more common in fair-skinned individuals; familial tendency	Well-demarcated, round to oval, brown to black papules or plaques with stuck-on waxy appearance; surface may have keratin plugs (horn cysts); range 0.2-3 cm; trunk, face, extremities; usually multiple; asymptomatic or mildly pruritic; may become irritated or inflamed	Develop in middle age and increase in number with aging; individual lesions grow slowly; persist indefinitely; sign of Leser-Trelat: sudden appearance of multiple lesions may indicate internal malignancy (gastric adenocarcinoma most common)	Melanoma (asymmetry, color variation, evolution), pigmented basal cell carcinoma, solar lentigo, verruca, actinic keratosis, melanocytic nevus	Clinical diagnosis; dermoscopy shows milia-like cysts, comedo-like openings, fissures and ridges (brain-like pattern), hairpin vessels; biopsy if concern for melanoma: shows acanthosis, hyperkeratosis, horn cysts	No treatment required; removal for cosmetic reasons, irritation, or diagnostic uncertainty: cryotherapy (first-line), shave excision, electrodesiccation and curettage, laser ablation; evaluate for internal malignancy if sign of Leser-Trelat	N	https://www.aafp.org/pubs/afp/issues/2024/1000/p353.html																
Serum Sickness	Fever, arthralgia, urticarial rash 7-14 days after antigen exposure (antibiotics, antitoxins); "rash and joint pain after penicillin"; immune complex-mediated hypersensitivity	Type III hypersensitivity reaction; immune complex formation (antigen-antibody complexes) with complement activation; immune complexes deposit in blood vessels, joints, kidneys causing inflammation; classic causes: heterologous antisera (antithymocyte globulin, antivenom), antibiotics (penicillins, cephalosporins, sulfonamides)	Rare since decreased use of animal-derived antisera; incidence varies by causative agent; occurs 7-14 days after first exposure or 1-3 days after re-exposure; affects all ages	Fever, malaise, arthralgia (large joints: knees, ankles, wrists); urticarial rash (may be purpuric); lymphadenopathy; edema of face, hands, feet; may have glomerulonephritis, vasculitis, neuropathy; gastrointestinal symptoms (nausea, vomiting, diarrhea)	Incubation 7-14 days after first exposure (1-3 days after re-exposure); symptoms develop acutely; duration 1-2 weeks; self-limited once antigen cleared; may recur with re-exposure	Serum sickness-like reaction (no immune complexes, no complement consumption), viral infection, drug reaction with eosinophilia and systemic symptoms, urticaria, vasculitis, systemic lupus erythematosus	Clinical diagnosis based on temporal relationship to antigen exposure; decreased complement C3 and C4; elevated erythrocyte sedimentation rate and C-reactive protein; urinalysis for proteinuria, hematuria; no eosinophilia (distinguishes from serum sickness-like reaction); circulating immune complexes may be detected	Discontinue offending agent; antihistamines for urticaria; nonsteroidal anti-inflammatory drugs for arthralgia; corticosteroids (prednisone 0.5-1 mg/kg/day for 1-2 weeks) for severe symptoms; supportive care; symptoms resolve within 1-2 weeks	N	https://www.ncbi.nlm.nih.gov/books/NBK513258/																
Serum Sickness-Like Reaction	Fever, arthralgia, urticarial rash after medication (especially cefaclor); "looks like serum sickness but isn't"; no immune complexes; more common in children	Non-immune complex-mediated hypersensitivity reaction; exact mechanism unclear; direct drug effect or metabolite-induced inflammation; not true type III hypersensitivity; normal complement levels; eosinophilia common; most common with cefaclor, other beta-lactams, bupropion, minocycline	More common than true serum sickness; affects 1-2% of patients taking cefaclor; more common in children; occurs with various medications	Fever, arthralgia, urticarial or erythematous rash; edema; lymphadenopathy; similar clinical presentation to serum sickness but normal complement levels; eosinophilia present; no vasculitis or glomerulonephritis	Onset 1-3 weeks after starting medication (may occur sooner with re-exposure); symptoms develop acutely; duration 1-2 weeks after drug discontinuation; self-limited	Serum sickness (has immune complexes, decreased complement, no eosinophilia), drug reaction with eosinophilia and systemic symptoms (more severe, involves liver, longer duration), viral infection, urticaria	Clinical diagnosis; normal complement C3 and C4 (distinguishes from true serum sickness); eosinophilia common; elevated erythrocyte sedimentation rate; no circulating immune complexes	Discontinue offending medication; antihistamines for urticaria; nonsteroidal anti-inflammatory drugs for arthralgia; corticosteroids (prednisone 0.5-1 mg/kg/day) for severe symptoms; symptoms resolve within 1-2 weeks of drug discontinuation	N	https://www.ncbi.nlm.nih.gov/books/NBK513258/																
Sporothrix schenckii (Sporotrichosis)	Lymphocutaneous infection with nodular lesions along lymphatic chain after rose thorn prick; "rose gardener's disease"; ascending nodules in sporotrichoid pattern	Dimorphic fungus; traumatic inoculation from soil, plants, organic matter contaminated with Sporothrix schenckii; thermal dimorphism (mold at room temperature, yeast at body temperature); zoonotic transmission from cats (epidemic in Rio de Janeiro); lymphatic spread causes sporotrichoid pattern	Worldwide distribution, especially tropical and subtropical zones; floriculture, agriculture, mining, wood exploitation associated; cat-associated epidemic in Rio de Janeiro with over 2000 human cases; incubation 1-12 weeks	Lymphocutaneous (75%): painless papule at inoculation site progressing to nodule or ulcer, ascending chain of nodules along lymphatics; Fixed cutaneous: solitary plaque without lymphatic spread; Disseminated: pulmonary, osteoarticular, meningeal involvement in immunocompromised; cats may have severe systemic disease	Incubation 1-12 weeks; primary lesion develops over days to weeks; lymphatic spread over weeks to months; chronic progressive course without treatment	Nocardiosis, atypical mycobacterial infection, tularemia, leishmaniasis, other causes of sporotrichoid lymphangitis	Culture on Sabouraud dextrose agar at room temperature (gold standard, most sensitive); histopathology often negative due to low organism burden; asteroid bodies (eosinophilic projections from yeast) may be seen; serology limited utility except meningitis; molecular assays available but limited availability	Itraconazole 200 mg daily for 3-6 months (first-line for cutaneous); saturated solution of potassium iodide alternative; amphotericin B for severe or disseminated disease; treat cats with itraconazole; avoid contact with infected cats	N	https://www.ncbi.nlm.nih.gov/books/NBK482364/																
Squamous Cell Carcinoma	Scaly, crusted, ulcerated nodule on sun-exposed skin in older adult; "non-healing sore on sun-damaged skin"; may arise from actinic keratosis; high-risk features include size greater than 2 cm, depth greater than 6 mm, perineural invasion	Malignant proliferation of keratinocytes; ultraviolet radiation-induced DNA damage (TP53 mutations); chronic inflammation, immunosuppression, human papillomavirus (especially anogenital), arsenic exposure; actinic keratosis is precursor; invasive potential with metastatic risk	Second most common skin cancer; incidence increasing; more common in fair-skinned individuals, older adults, males; immunosuppressed patients (organ transplant) have 65-250 times increased risk; 250,000-500,000 cases annually in United States	Scaly, crusted, hyperkeratotic papule, plaque, or nodule on sun-exposed areas (head, neck, dorsal hands, forearms); may ulcerate or bleed; high-risk features: diameter greater than 2 cm, poorly defined borders, rapid growth, location on ear or lip, depth greater than 6 mm, perineural invasion, poorly differentiated; immunosuppressed patients have more aggressive disease	Develops over months; grows progressively; metastatic potential increases with high-risk features; Brigham and Women's Hospital stage T2b: 10-year cumulative incidence of nodal metastasis 24%, stage T3: 60%	Actinic keratosis (precursor, not invasive), keratoacanthoma (rapid growth, may regress), basal cell carcinoma, seborrheic keratosis, verruca, amelanotic melanoma	Clinical diagnosis with biopsy confirmation; shave, punch, or excisional biopsy; histopathology shows atypical keratinocytes invading dermis; assess depth, differentiation, perineural invasion, lymphovascular invasion; staging using Brigham and Women's Hospital or American Joint Committee on Cancer 8th edition; imaging for high-risk tumors	Surgical excision with 4-6 mm margins for low-risk, 6-10 mm for high-risk; Mohs micrographic surgery for high-risk or cosmetically sensitive areas; radiation therapy for non-surgical candidates; systemic therapy for advanced disease: cemiplimab (programmed death-1 inhibitor), pembrolizumab; adjuvant radiation for perineural invasion or positive margins	N	https://www.nejm.org/doi/full/10.1056/NEJMra2206348																
Staphylococcal Scalded Skin Syndrome	Tender erythroderma with flaccid bullae and superficial exfoliation in young child; "looks like scalded skin"; positive Nikolsky sign; spares mucous membranes	Exfoliative toxins (exfoliatin A and B) from Staphylococcus aureus cause intraepidermal splitting at zona granulosa; toxins act as serine proteases cleaving desmoglein-1; hematogenous spread of toxin from localized infection; children lack toxin-neutralizing antibodies and have immature renal clearance	Predominantly affects children under 6 years (lack of toxin-neutralizing antibodies, immature renal excretion); neonates and young children most susceptible; adults rarely affected (renal failure, immunosuppression); mortality 3-5% in children, higher in adults	Prodrome: fever, irritability, skin tenderness; Erythroderma: diffuse tender erythema starting periorificially (mouth, nose, eyes) and flexural areas; Nikolsky sign positive (lateral pressure causes skin sloughing); flaccid bullae rupture easily leaving denuded areas; radial crusting around mouth; mucous membranes spared (distinguishes from toxic epidermal necrolysis); head-to-toe exfoliation over 2-3 days	Prodrome 1-2 days; acute exfoliation 2-3 days; healing with desquamation over 10-14 days; no scarring with proper treatment	Toxic epidermal necrolysis (involves mucous membranes, older patients, drug-induced), bullous impetigo (localized), Kawasaki disease, scarlet fever, burns	Clinical diagnosis; culture from suspected infection site (conjunctiva, nasopharynx, umbilicus), not from denuded skin; blood cultures often negative; skin biopsy shows intraepidermal split at granular layer with minimal inflammation; frozen section can differentiate from toxic epidermal necrolysis	Intravenous anti-staphylococcal antibiotics: nafcillin or oxacillin 150-200 mg/kg/day divided every 6 hours; vancomycin if methicillin-resistant Staphylococcus aureus suspected; supportive care: fluid resuscitation, temperature regulation, pain management, wound care; avoid corticosteroids; healing occurs within 10-14 days without scarring	Y	https://www.ncbi.nlm.nih.gov/books/NBK534846/																
Southern Tick-Associated Rash Illness	Erythema migrans-like rash after lone star tick (Amblyomma americanum) bite; "Lyme-like rash in the South"; no disseminated disease; cause unknown	Unknown etiology; erythema migrans-like rash following lone star tick bite; not caused by Borrelia burgdorferi; may be accompanied by systemic symptoms but no disseminated or severe disease reported; diagnostic tests not available	Occurs in distribution of lone star tick: central Texas and Oklahoma eastward across southern states, Atlantic Coast to Maine; also reported in Long Island, New York; affects all ages	Erythema migrans-like expanding red rash with central clearing at site of lone star tick bite; may have fever, headache, fatigue, myalgia; no disseminated manifestations (no arthritis, carditis, or neurologic involvement); self-limited	Rash appears 7 days after tick bite (similar to Lyme disease); expands over days to weeks; resolves spontaneously; systemic symptoms mild and transient	Lyme disease (caused by Borrelia burgdorferi from Ixodes tick, can have disseminated disease), cellulitis, hypersensitivity reaction to tick bite, erythema multiforme	Clinical diagnosis based on history of lone star tick bite and characteristic rash; Lyme serology negative; no diagnostic test available for Southern Tick-Associated Rash Illness; tick identification important	Uncertain if antibiotic treatment necessary or beneficial; often treated empirically with same antibiotics as Lyme disease (doxycycline 100 mg twice daily for 10-14 days) due to clinical similarity; self-limited course	N	https://www.cdc.gov/lyme/resources/toolkit/pdf/tickborne-diseases-us-2022-508.pdf																
Stasis Dermatitis	Bilateral lower leg erythema, scaling, hyperpigmentation in patient with chronic venous insufficiency; "brown scaly legs with varicose veins"; medial malleolus involvement	Venous hypertension from venous reflux due to incompetent valves, valve destruction, or venous obstruction; red blood cell extravasation releases ferric ion; metalloproteinases upregulated causing tissue inflammation and damage; chronic inflammation leads to hemosiderin deposition (brown pigmentation)	Common in older adults; affects 6-7% of population over 50 years; more common in females; risk factors: obesity, prolonged standing, prior deep vein thrombosis, pregnancy, leg trauma	Bilateral poorly demarcated erythematous patches and plaques on lower legs, especially medial malleoli; brown hyperpigmentation (hemosiderin deposition); scaling, lichenification; pruritus common; edema; may progress to lipodermatosclerosis (induration, inverted champagne bottle appearance), atrophie blanche (white atrophic scars), venous ulceration	Chronic progressive course over months to years; acute flares with increased erythema and pruritus; may progress to venous ulceration if untreated	Cellulitis (unilateral, acute, fever), contact dermatitis (allergic to topical medications common), pigmented purpuric dermatoses, pretibial myxedema, nummular eczema	Clinical diagnosis; duplex ultrasound demonstrates venous reflux (greater than 0.5 seconds in superficial veins, greater than 1 second in deep veins); skin biopsy if diagnosis uncertain: shows spongiosis, hemosiderin deposition, fibrosis	Compression therapy (20-30 mm Hg graduated compression stockings) is cornerstone; leg elevation; emollients; topical corticosteroids (mid to high potency) for acute inflammation; treat secondary infection; interventional: endovenous thermal ablation, ultrasound-guided foam sclerotherapy for venous reflux; avoid contact allergens (neomycin, lanolin, fragrance)	N	https://www.aafp.org/pubs/afp/issues/2017/0601/p746.html																
Stevens-Johnson Syndrome	Acute onset of painful mucocutaneous blistering with target lesions and less than 10% body surface area involvement; "blisters with mucositis"; drug-induced (sulfonamides, anticonvulsants, allopurinol); positive Nikolsky sign	Severe delayed hypersensitivity reaction (type IV); cytotoxic T-cell and natural killer cell-mediated keratinocyte apoptosis; drugs most common cause (70-90%): sulfonamides, anticonvulsants (lamotrigine, carbamazepine, phenytoin), allopurinol, nonsteroidal anti-inflammatory drugs; Mycoplasma pneumoniae in children; genetic susceptibility (HLA-B<em>1502 with carbamazepine in Asians, HLA-B</em>5801 with allopurinol)	Incidence 1-6 per million per year; all ages but more common in adults; female predominance; higher risk in HIV, systemic lupus erythematosus, immunocompromised; mortality 1-5% for Stevens-Johnson syndrome, 25-35% for toxic epidermal necrolysis	Prodrome: fever, malaise, upper respiratory symptoms 1-3 days before rash; Mucosal involvement (greater than 90%): painful erosions of oral mucosa, conjunctiva, genitalia (at least 2 sites); Cutaneous: erythematous macules with dusky centers (atypical targets), vesicles, bullae; positive Nikolsky sign; Stevens-Johnson syndrome: less than 10% body surface area; Stevens-Johnson syndrome/toxic epidermal necrolysis overlap: 10-30%; toxic epidermal necrolysis: greater than 30%; complications: sepsis, fluid/electrolyte imbalance, acute respiratory distress syndrome, ocular sequelae	Onset 1-3 weeks after drug exposure (4-28 days); acute progression over days; skin detachment peaks at 4-5 days; re-epithelialization over 2-3 weeks; long-term sequelae: ocular (dry eyes, symblepharon, blindness), cutaneous (pigmentary changes, scarring), genital (vaginal stenosis)	Toxic epidermal necrolysis (greater than 30% body surface area), staphylococcal scalded skin syndrome (spares mucosa, younger age), erythema multiforme (true target lesions, less mucosal involvement), bullous pemphigoid, paraneoplastic pemphigus	Clinical diagnosis; skin biopsy shows full-thickness epidermal necrosis with subepidermal blister; SCORTEN score (age greater than 40, malignancy, heart rate greater than 120, body surface area greater than 10%, serum urea greater than 10 mmol/L, bicarbonate less than 20 mmol/L, glucose greater than 14 mmol/L) predicts mortality; identify causative drug	Immediate discontinuation of suspected drug; transfer to burn unit or intensive care; supportive care: fluid resuscitation, wound care, nutritional support, pain management; immunomodulatory therapy controversial: cyclosporine 3-5 mg/kg/day may halt progression; intravenous immunoglobulin, systemic corticosteroids, tumor necrosis factor inhibitors used but limited evidence; ophthalmology, urology, gynecology consultations; avoid sulfonamide antibiotics	Y	https://www.ncbi.nlm.nih.gov/books/NBK459323/																
Sturge-Weber Syndrome	Port-wine stain (facial capillary malformation) in trigeminal V1 distribution with ipsilateral leptomeningeal angioma; "port-wine birthmark with seizures"; glaucoma and neurologic complications	Somatic mosaic mutation in GNAQ gene (most common), also GNA11 and GNB2; aberrant endothelial cell overgrowth causes capillary-venous malformations; impaired brain perfusion leads to venous stroke, stroke-like episodes, seizures; common embryologic progenitors explain facial and brain predilection	Rare neurocutaneous disorder; affects 1 in 20,000 to 50,000 live births; no gender or ethnic predominance; sporadic, not inherited; risk of brain involvement increased with hemifacial, forehead, or medial facial port-wine stain	Facial port-wine stain (typically V1 distribution); ipsilateral leptomeningeal angioma with progressive brain atrophy and calcifications; ipsilateral glaucoma; seizures (75-90%); stroke-like episodes; hemiparesis (transient or permanent); visual field deficits; headaches; cognitive and behavioral impairment; dilated ipsilateral choroid plexus on imaging	Port-wine stain present at birth; seizures typically begin in first year of life; progressive brain atrophy and calcifications over time; stroke-like episodes can occur throughout life; cognitive decline may be progressive	Isolated port-wine stain, Klippel-Trenaunay syndrome, other neurocutaneous syndromes, epilepsy from other causes	Magnetic resonance imaging with contrast shows leptomeningeal angiomatosis (enhancement), progressive atrophy, calcifications, dilated choroid plexus; electroencephalography for seizures; ophthalmologic examination for glaucoma; genetic testing for GNAQ, GNA11, GNB2 mutations	Seizures: anti-seizure medications; presymptomatic treatment may delay seizure onset; epilepsy surgery for intractable seizures with significant hemiparesis; Stroke-like episodes: low-dose aspirin (3-5 mg/kg/day) reduces frequency and severity; Glaucoma: typically requires surgery; Port-wine stain: laser therapy (pulsed dye laser); Sirolimus shows preliminary benefit for cognition; cannabidiol for seizures	Y	https://www.ahajournals.org/doi/10.1161/STROKEAHA.122.038585																
Subacute Cutaneous Lupus Erythematosus	Photosensitive annular or papulosquamous rash on sun-exposed areas; "ring-shaped scaly patches after sun exposure"; strongly associated with anti-Ro/Sjögren syndrome A antibodies; may occur with or without systemic lupus erythematosus	Autoimmune disease with anti-Ro/Sjögren syndrome A antibodies (72.1% of cases); ultraviolet radiation triggers inflammatory response in genetically susceptible individuals; type 1 interferon pathway activation; drug-induced cases (antihypertensives, terbinafine, proton pump inhibitors) involve interferon-1 pathway	Affects 10-15% of systemic lupus erythematosus patients; can occur independently without systemic disease; peak age 30-50 years; female predominance; more common in Caucasians; drug-induced form increasingly recognized	Photosensitive annular (ring-shaped) or papulosquamous (scaly) plaques on sun-exposed areas (shoulders, upper back, chest, arms, neck); spares face and knuckles; non-scarring; may have mild systemic symptoms; 50% have systemic lupus erythematosus; anti-Ro/Sjögren syndrome A antibody positive in 72.1%	Develops over weeks to months; lesions appear or worsen after sun exposure; chronic relapsing course; may resolve with hypopigmentation but no scarring; drug-induced form resolves weeks to months after drug discontinuation	Psoriasis, tinea corporis, pityriasis rosea, dermatomyositis, polymorphous light eruption, discoid lupus erythematosus	Anti-Ro/Sjögren syndrome A antibodies (positive in 72.1%); antinuclear antibodies; skin biopsy shows interface dermatitis, vacuolar degeneration of basal layer; direct immunofluorescence shows granular immunoglobulin G and complement C3 at dermal-epidermal junction; evaluate for systemic lupus erythematosus	Sun protection (broad-spectrum sunscreen SPF 50 or higher, protective clothing); smoking cessation; discontinue offending drug if drug-induced; topical corticosteroids; topical calcineurin inhibitors; hydroxychloroquine 200-400 mg daily (first-line systemic); alternatives: quinacrine, methotrexate, mycophenolate mofetil; thalidomide for refractory cases	N	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30237-5/fulltext																
Superficial Spreading Melanoma	Asymmetric pigmented lesion with irregular borders, color variation, diameter greater than 6 mm, and evolution; "ABCDE melanoma"; most common melanoma subtype; slow radial growth phase	Malignant transformation of melanocytes; uncontrolled proliferation with pagetoid spread in epidermis (radial growth phase) followed by dermal invasion (vertical growth phase); mutations in BRAF (40-50%), NRAS (15-20%), NF1; ultraviolet radiation-induced DNA damage	Most common melanoma subtype (67-70% of all melanomas); median age at diagnosis 66 years; more common in fair-skinned individuals; trunk in males, legs in females most common sites; two-thirds diagnosed between ages 30-50	Asymmetric pigmented macule, papule, or plaque; irregular or notched borders; color variation (tan, brown, black, red, white, blue); diameter typically greater than 6 mm; evolving size, shape, or color; slow enlargement over months to years; may have ulceration or bleeding	Prolonged radial growth phase (months to years) with slow horizontal spread; eventual vertical growth phase with dermal invasion and metastatic potential; Breslow depth most important prognostic factor	Atypical nevus, seborrheic keratosis, lentigo maligna melanoma, nodular melanoma, pigmented basal cell carcinoma, solar lentigo	Dermoscopy improves diagnostic accuracy; excisional biopsy with 1-3 mm margin for diagnosis; histopathology shows atypical melanocytes with pagetoid spread, mitoses; Breslow depth (tumor thickness) determines prognosis; sentinel lymph node biopsy for tumors greater than 0.8 mm or high-risk features; staging imaging for stage IIB and higher	Wide local excision with margins based on Breslow depth: in situ (0.5-1 cm), less than 1 mm (1 cm), 1-2 mm (1-2 cm), greater than 2 mm (2 cm); sentinel lymph node biopsy for staging; adjuvant therapy for stage IIB-IV: immune checkpoint inhibitors (nivolumab, pembrolizumab), targeted therapy for BRAF-mutated tumors (dabrafenib plus trametinib); regular surveillance	Y	https://www.aafp.org/pubs/afp/issues/2024/1000/p367.html																
Sweet Syndrome (Acute Febrile Neutrophilic Dermatosis)	Tender erythematous papules, plaques, or nodules with fever and neutrophilia; "painful red bumps with fever"; associated with malignancy (especially acute myelogenous leukemia), inflammatory diseases, drugs (granulocyte-colony stimulating factor)	Inflammatory non-infectious neutrophilic dermatosis; cytokine-mediated (interleukin-1, interleukin-6, interleukin-8, granulocyte-colony stimulating factor); dense neutrophilic infiltrate in dermis without vasculitis; associated with malignancy (33%, especially acute myelogenous leukemia), drugs, infections, inflammatory diseases	Rare; female predominance; peak age 30-60 years; three clinical settings: classical/idiopathic (most common), malignancy-associated (33%, especially hematologic), drug-induced (granulocyte-colony stimulating factor most common)	Tender erythematous papules, plaques, pustules, or nodules on upper limbs, trunk, head, neck; fever (temperature greater than 38 degrees Celsius); elevated inflammatory markers (erythrocyte sedimentation rate, C-reactive protein); neutrophilia; may have arthralgia, conjunctivitis, oral ulcers; malignancy-associated form may precede, follow, or appear concurrent with cancer diagnosis	Acute onset over days; lesions appear in crops; dramatic response to corticosteroids within 24-48 hours; may recur with malignancy relapse or drug re-exposure; classical form may recur in one-third of patients	Erythema nodosum, cellulitis, erysipelas, urticaria, vasculitis, pyoderma gangrenosum, drug eruption	Skin biopsy shows dense neutrophilic infiltrate in dermis without vasculitis; elevated erythrocyte sedimentation rate and C-reactive protein; neutrophilia; evaluate for underlying malignancy (complete blood count, bone marrow biopsy if hematologic malignancy suspected), infection, inflammatory disease	Systemic corticosteroids (prednisone 0.5-1 mg/kg/day) are first-line; dramatic response within 24-48 hours; taper over 4-6 weeks; alternatives: potassium iodide, colchicine, indomethacin, dapsone, cyclosporine; treat underlying malignancy or infection; discontinue offending drug	N	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211350/																
Syphilis	Primary: painless chancre at inoculation site; Secondary: diffuse rash including palms and soles, condyloma lata, lymphadenopathy; "painless ulcer then rash on palms"; caused by Treponema pallidum	Infection with Treponema pallidum (spirochete bacterium); transmitted via contact with infectious lesions during sex or transplacentally; primary chancre at inoculation site; hematogenous dissemination causes secondary manifestations; latent period follows; tertiary syphilis (gummas, cardiovascular, neurosyphilis) if untreated	Estimated 8 million new cases worldwide in 2022; United States cases increased 61% from 2019-2023; men who have sex with men comprised 32.7% of males with primary and secondary syphilis in 2023; congenital syphilis increased 106% from 2019-2023	Primary (3-90 days after exposure): painless chancre (ulcer) at inoculation site, regional lymphadenopathy; Secondary (4-10 weeks after chancre): diffuse maculopapular rash including palms and soles, condyloma lata, mucous patches, lymphadenopathy, fever, malaise; Latent: asymptomatic; Tertiary (years later): gummas, aortitis, neurosyphilis (meningitis, stroke, tabes dorsalis); Congenital: stillbirth, neonatal death, skeletal abnormalities, hepatosplenomegaly	Primary chancre appears 3 weeks after exposure (range 3-90 days), heals in 3-6 weeks; secondary syphilis 4-10 weeks after chancre, lasts weeks to months; early latent (less than 1 year), late latent (greater than 1 year); tertiary develops years to decades later if untreated	Primary: herpes simplex, chancroid, lymphogranuloma venereum, traumatic ulcer; Secondary: pityriasis rosea, drug eruption, viral exanthem, secondary yaws; Tertiary: other causes of aortitis, chronic meningitis	Serologic testing: nontreponemal tests (rapid plasma reagin, venereal disease research laboratory) for screening and monitoring; treponemal tests (enzyme immunoassay, chemiluminescence immunoassay, Treponema pallidum particle agglutination) for confirmation; cerebrospinal fluid venereal disease research laboratory for neurosyphilis; dark-field microscopy or polymerase chain reaction from lesions	Benzathine penicillin G 2.4 million units intramuscularly: single dose for early syphilis (primary, secondary, early latent); 3 weekly doses for late latent or tertiary syphilis; aqueous crystalline penicillin G 18-24 million units per day intravenously for 10-14 days for neurosyphilis; doxycycline 100 mg twice daily for 14-28 days if penicillin-allergic (non-pregnant); screen all pregnant patients 3 times (first visit, third trimester, delivery)	Y	https://jamanetwork.com/journals/jama/fullarticle/2840085																
Systemic Lupus Erythematosus	Multisystem autoimmune disease with malar rash, photosensitivity, oral ulcers, arthritis, serositis, renal disease; "butterfly rash with joint pain and kidney disease"; positive antinuclear antibodies; female predominance	Systemic inflammation with elevated type 1 interferon and autoantibodies against nuclear antigens (anti-double-stranded DNA, anti-Smith, anti-ribonucleoprotein, anti-Ro/Sjögren syndrome A, anti-La/Sjögren syndrome B); genetic predisposition plus environmental triggers (ultraviolet light, smoking, Epstein-Barr virus, silica); immune complex deposition causes organ damage	Affects approximately 3.4 million people worldwide; 90% female; prevalence 30-150 per 100,000; more common in African Americans, Hispanics, Asians; peak age 20-40 years; 40% develop lupus nephritis	Constitutional: fever (greater than 38.3 degrees Celsius), fatigue, weight loss; Mucocutaneous: malar rash (31%), photosensitivity, acute cutaneous lupus, subacute cutaneous lupus, discoid lupus, oral ulcers (30%), alopecia (40-70%); Musculoskeletal: arthralgia, arthritis; Serositis: pleuritis, pericarditis; Renal: proteinuria, hematuria, lupus nephritis (40%); Hematologic: anemia, leukopenia, thrombocytopenia; Neurologic: seizures, psychosis; Raynaud phenomenon (16%)	Chronic relapsing course; onset typically in 20s-30s; disease activity fluctuates with flares and remissions; 10% of lupus nephritis patients develop end-stage kidney disease after 10 years; improved survival (10-year survival greater than 90%) with modern treatment	Rheumatoid arthritis, Sjögren syndrome, mixed connective tissue disease, drug-induced lupus, undifferentiated connective tissue disease, dermatomyositis, vasculitis	2019 European Alliance of Associations for Rheumatology/American College of Rheumatology criteria (96.1% sensitive, 93.4% specific): requires antinuclear antibodies titer greater than or equal to 1:80 plus weighted criteria; specific autoantibodies: anti-double-stranded DNA, anti-Smith, antiphospholipid; low complement C3 and C4; urinalysis for proteinuria and hematuria; complete blood count for cytopenias	Hydroxychloroquine 200-400 mg daily (standard of care for all patients, reduces mortality); nonsteroidal anti-inflammatory drugs for arthralgia; corticosteroids for flares; immunosuppressants for moderate to severe disease: azathioprine, mycophenolate mofetil, cyclophosphamide; biologics: belimumab (B-lymphocyte stimulator inhibitor), anifrolumab (type 1 interferon receptor antagonist), voclosporin for lupus nephritis; sun protection; smoking cessation	Y	https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.2315																
Takayasu Arteritis	Large vessel vasculitis with limb claudication, blood pressure discrepancy between arms, absent pulses, bruits; "pulseless disease"; young Asian women; affects aorta and major branches	Granulomatous inflammation of aorta and major branches; vessel wall inflammation leads to stenosis, occlusion, aneurysm formation; intimal hyperplasia and adventitial fibrosis; unknown etiology; genetic susceptibility (HLA-B52 association)	Incidence 0.4-2.6 per million per year; more common in Asia, Middle East, Latin America; female to male ratio 8-9:1; peak age 10-40 years; most common large vessel vasculitis in young women	Constitutional: fever, malaise, weight loss, night sweats; Vascular: limb claudication (especially upper extremities), blood pressure difference greater than 10 mm Hg between arms, diminished or absent pulses, arterial bruits (subclavian, carotid, abdominal aorta), Raynaud phenomenon; Neurologic: dizziness, syncope, visual disturbances, stroke; Cardiac: hypertension, aortic regurgitation, heart failure; Renal: renovascular hypertension; Skin: erythema nodosum	Acute inflammatory phase: constitutional symptoms, elevated inflammatory markers; Chronic occlusive phase: vascular insufficiency symptoms; progressive over months to years without treatment; may have periods of remission and relapse	Giant cell arteritis (older age, temporal artery involvement), atherosclerosis, fibromuscular dysplasia, other large vessel vasculitides, thoracic outlet syndrome	Elevated erythrocyte sedimentation rate and C-reactive protein; anemia; imaging: computed tomography angiography or magnetic resonance angiography shows vessel wall thickening, stenosis, occlusion, aneurysm; positron emission tomography shows vessel wall inflammation; angiography shows smooth tapered stenoses, occlusions, aneurysms; 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology criteria: age less than or equal to 60 years plus imaging evidence of large vessel vasculitis plus score greater than or equal to 5 points	Glucocorticoids (prednisone 0.5-1 mg/kg/day, taper over 12-18 months) are first-line; steroid-sparing agents: methotrexate, azathioprine, mycophenolate mofetil; biologics for refractory disease: tumor necrosis factor inhibitors (infliximab, adalimumab), tocilizumab (interleukin-6 receptor antagonist); antiplatelet therapy (aspirin); blood pressure control; revascularization (angioplasty, bypass surgery) for critical stenosis during quiescent phase	Y	https://pubmed.ncbi.nlm.nih.gov/36599755																
Telogen Effluvium	Acute diffuse hair shedding 2-3 months after physiological stressor (childbirth, illness, surgery, weight loss); "sudden hair loss after stress"; increased hair in telogen phase; positive hair pull test	Premature shift of anagen (growth phase) hair follicles to telogen (resting phase) triggered by physiological stress; stressors include childbirth, severe illness, surgery, rapid weight loss, medications, nutritional deficiencies, thyroid disease; hair sheds 2-3 months after trigger when telogen phase ends	Very common; affects all ages; more common in women; acute telogen effluvium affects up to 50% of women postpartum; chronic telogen effluvium affects middle-aged women (30-60 years)	Acute diffuse hair shedding with increased hair on pillow, in shower drain, on hairbrush; generalized thinning without focal areas of complete hair loss; positive hair pull test (greater than 6 hairs per pull from 5 areas); scalp appears normal without inflammation or scarring; patient often distressed; may have bitemporal recession	Acute telogen effluvium: hair shedding begins 2-3 months after trigger, peaks at 3-4 months, resolves spontaneously within 6 months once trigger removed; Chronic telogen effluvium: fluctuating course over months to years with periods of increased shedding	Androgenetic alopecia (gradual onset, patterned distribution, miniaturized hairs), alopecia areata (patchy hair loss, exclamation point hairs), anagen effluvium (rapid hair loss during chemotherapy), scarring alopecia, thyroid disease, iron deficiency	Clinical diagnosis based on history of trigger 2-3 months before onset; hair pull test positive (greater than 6 hairs, most with telogen bulbs); scalp examination normal; trichoscopy shows increased percentage of telogen hairs; laboratory: complete blood count, ferritin, thyroid-stimulating hormone, comprehensive metabolic panel to identify triggers; scalp biopsy rarely needed: shows increased telogen/anagen ratio (normal less than 20%, telogen effluvium greater than 20%)	Identify and address underlying trigger; reassurance that condition is self-limited; nutritional supplementation if deficiencies identified (iron, zinc, vitamin D, biotin); topical minoxidil 5% may accelerate recovery and reduce shedding; treat underlying conditions (thyroid disease, nutritional deficiencies); avoid harsh hair treatments; gentle hair care	N	https://pubmed.ncbi.nlm.nih.gov/33541773																
Thromboangiitis Obliterans (Buerger Disease)	Young male smoker with distal extremity ischemia, claudication, Raynaud phenomenon, superficial thrombophlebitis; "smoker with painful fingers and toes"; strongly associated with tobacco use	Segmental inflammatory thrombosis of small and medium arteries and veins of distal extremities; acute phase shows highly cellular inflammatory thrombus with relative sparing of vessel wall; chronic phase shows organized thrombus and vascular fibrosis; strongly associated with tobacco use; immune-mediated mechanism suspected	Rare; prevalence 12.6-20 per 100,000; more common in Asia, Middle East, Eastern Europe; male to female ratio 3:1 to 7.5:1; age of onset typically 20-45 years; nearly 100% are current or recent tobacco users	Distal extremity ischemia: claudication of feet, legs, hands, arms; rest pain; ischemic ulcers and gangrene of fingers and toes; Raynaud phenomenon (40%); migratory superficial thrombophlebitis (40%); cold sensitivity; absent distal pulses with preserved proximal pulses; may have erectile dysfunction in males	Chronic progressive course with episodic flares; symptoms worsen with continued tobacco use; may stabilize or improve with smoking cessation; digital ulceration and gangrene develop over months to years; amputation required in 25-30% despite treatment	Atherosclerosis (older age, proximal disease, risk factors), autoimmune vasculitis, hypercoagulable states, embolic disease, scleroderma, antiphospholipid syndrome, ergotism	Clinical diagnosis based on age less than 45 years, current or recent tobacco use, distal extremity ischemia, exclusion of other causes; Shionoya criteria: smoking history, onset before age 50, infrapopliteal arterial occlusion, upper limb involvement or migratory phlebitis, absence of atherosclerotic risk factors; angiography shows segmental occlusions with corkscrew collaterals in distal vessels; normal proximal vessels; laboratory: normal acute phase reactants, negative autoimmune serologies, normal hypercoagulable workup	Absolute smoking cessation (essential, only intervention that alters disease course); smoking cessation counseling, nicotine replacement, varenicline, bupropion; pain management; wound care; prostanoids (iloprost) for critical limb ischemia; calcium channel blockers for Raynaud phenomenon; antiplatelet therapy; avoid vasoconstrictors; revascularization rarely feasible due to distal disease; amputation for non-healing ulcers or gangrene	Y	https://www.ncbi.nlm.nih.gov/books/NBK430900/																
Tinea Capitis	Scaly patches of alopecia with broken hairs ("black dots") on scalp in child; "scalp ringworm with hair loss"; may have kerion (boggy, pustular mass); requires systemic antifungals	Dermatophyte infection of scalp and hair follicles; most commonly Trichophyton tonsurans (anthropophilic, endothrix) in United States, Microsporum canis (zoophilic, ectothrix) in other regions; fungal invasion of hair shaft causes breakage; inflammatory response varies by species	Predominantly affects children 3-14 years; more common in African American children; transmitted by direct contact or fomites; zoophilic infections cause more inflammation	Scaly patches of alopecia with broken hairs at scalp surface (black dot pattern); diffuse scaling resembling seborrheic dermatitis; kerion: tender, boggy, pustular plaque that may scar if untreated; posterior cervical lymphadenopathy common; pruritus variable	Develops over weeks to months; progressive without treatment; kerion develops acutely over days; permanent scarring alopecia if kerion untreated; resolves with appropriate systemic therapy over 6-12 weeks	Seborrheic dermatitis, psoriasis, alopecia areata, trichotillomania, bacterial folliculitis	Potassium hydroxide preparation of plucked hairs and scale shows hyphae and spores; fungal culture on Sabouraud dextrose agar for species identification (takes 2-4 weeks); Wood lamp examination (only Microsporum species fluoresce green)	Systemic antifungals required: griseofulvin 20-25 mg/kg/day for 6-12 weeks (first-line in children), terbinafine 62.5-250 mg daily based on weight for 4-6 weeks, itraconazole or fluconazole alternatives; adjunctive antifungal shampoo (ketoconazole 2%, selenium sulfide 2.5%) twice weekly reduces spore shedding; treat household contacts if infected	N	https://pubmed.ncbi.nlm.nih.gov/38256510																
Tinea Corporis	Annular scaly plaques with raised borders and central clearing on trunk or extremities; "ringworm"; expanding red ring with scale	Dermatophyte infection of glabrous (non-hair-bearing) skin; most commonly Trichophyton rubrum, also Trichophyton mentagrophytes, Microsporum canis; fungal hyphae invade stratum corneum; inflammatory response at advancing border	Affects all ages; more common in warm humid climates; transmitted by direct contact with infected humans, animals, or fomites; wrestlers at risk (tinea corporis gladiatorum)	Annular erythematous plaques with raised scaly border and central clearing; may be single or multiple; pruritus common; lesions expand centrifugally; may have vesicles or pustules at border	Develops over days to weeks; expands slowly without treatment; resolves with treatment over 2-4 weeks	Pityriasis rosea (herald patch, Christmas tree distribution), nummular eczema (more pruritic, no central clearing), granuloma annulare (no scale), subacute cutaneous lupus, psoriasis	Clinical diagnosis; potassium hydroxide preparation of scale shows branching hyphae; fungal culture for confirmation and species identification; consider culture for recalcitrant cases (emerging resistant Trichophyton species)	Topical antifungals for localized disease: terbinafine 1%, clotrimazole 1%, ketoconazole 2%, miconazole 2% twice daily for 2-4 weeks; oral antifungals for extensive or recalcitrant disease: terbinafine 250 mg daily, itraconazole 200 mg daily, fluconazole 150-300 mg weekly for 2-4 weeks; avoid combination antifungal-corticosteroid products	N	https://pubmed.ncbi.nlm.nih.gov/41400219																
Tinea Versicolor	Hypopigmented or hyperpigmented scaly patches on trunk; "spaghetti and meatballs" on potassium hydroxide prep; caused by Malassezia; yellowish-green fluorescence under Wood lamp	Superficial fungal infection caused by Malassezia species (Malassezia furfur, Malassezia globosa); lipophilic yeast that is part of normal skin flora; overgrowth in warm humid conditions; produces azelaic acid causing hypopigmentation	Very common; affects adolescents and young adults; more common in warm humid climates; not contagious; recurrence common (60-80% within 2 years)	Multiple round to oval macules and patches on trunk, neck, upper arms; lesions may be hypopigmented, hyperpigmented, or erythematous (versicolor means varied color); fine scale with scraping; asymptomatic or mildly pruritic; more noticeable after sun exposure	Chronic course; develops over weeks to months; worsens in summer; pigmentary changes persist for weeks to months after treatment	Pityriasis alba (facial distribution in children), vitiligo (complete depigmentation, well-demarcated), post-inflammatory hypopigmentation, seborrheic dermatitis	Clinical diagnosis; potassium hydroxide preparation shows short hyphae and round yeast cells (spaghetti and meatballs appearance); Wood lamp examination shows subtle yellowish-green fluorescence	Topical antifungals: ketoconazole 2% shampoo used as body wash (apply for 5-10 minutes, rinse) daily for 1-2 weeks, selenium sulfide 2.5% lotion, zinc pyrithione; oral antifungals for extensive or recalcitrant disease: fluconazole 300-400 mg single dose or weekly for 2 weeks, itraconazole 200 mg daily for 5-7 days; prophylaxis with monthly topical treatment reduces recurrence	N	https://www.nc.cdc.gov/travel/yellowbook/2024/posttravel-evaluation/dermatologic-conditions																
Toxic Epidermal Necrolysis	Acute onset of painful skin detachment greater than 30% body surface area with mucosal involvement; "skin peeling off in sheets"; positive Nikolsky sign; drug-induced (allopurinol, anticonvulsants, sulfonamides)	Severe delayed type IV hypersensitivity reaction; cytotoxic T-cell and natural killer cell-mediated keratinocyte apoptosis via Fas-Fas ligand, granulysin, perforin-granzyme pathways; full-thickness epidermal necrosis; drugs most common cause (allopurinol, anticonvulsants, sulfonamides, nonsteroidal anti-inflammatory drugs); genetic susceptibility (HLA-B<em>1502 with carbamazepine in Asians, HLA-B</em>5801 with allopurinol)	Incidence 0.4-1.2 per million per year; all ages; female predominance; higher risk in HIV, systemic lupus erythematosus, immunocompromised; mortality 25-35%	Prodrome: fever, malaise, upper respiratory symptoms 1-3 days before rash; painful erythematous macules with dusky centers progressing to confluent erythema; flaccid bullae and skin detachment greater than 30% body surface area; positive Nikolsky sign (lateral pressure causes skin sloughing); mucosal involvement (oral, ocular, genital) in greater than 90%; complications: sepsis, fluid and electrolyte imbalance, acute respiratory distress syndrome, multiorgan failure, ocular sequelae (symblepharon, blindness)	Onset 1-3 weeks after drug exposure (4-28 days); acute progression over days; skin detachment peaks at 4-5 days; re-epithelialization over 2-4 weeks; long-term sequelae common	Stevens-Johnson syndrome (less than 10% body surface area), staphylococcal scalded skin syndrome (spares mucosa, younger age, intraepidermal split), erythema multiforme, bullous pemphigoid, paraneoplastic pemphigus	Clinical diagnosis; skin biopsy shows full-thickness epidermal necrosis with subepidermal blister; SCORTEN score predicts mortality (age greater than 40, malignancy, heart rate greater than 120, body surface area greater than 10%, serum urea greater than 10 mmol/L, bicarbonate less than 20 mmol/L, glucose greater than 14 mmol/L); identify causative drug	Immediate discontinuation of suspected drug; transfer to burn unit or intensive care; supportive care: fluid resuscitation (2-4 mL/kg per percent body surface area), wound care, nutritional support, pain management, temperature regulation; immunomodulatory therapy: cyclosporine 3-5 mg/kg/day may halt progression; intravenous immunoglobulin, systemic corticosteroids controversial; ophthalmology consultation essential; avoid sulfonamide antibiotics	Y	https://pubmed.ncbi.nlm.nih.gov/38631147																
Toxic Shock Syndrome	Acute onset of high fever, hypotension, diffuse erythroderma with desquamation, multiorgan dysfunction; "sunburn rash with shock"; associated with tampon use or Staphylococcus aureus infection	Exotoxin-mediated disease; Staphylococcus aureus toxic shock syndrome toxin-1 or Streptococcus pyogenes exotoxins act as superantigens causing massive T-cell activation and cytokine release (tumor necrosis factor-alpha, interleukin-1, interleukin-6); leads to capillary leak, hypotension, multiorgan failure	Rare; incidence decreased since 1980s with tampon changes; Staphylococcus aureus toxic shock syndrome: menstrual (tampon use) and non-menstrual (post-surgical, skin infections); Streptococcal toxic shock syndrome: associated with invasive group A Streptococcus infections (necrotizing fasciitis, bacteremia); affects all ages	Fever (temperature greater than 38.9 degrees Celsius); hypotension (systolic blood pressure less than 90 mm Hg or orthostatic drop); diffuse macular erythroderma (sunburn-like rash); desquamation 1-2 weeks after onset (especially palms and soles); multiorgan involvement (3 or more systems): gastrointestinal (vomiting, diarrhea), muscular (severe myalgia, elevated creatine kinase), mucous membrane (vaginal, oropharyngeal, conjunctival hyperemia), renal, hepatic, hematologic (thrombocytopenia), central nervous system (altered mental status without focal findings)	Acute onset over hours to days; hypotension develops within 48 hours; desquamation occurs 1-2 weeks after onset; mortality 5-15% for Staphylococcus aureus, 30-70% for Streptococcal toxic shock syndrome	Septic shock from other causes, Rocky Mountain spotted fever, leptospirosis, measles, scarlet fever, Kawasaki disease, drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome	Clinical diagnosis using Centers for Disease Control and Prevention criteria; blood cultures (often negative in Staphylococcus aureus toxic shock syndrome, positive in Streptococcal toxic shock syndrome); wound or vaginal cultures; complete blood count (thrombocytopenia), comprehensive metabolic panel (elevated creatinine, bilirubin, transaminases), creatine kinase (elevated); urinalysis (sterile pyuria)	Aggressive fluid resuscitation; vasopressors for refractory hypotension; remove source (tampon, wound debridement); anti-staphylococcal antibiotics: nafcillin or oxacillin 2 grams intravenously every 4 hours plus clindamycin 900 mg intravenously every 8 hours (inhibits toxin production); vancomycin if methicillin-resistant Staphylococcus aureus; for Streptococcal: penicillin G 4 million units intravenously every 4 hours plus clindamycin; intravenous immunoglobulin 1-2 grams/kg for severe cases; intensive care support	Y	https://pubmed.ncbi.nlm.nih.gov/30785787																
Transient Neonatal Pustular Melanosis	Superficial pustules at birth that rupture leaving hyperpigmented macules with collarette of scale; "pustules at birth then brown spots"; benign, self-limited; more common in African American infants	Benign self-limited pustular eruption of unknown etiology; sterile pustules contain neutrophils; not infectious or inflammatory; represents desquamation of superficial epidermis; hyperpigmentation from post-inflammatory melanin deposition	Affects 0.2-4.4% of newborns; more common in African American infants (4.4%) than Caucasian infants (0.6%); present at birth; no gender predominence	Superficial pustules on non-erythematous base present at birth; pustules rupture easily leaving hyperpigmented macules with collarette of scale; distribution: forehead, neck, lower back, shins; no systemic symptoms; infant otherwise healthy	Pustules present at birth or appear within first 24-48 hours; pustules rupture within 24-48 hours; hyperpigmented macules persist for weeks to months (up to 3 months); complete resolution without scarring	Erythema toxicum neonatorum (appears day 2-5, eosinophils on smear), neonatal pustular melanosis (pustules at birth, neutrophils), miliaria, congenital candidiasis, neonatal herpes simplex, bacterial infection (impetigo, staphylococcal pustulosis)	Clinical diagnosis; Gram stain and Wright stain of pustule contents show neutrophils without organisms; bacterial and viral cultures negative; skin biopsy (rarely needed) shows subcorneal or intracorneal pustule with neutrophils	Observation and reassurance; no treatment required; resolves spontaneously; rule out infection if atypical features or systemic symptoms	N	https://pubmed.ncbi.nlm.nih.gov/14597015																
Tuberous Sclerosis Complex	Neurocutaneous disorder with ash-leaf spots (hypopigmented macules), facial angiofibromas, shagreen patches, seizures, intellectual disability; "white spots and bumps on face with seizures"; autosomal dominant	Autosomal dominant disorder; mutations in TSC1 (hamartin) or TSC2 (tuberin) genes; loss of tumor suppressor function leads to constitutive activation of mammalian target of rapamycin pathway; results in hamartomas in multiple organs (brain, skin, kidneys, heart, lungs)	Incidence 1 in 6000 live births; affects all ethnicities equally; two-thirds are de novo mutations, one-third inherited; no gender predominance	Skin (90%): ash-leaf spots (hypopigmented macules, best seen with Wood lamp, present from infancy), facial angiofibromas (adenoma sebaceum, red papules on nose and cheeks, appear age 2-5), shagreen patches (connective tissue nevi on lower back), ungual fibromas (periungual fibromas, appear in adolescence); Neurologic: seizures (80-90%, often infantile spasms), intellectual disability (50%), autism; Cardiac: cardiac rhabdomyomas (present in infancy, often regress); Renal: angiomyolipomas, renal cysts, renal cell carcinoma; Pulmonary: lymphangioleiomyomatosis (women of childbearing age)	Ash-leaf spots present at birth or early infancy; facial angiofibromas appear age 2-5 years; seizures typically begin in first year; cardiac rhabdomyomas may regress; renal angiomyolipomas develop in childhood to adolescence; progressive multisystem involvement throughout life	Neurofibromatosis type 1, other neurocutaneous syndromes, isolated seizure disorders, isolated cardiac rhabdomyomas	Clinical diagnosis using 2012 International Tuberous Sclerosis Complex Consensus Conference criteria: 2 major features or 1 major plus 2 minor features; genetic testing for TSC1 or TSC2 mutations (pathogenic variant alone sufficient for diagnosis); brain magnetic resonance imaging for cortical tubers and subependymal nodules; electroencephalography for seizures; echocardiography for cardiac rhabdomyomas; renal ultrasound or magnetic resonance imaging for angiomyolipomas; ophthalmologic examination; Wood lamp examination for ash-leaf spots	Seizures: anti-seizure medications; mammalian target of rapamycin inhibitors (everolimus, sirolimus) for subependymal giant cell astrocytomas, renal angiomyolipomas, lymphangioleiomyomatosis; facial angiofibromas: laser therapy, topical sirolimus; multidisciplinary surveillance and management; genetic counseling; educational and social support	Y	https://pubmed.ncbi.nlm.nih.gov/39389658																
Urticaria	Pruritic wheals (hives) with circumferential erythema lasting less than 24 hours; acute (less than 6 weeks) or chronic (greater than 6 weeks); "itchy bumps that come and go"; may have angioedema	Mast cell activation and degranulation with release of histamine and other mediators; acute urticaria: triggered by infections, drugs, foods; chronic spontaneous urticaria: autoantibodies (anti-IgE, anti-FcεRI), complement activation, coagulation pathway involvement; chronic inducible urticaria: specific triggers (cold, pressure, heat, exercise)	Lifetime prevalence up to 20%; acute urticaria much more common than chronic; chronic urticaria affects 0.5-1% of population; chronic spontaneous urticaria more common in adults 30-50 years; female predominance	Pruritic wheals (raised, erythematous, circumscribed lesions) ranging from millimeters to centimeters; individual wheals resolve within 24 hours without residual bruising; angioedema (deeper swelling of face, extremities, torso) in two-thirds of patients; chronic inducible urticaria has specific triggers (dermographism, cold, cholinergic, delayed pressure)	Acute urticaria: less than 6 weeks duration; Chronic urticaria: greater than 6 weeks duration, persists greater than 1 year in most patients; individual wheals last less than 24 hours; chronic spontaneous urticaria has unpredictable flares	Urticarial vasculitis (wheals last greater than 24 hours, painful/burning, residual bruising), contact dermatitis, erythema multiforme, bullous pemphigoid, mastocytosis, autoinflammatory syndromes	Clinical diagnosis based on history and examination; provocation testing for chronic inducible urticaria; skin biopsy if concern for urticarial vasculitis (shows leukocytoclastic vasculitis); complete blood count, erythrocyte sedimentation rate, C-reactive protein to exclude differential diagnoses; Urticaria Control Test to assess disease control	Acute urticaria: second-generation H1 antihistamines (cetirizine, loratadine, fexofenadine); short course corticosteroids for severe cases; Chronic spontaneous urticaria: second-generation H1 antihistamines (standard dose, up-dose to 4 times if needed); omalizumab 300 mg subcutaneously monthly for antihistamine-refractory disease; cyclosporine 3-5 mg/kg/day for omalizumab-refractory disease; avoid triggers in chronic inducible urticaria	N	https://pubmed.ncbi.nlm.nih.gov/36109590																
Urticarial Vasculitis	Urticarial lesions lasting greater than 24 hours with burning/pain, resolving with residual bruising; "painful hives that leave bruises"; hypocomplementemic form associated with systemic symptoms	Immune complex-mediated small vessel vasculitis; complement activation with anaphylatoxin production; neutrophil recruitment and activation; leukocytoclastic vasculitis with fibrinoid necrosis; normocomplementemic or hypocomplementemic (with anti-C1q antibodies); hypocomplementemic urticarial vasculitis syndrome has multiorgan involvement	Rare; more common in women; peak age 30-50 years; hypocomplementemic form associated with systemic lupus erythematosus, Sjögren syndrome, hepatitis B or C, cryoglobulinemia	Urticarial wheals lasting greater than 24 hours (often 3 days); burning or painful sensation more than pruritus; residual hyperpigmentation or bruising after resolution; may have angioedema; hypocomplementemic urticarial vasculitis syndrome: arthralgias, glomerulonephritis, uveitis or episcleritis, recurrent abdominal pain, obstructive lung disease	Individual lesions last 24 hours to several days; chronic relapsing course; hypocomplementemic form more severe with systemic manifestations	Chronic spontaneous urticaria (wheals last less than 24 hours, no residual bruising), erythema multiforme, bullous pemphigoid, systemic lupus erythematosus, other vasculitides	Skin biopsy shows leukocytoclastic vasculitis with fibrinoid necrosis; direct immunofluorescence shows immunoglobulin and complement deposition; complement levels (C3, C4, C1q): decreased in hypocomplementemic form; anti-C1q antibodies in hypocomplementemic urticarial vasculitis syndrome; evaluate for underlying systemic disease	Normocomplementemic: antihistamines, colchicine, dapsone, hydroxychloroquine; Hypocomplementemic urticarial vasculitis syndrome: systemic corticosteroids, immunosuppressants (azathioprine, mycophenolate mofetil, cyclophosphamide), rituximab for refractory cases; treat underlying disease	N	https://pubmed.ncbi.nlm.nih.gov/35396080																
Varicella-Zoster Virus	Primary infection (varicella): pruritic vesicular rash in different stages starting on face/trunk spreading to extremities; Reactivation (zoster): painful unilateral vesicular rash in dermatomal distribution; "chickenpox then shingles years later"	Primary infection: varicella-zoster virus (herpesvirus) transmitted by respiratory droplets or direct contact; viral replication in respiratory tract, viremia, dissemination to skin; Reactivation: virus remains latent in dorsal root ganglia; reactivates with aging or immunosuppression causing dermatomal distribution	Varicella: highly contagious; incubation 10-21 days; vaccine has reduced incidence by greater than 90%; Zoster: lifetime risk 30%; incidence increases with age; 1 million cases annually in United States; risk increased in immunocompromised	Varicella: prodrome of fever, malaise; pruritic vesicular rash starting on face/trunk, spreading to extremities; lesions in different stages (macules, papules, vesicles, crusts); oral enanthem; Zoster: prodrome of pain in dermatome; unilateral vesicular rash in dermatomal distribution; acute pain; postherpetic neuralgia in 10-20%; complications: bacterial superinfection, pneumonia, encephalitis, disseminated disease in immunocompromised	Varicella: incubation 10-21 days; rash appears in crops over 3-5 days; crusting by 7-10 days; Zoster: prodrome 1-5 days; vesicular rash 7-10 days; postherpetic neuralgia defined as pain greater than 90 days after rash onset	Varicella: impetigo, insect bites, hand-foot-mouth disease, smallpox; Zoster: herpes simplex, contact dermatitis, cellulitis	Varicella: clinical diagnosis; polymerase chain reaction or direct fluorescent antibody from vesicle fluid if confirmation needed; Zoster: clinical diagnosis; polymerase chain reaction from vesicle fluid for atypical presentations; serology (IgM, IgG) for immunity assessment	Varicella: supportive care in healthy children; acyclovir 800 mg orally 5 times daily or valacyclovir 1 gram orally 3 times daily for 5-7 days in adults, immunocompromised, or severe disease; Zoster: valacyclovir 1 gram orally 3 times daily or famciclovir 500 mg orally 3 times daily for 7 days (start within 72 hours); pain management; vaccination for prevention	N	https://pubmed.ncbi.nlm.nih.gov/40801156																
Venous Ulcers	Shallow ulcer with irregular borders on medial malleolus in patient with chronic venous insufficiency; surrounding hemosiderin deposition, edema, lipodermatosclerosis; "ulcer on ankle with brown skin and swelling"	Venous hypertension from venous reflux (incompetent valves) or obstruction; red blood cell extravasation releases iron causing hemosiderin deposition; chronic inflammation and tissue damage; impaired wound healing from venous stasis	Most common cause of leg ulcers (70-90%); affects 1-3% of population; more common in older adults, females; risk factors: obesity, prolonged standing, prior deep vein thrombosis, pregnancy, leg trauma	Shallow ulcer with irregular borders on medial malleolus (gaiter area); surrounding hemosiderin deposition (brown pigmentation); edema; lipodermatosclerosis (induration, inverted champagne bottle appearance); varicose veins; atrophie blanche (white atrophic scars); minimal pain (unless infected); exudate	Chronic progressive course over months to years; ulcers may persist for months to years without treatment; recurrence common (60-70% within 5 years)	Arterial ulcers (painful, distal location, absent pulses), neuropathic ulcers (pressure points, decreased sensation), mixed arterial-venous ulcers, pyoderma gangrenosum, malignancy (Marjolin ulcer)	Clinical diagnosis; ankle-brachial index to exclude arterial disease (greater than 0.8 required for compression); duplex ultrasound shows venous reflux (greater than 0.5 seconds superficial, greater than 1 second deep veins); wound culture if signs of infection; biopsy if atypical or non-healing	Compression therapy (20-30 mm Hg graduated compression stockings) is cornerstone; leg elevation; wound care (moist wound healing, debridement); treat infection if present; pentoxifylline 400 mg 3 times daily as adjunct; endovenous ablation for venous reflux improves healing; skin grafting for large non-healing ulcers	N	https://pubmed.ncbi.nlm.nih.gov/40079722																
Vernix Caseosa Loss	Physiologic peeling and desquamation in newborn, especially post-term infants; "normal newborn skin shedding"; more prominent on hands and feet	Physiologic shedding of stratum corneum after birth; transition from intrauterine aqueous environment to dry extrauterine environment; vernix caseosa (protective waxy coating) loss exposes immature stratum corneum to air; increased desquamation in post-term infants due to prolonged amniotic fluid exposure	Affects nearly all newborns to some degree; more prominent in post-term infants (greater than 42 weeks gestation); typically begins in first few days of life	Superficial peeling and flaking of skin, most prominent on hands, feet, ankles, wrists; underlying skin appears normal; no erythema or inflammation; infant otherwise well-appearing; may have fine, dry, cracked appearance	Begins within first few days of life; peaks at 1-2 weeks; resolves spontaneously within 2-4 weeks without intervention	Congenital ichthyosis, collodion baby, transient neonatal pustular melanosis, congenital candidiasis, congenital syphilis	Clinical diagnosis in well-appearing newborn with typical presentation; skin biopsy or potassium hydroxide preparation if concern for infectious or ichthyotic process; rule out congenital infections if atypical features present	Observation and reassurance; gentle moisturizers if desired for comfort; avoid harsh soaps; no specific treatment required; resolves spontaneously	N	https://www.aafp.org/pubs/afp/issues/2024/0300/p212.html																
Verrucae (Warts)	Hyperkeratotic papules with black dots (thrombosed capillaries) on hands or feet; "warts with black dots"; caused by human papillomavirus; common in children and adolescents	Human papillomavirus infection of keratinocytes; most commonly types 1, 2, 4 (plantar), 2, 27, 57, 63 (common warts); viral replication causes epidermal hyperplasia and hyperkeratosis; thrombosed capillaries appear as black dots; transmitted by direct contact or fomites	Very common; affects over 40% of children in second decade of life; prevalence peaks age 10-19 years; plantar warts (verrucae plantaris) more resistant to treatment than warts elsewhere	Common warts: hyperkeratotic papules with rough surface on hands, fingers, knees, elbows; Plantar warts: painful hyperkeratotic lesions on plantar surface with black dots (thrombosed capillaries); interruption of dermatoglyphics; may be single or mosaic pattern; usually asymptomatic except plantar warts cause pain with ambulation	Develop over weeks to months; 65% resolve spontaneously within 2 years without treatment; plantar warts more persistent and resistant to treatment	Corns and calluses (no black dots, preserve dermatoglyphics), molluscum contagiosum, seborrheic keratosis, squamous cell carcinoma	Clinical diagnosis based on characteristic appearance; dermoscopy shows thrombosed capillaries; skin biopsy rarely needed: shows papillomatosis, hyperkeratosis, koilocytes	First-line: salicylic acid 17-40% daily with debridement; cryotherapy with liquid nitrogen every 2-4 weeks; alternatives: cantharidin, imiquimod, duct tape occlusion; refractory cases: intralesional immunotherapy (Candida antigen, mumps-measles-rubella vaccine), hyperthermia, pulsed dye laser; observation acceptable (spontaneous resolution common)	N	https://pubmed.ncbi.nlm.nih.gov/36554279																
Vitamin A Deficiency	Night blindness, xerophthalmia (dry eyes), Bitot spots (foamy conjunctival patches), keratomalacia; "can't see at night"; follicular hyperkeratosis; increased infections	Deficiency of vitamin A (retinol); impaired rhodopsin synthesis causes night blindness; epithelial keratinization abnormalities cause xerophthalmia, follicular hyperkeratosis; impaired immune function increases infection susceptibility; causes: inadequate dietary intake, malabsorption, liver disease, measles infection	Leading cause of preventable blindness in children worldwide; rare in developed countries; common in developing countries with limited access to vitamin A-rich foods; affects 190 million preschool children globally; increased risk during pregnancy, lactation, infancy	Ocular: night blindness (earliest sign), xerophthalmia (dry eyes), Bitot spots (foamy white triangular patches on conjunctiva), corneal xerosis, keratomalacia (corneal ulceration and necrosis leading to blindness); Dermatologic: follicular hyperkeratosis (rough, bumpy skin especially on extensor surfaces); Systemic: growth retardation, increased susceptibility to infections (measles, diarrhea, respiratory infections), anemia	Develops over weeks to months of inadequate intake; night blindness appears first; xerophthalmia and Bitot spots develop with worsening deficiency; keratomalacia is late manifestation indicating severe deficiency; irreversible blindness if untreated	Other causes of night blindness (retinitis pigmentosa, congenital stationary night blindness), zinc deficiency, protein-energy malnutrition, other causes of keratinization disorders	Serum retinol less than 0.70 micromol/L (less than 20 micrograms/dL) indicates deficiency; dose-response test: serum retinol increases greater than 20% after vitamin A dose if deficient; isotope dilution assay for total body stores; clinical diagnosis based on xerophthalmia in endemic areas	Treatment dose: vitamin A 200,000 international units orally on days 1, 2, and 14 (children 12 months and older); 100,000 international units for infants 6-11 months; 50,000 international units for infants under 6 months; Prevention: vitamin A supplementation programs in endemic areas; dietary diversification; food fortification	Y	https://pubmed.ncbi.nlm.nih.gov/27128154																
Vitamin C Deficiency (Scurvy)	Perifollicular hemorrhages, corkscrew hairs, swollen bleeding gums, poor wound healing; "bleeding gums and corkscrew hairs"; musculoskeletal pain in children	Deficiency of vitamin C (ascorbic acid); impaired collagen synthesis due to lack of cofactor for prolyl and lysyl hydroxylase; defective collagen causes capillary fragility, poor wound healing, bone abnormalities; causes: inadequate dietary intake (restrictive diets, food insecurity), malabsorption, increased requirements	Rare in developed countries but increasingly reported; risk factors: restrictive diets (autism spectrum disorder, developmental disabilities), food insecurity, alcoholism, malabsorption, post-bariatric surgery; children and elderly at higher risk	Dermatologic: perifollicular petechiae and hemorrhages, corkscrew hairs, poor wound healing, easy bruising; Oral: swollen, bleeding, friable gums (in dentate patients), loose teeth; Musculoskeletal: bone pain, pseudoparalysis in children, hemarthrosis, subperiosteal hemorrhage; Systemic: fatigue, weakness, anemia, depression; may present with syncope	Develops after 1-3 months of vitamin C deficiency; early symptoms: fatigue, weakness, irritability; cutaneous and gingival manifestations appear at 3-5 months; musculoskeletal symptoms prominent in children; symptoms improve within days to weeks of vitamin C supplementation	Vasculitis, child abuse (in children with bone pain and hemorrhages), leukemia, other bleeding disorders, inflammatory arthritis, autoimmune diseases	Serum ascorbic acid less than 11.4 micromol/L (less than 0.2 mg/dL) diagnostic; leukocyte ascorbic acid more accurate but less available; imaging in children: ground-glass osteopenia, metaphyseal corner fractures, subperiosteal hemorrhage, Wimberger ring sign (dense metaphyseal line); elevated inflammatory markers common; anemia	Vitamin C (ascorbic acid) 1-2 grams daily in divided doses for adults; 100-300 mg daily for children; continue until clinical resolution (typically 1-3 months); maintenance: 100 mg daily for adults, 35-50 mg daily for children; dietary counseling; treat underlying cause	N	https://pubmed.ncbi.nlm.nih.gov/35277043																
Vitiligo	Well-demarcated depigmented macules and patches; "white patches on hands and face"; often symmetric; associated with autoimmune diseases (thyroid disease, alopecia areata, diabetes mellitus)	Autoimmune destruction of melanocytes; genetic susceptibility plus environmental triggers; oxidative stress; T-cell mediated melanocyte loss; Koebner phenomenon (new lesions at sites of trauma); nonsegmental (85-90%) has immunologic basis; segmental has neurogenic component	Prevalence approximately 0.5-1% worldwide; affects all ethnicities equally; 50% develop before age 20; equal gender distribution; family history in 30%; associated with autoimmune diseases (thyroid disease most common)	Well-demarcated depigmented (not hypopigmented) macules and patches; nonsegmental: symmetric distribution on face, hands, body folds, genitalia; segmental: unilateral dermatomal distribution; hair depigmentation (poliosis) in late stages; Wood lamp examination enhances visualization; significant psychological impact and quality of life impairment	Nonsegmental: unpredictable course, may be slowly progressive or have rapid acceleration phases; segmental: early onset, stabilizes after 1-2 years; spontaneous repigmentation rare; chronic relapsing course	Post-inflammatory hypopigmentation (history of inflammation), pityriasis alba (ill-defined borders, facial in children), tinea versicolor (fine scale, potassium hydroxide positive), nevus depigmentosus (present from birth), chemical leukoderma	Clinical diagnosis; Wood lamp examination enhances depigmentation; skin biopsy rarely needed (shows absent melanocytes); screen for thyroid disease (thyroid-stimulating hormone, thyroid peroxidase antibodies); assess disease extent and activity; Vitiligo Area Scoring Index for severity	Localized: high-potency topical corticosteroids or topical calcineurin inhibitors (tacrolimus, pimecrolimus); topical ruxolitinib cream (JAK inhibitor, first FDA-approved targeted therapy); Widespread: narrowband ultraviolet B phototherapy (first-line for extensive disease); Systemic: oral corticosteroids for rapidly progressive disease; Surgical: autologous melanocyte transplantation for stable localized disease; sun protection and camouflage; psychological support	N	https://www.nejm.org/doi/full/10.1056/NEJMcp0804388																
Xeroderma Pigmentosum	Child with severe sunburn after minimal sun exposure, freckle-like pigmentation on sun-exposed areas, multiple skin cancers at young age	Autosomal recessive disorder caused by defects in nucleotide excision repair genes (XPA-XPG) or DNA polymerase eta (XPV); inability to repair UV-induced DNA damage	1 in 20,000 in Japan to 1 in 250,000 in USA; approximately 2.3 per million live births in Western Europe	Extreme photosensitivity with severe sunburn or early lentiginosis on sun-exposed areas, premature skin aging, multiple skin cancers (basal cell carcinoma, squamous cell carcinoma, melanoma) at young age, ocular surface disease, 25% have progressive neurological degeneration	Skin changes from birth or early childhood; skin cancers develop decades earlier than general population; progressive if UV protection inadequate	Cockayne syndrome, polymorphic light eruption, solar urticaria, other photosensitivity disorders, Peutz-Jeghers syndrome	Clinical diagnosis confirmed by cellular DNA repair assays, complementation group analysis, genetic testing for XP genes, skin biopsy showing UV damage	Strict UV protection including sunscreen, protective clothing, UV-blocking films on windows, early detection and removal of skin cancers, regular dermatologic and ophthalmologic surveillance; no curative treatment	Y	https://www.ncbi.nlm.nih.gov/books/NBK1397/																
Xerotic Dermatitis (Xerosis)	Dry, scaly, cracked skin especially on lower legs in elderly or winter months; "dry itchy skin in winter"; fish-scale appearance; may have eczema craquelé (crazy paving pattern of fissures)	Impaired epidermal barrier function; decreased natural moisturizing factors; reduced sebum production; environmental factors (low humidity, cold weather, excessive bathing); aging decreases stratum corneum hydration; underlying conditions (hypothyroidism, malnutrition, medications)	Very common; increases with age; more common in winter months (low humidity); affects lower extremities most commonly; risk factors: elderly, frequent bathing, harsh soaps, low humidity environments	Dry, rough, scaly skin with fine fissures; lower legs most commonly affected; pruritus (often worse at night); eczema craquelé (asteatotic eczema): polygonal cracking resembling cracked porcelain or crazy paving; may progress to nummular eczema or secondary infection from scratching	Worsens in winter months (low humidity); improves in summer; chronic relapsing course; acute exacerbations with environmental triggers or excessive bathing	Ichthyosis vulgaris (lifelong, genetic), atopic dermatitis (more inflammatory, flexural), contact dermatitis, nummular eczema, asteatotic eczema, hypothyroidism, nutritional deficiencies	Clinical diagnosis based on appearance and history; skin biopsy rarely needed; evaluate for underlying causes if severe or refractory (thyroid function tests, nutritional assessment)	Emollients and moisturizers (petrolatum-based, urea, lactic acid, ceramides) applied immediately after bathing; reduce bathing frequency and water temperature; avoid harsh soaps; use mild cleansers; humidification of indoor air; low-potency topical corticosteroids for inflamed areas; treat underlying conditions	N	https://www.aafp.org/pubs/afp/issues/2007/0515/p1490.html																
Zinc Deficiency	Acrodermatitis enteropathica-like rash (periorificial and acral dermatitis), alopecia, diarrhea, growth retardation; "rash around mouth and on hands with diarrhea"; impaired wound healing; taste disorders	Deficiency of zinc (essential trace element); impaired DNA synthesis, RNA transcription, cell division; zinc required for hundreds of enzymes; causes: inadequate dietary intake, malabsorption (inflammatory bowel disease, celiac disease), increased losses (chronic liver disease, chronic kidney disease), acrodermatitis enteropathica (genetic zinc transporter defect), total parenteral nutrition without zinc supplementation	Common in chronic liver disease (prevalence 84-96% in cirrhosis); acrodermatitis enteropathica rare (autosomal recessive); risk factors: malabsorption, chronic liver disease, chronic kidney disease, alcoholism, vegetarian diet, pregnancy, lactation	Dermatologic: periorificial and acral dermatitis (erythematous, scaly, sometimes vesiculobullous), alopecia, paronychia, impaired wound healing; Gastrointestinal: diarrhea, anorexia; Growth: growth retardation in children; Immune: increased susceptibility to infections; Other: hypogonadism, taste disorders (dysgeusia), night blindness, behavioral changes	Develops over weeks to months of inadequate intake or increased losses; symptoms improve within days to weeks of zinc supplementation; dermatitis resolves first	Acrodermatitis enteropathica (genetic form), biotin deficiency, essential fatty acid deficiency, necrolytic migratory erythema (glucagonoma), pellagra, other nutritional deficiencies	Plasma or serum zinc less than 10.4 micromol/L (less than 68 micrograms/dL) in women or less than 11.0 micromol/L (less than 72 micrograms/dL) in men indicates deficiency; adjust for inflammation (zinc decreases with inflammation); alkaline phosphatase may be low; clinical response to zinc supplementation confirms diagnosis	Zinc supplementation: zinc sulfate 220 mg (50 mg elemental zinc) orally 1-3 times daily; zinc acetate hydrate for chronic liver disease; treat underlying cause; dietary counseling (red meat, shellfish, legumes, nuts, whole grains); monitor for copper deficiency with prolonged high-dose zinc; symptoms improve within 1-2 weeks	N	https://www.nejm.org/doi/full/10.1056/NEJMra2314150																
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
																										
